IRF5 inhibitors and uses thereof

Compounds inhibiting IRF5 protein, as represented by Formulas Z, A, I, II, B, C, D, and E, address the need for therapeutic agents to manage autoimmune disorders by modulating IRF5 activity, offering treatment and research applications.

WO2026236688A1PCT designated stage Publication Date: 2026-11-12KYMERA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027408
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-01-14
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There is a high unmet need to develop drugs targeting interferon regulatory factor 5 (IRF5) to modulate its activity, as chronic Type I IFN response can promote autoimmunity and there is a lack of effective therapeutic agents to manage autoimmune disorders.

Method used

Development of compounds, such as those represented by Formulas Z, A, I, II, B, C, D, and E, and their pharmaceutically acceptable salts, which act as inhibitors of IRF5 protein to modulate its activity and are useful in treating autoimmune disorders and inflammatory responses.

Benefits of technology

The compounds effectively inhibit IRF5 protein activity, providing therapeutic benefits in treating autoimmune disorders and inflammatory conditions, and are also useful for studying IRF5 protein in biological and pathological phenomena.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000002_0001
    Figure IMGF000002_0001
  • Figure IMGF000002_0002
    Figure IMGF000002_0002
  • Figure IMGF000003_0001
    Figure IMGF000003_0001
Patent Text Reader

Abstract

The present disclosure provides compounds and compositions useful for the modulation of interferon regulatory factor 5 ("IRF5") protein, as well as methods of using the same for treating diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No.: KME-305WO IRF5 INHIBITORS AND USES THEREOFCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of and priority to U. S. Provisional Application No.63 / 802,550, filed May 8, 2025: and U. S. Provisional Application No. 63 / 960,450, filed January 14, 2026, each of which is incorporated herein by reference in its entirety.FIELD

[0002] The present disclosure relates to compounds and methods useful for the modulation of interferon regulatory factor 5 (1RF5). The present disclosure also provides pharmaceutically acceptable compositions comprising compounds disclosed herein and methods of using said compositions in the treatment of various diseases.BACKGROUND

[0003] Interferon regulatory factor 5 (IRF5) is a transcription factor belonging to the interferon regulatory factor family. The activation of IRF5 is dependent on both the initiating signal and the cell types involved. IRF5 produces Type I interferon (IFN) response, which is made up of interferon beta 1 (IFNB1) gene and 13 closely related interferon alpha (IFNA) genes. The activity of IRF5 downstream of various pattern recognition receptors (PRRs) determines the extent of the Type I IFN production and the pattern of cytokines induces.

[0004] Type I IFN activity is important as a line of defense against pathogens. Chronic Type I IFN response can promote autoimmunity by increasing associated antigen (Ag) presentation, lymphocyte-mediated adaptive immune responses, and chemokine expression. IRF5 has been identified as an autoimmune susceptibility gene and correlates with higher levels of Type I IFN, tumor necrosis factor alpha (TNFa), interleukin 6 (IL6), plasmablasts, and antinuclear antibodies (ANAs). Global immunosuppression to control disease activity remains the standard of care for autoimmune disorders, and there is still a high unmet need to develop drugs against targets involved in disease progression.

[0005] Accordingly, there remains a need to develop IRF5 inhibitors useful as therapeutic agents.SUMMARY

[0006] Compounds disclosed herein, and pharmaceutically acceptable compositions thereof, are effective as inhibitors of IRF5 protein.

[0007] Disclosed herein, in some embodiments, are compounds of Formula Z:Page 1 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula Z,or a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein.

[0008] Disclosed herein, in some embodiments, are compounds of Formula A:Formula A,or a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein.

[0009] Disclosed herein, in some embodiments, are compounds of Formula I:Page 2 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula I,or a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein.

[0010] Disclosed herein, in some embodiments, are compounds of Formula II:Formula II,or a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein.

[0011] Disclosed herein, in some embodiments, are compounds of Formula B:Page 3 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula B,or a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein.

[0012] Disclosed herein, in some embodiments, are compounds of Formula C:Formula C,or a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein.

[0013] Disclosed herein, in some embodiments, are compounds of Formula D:Page 4 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula D,or a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein.

[0014] Disclosed herein, in some embodiments, are compounds of Formula E:Formula E,or a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein.

[0015] Compounds disclosed herein, and pharmaceutically acceptable compositions thereof, are useful for treating a variety of diseases, disorders or conditions, associated with inflammatory responses and / or immune pathways implicating IRF5 protein. Such diseases, disorders, or conditions include those described herein.Page 5 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0016] Compounds disclosed herein are also useful for the study of IRF5 protein in biological and pathological phenomena; the study of inflammatory responses and / or immune pathways occurring in bodily tissues; and the comparative evaluation of new IRF5 inhibitors, in vitro or in vivo.DETAILED DESCRIPTION

[0017] As generally described herein, the present disclosure features compounds, or pharmaceutically acceptable salts thereof (e.g., compounds of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, and Formula E, and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof) and compositions comprising said compounds useful as modulators (e.g., inhibitors) of IRF5 protein. Compounds and compositions disclosed herein are also useful for treating diseases or disorders.Definitions

[0018] As used herein, the following definitions apply to the terms as used to describe the present disclosure, unless otherwise indicated or apparent from context. Unless explicitly indicated otherwise, or apparent from context, the terms below do not exclude the meaning that the term has acquired in the art to which it pertains. The definitions below are provided to facilitate the description of the disclosure, but they are not intended to limit the scope of the disclosure.Chemical Definitions

[0019] Chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March’s Advanced Organic Chemistry”, 5thEd., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.

[0020] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the present disclosure. Unless otherwise stated, all Page 6 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO tautomeric forms of the compounds of the present disclosure are within the scope of the present disclosure. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures including the replacement of each of one or more hydrogen atoms by deuterium or tritium, or the replacement of each of one or more carbon atoms by a13C- or14C-enriched carbon are within the scope of the present disclosure. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present disclosure.

[0021] When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example “Ci-Ce alkyl” is intended to encompass, Ci, C2, C3, C4, C5, Ce, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2, C2-C6, C2-C5, C2-C4, C2-C3, C.3-C6, C3-C5, C3-C4, C4-C6, C4-C5, and C5-C6alkyl.

[0022] The term “aliphatic” or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “carbocycle,” “cycloaliphatic,”), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. In some embodiments, “cycloaliphatic” (or “carbocycle”) refers to a monocyclic C3-C6 hydrocarbon that is substituted or unsubstituted and is completely saturated (i.e., cycloalkyl) or that contains one or more units of unsaturation (i.e., cycloalkenyl), but which is not aromatic, that has a single point of attachment to the rest of the molecule. In some embodiments, a carbocyclic ring may be a 5-12 membered bicyclic, bridged bicyclic, or spirocyclic ring (e.g., spirocyclic carbocycle ring). A carbocyclic ring may include one or more oxo (=0) or thioxo (=S) substituent. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl) alkyl or (cycloalkyl)alkenyl. A carbocyclic ring may include one or more bridged bicyclic and / or spirocyclic ring. A carbocyclic ring may include a bridged bicyclic carbocycle and a bridged bicyclic heterocycle.Page 7 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0023] As used herein, the term “bridged bicyclic” refers to any bicyclic ring system, i.e., carbocyclic or heterocyclic, saturated or partially unsaturated, having at least one bridge and is substituted or unsubstituted. As defined by IUPAC, a “bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a “bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen). In some embodiments, a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such bridged bicyclic groups are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bridged bicyclics include:

[0024] As used herein, the term “bridged bicyclic carbocycle” refers to any bicyclic carbocyclic ring system, saturated or partially unsaturated, having at least one bridge and is substituted or unsubstituted. As defined by IUPAC, a “bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a “bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen). In some embodiments, a bridged bicyclic carbocycle has 7-12 carbon ring members. Such bridged bicyclic carbocycles are well known in the art and include those groups set forth below Page 8 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO where each group is attached to the rest of the molecule at any substitutable carbon atom. Unless otherwise specified, a bridged bicyclic carbocycle is optionally substituted with one or more substituents as set forth for aliphatic groups. Exemplary bridged bicyclic carbocyclesinclude:

[0025] As used herein, the term “bridged bicyclic heterocycle” refers to any bicyclic heterocyclic ring system, saturated or partially unsaturated, having at least one bridge and is substituted or unsubstituted. As defined by IUPAC, a “bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a “bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen). In some embodiments, a bridged bicyclic heterocycle has 7-12 ring members and 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such bridged bicyclic heterocycles are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom.

[0026] Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bridged bicyclic heterocycles include:

[0027] As used herein, the term “spirocyclic ring” refers to a spirocyclic ring system, where two rings are connected through exactly one shared atom. In an embodiment, the shared atom is a quaternary carbon atom. In an embodiment, the shared atom is a nitrogen atom. The rings may each independently be a carbocyclic or heterocyclic ring. Each ring can be a saturated or partially unsaturated ring. In an embodiment, one ring is carbocyclic and one ring is heterocyclic. In an embodiment, the two rings are carbocyclic rings. In an embodiment, the two rings are heterocyclic rings.

[0028] As used herein, the term “alkyl” refers to a radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 20 carbon atoms (“C1-C20 alkyl”). In somePage 9 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO embodiments, an alkyl group has 1 to 12 carbon atoms (“C1-C12 alkyl”). In some embodiments, an alkyl group has 1 to 10 carbon atoms (“C1-C10 alkyl”). In some embodiments, an alkyl group has 1 to 9 carbon atoms (“C1-C9 alkyl”). In some embodiments, an alkyl group has 1 to 8 carbon atoms (“Ci-Cs alkyl”). In some embodiments, an alkyl group has 1 to 7 carbon atoms (“C1-C7 alkyl”). In some embodiments, an alkyl group has 1 to 6 carbon atoms (“Ci-Ce alkyl”, also referred to herein as “lower alkyl”). In some embodiments, an alkyl group has 1 to 5 carbon atoms (“C1-C5 alkyl”). In some embodiments, an alkyl group has 1 to 4 carbon atoms (“C1-C4 alkyl”). In some embodiments, an alkyl group has 1 to 3 carbon atoms (“C1-C3 alkyl”). In some embodiments, an alkyl group has 1 to 2 carbon atoms (“C1-C2 alkyl”). In some embodiments, an alkyl group has 1 carbon atom (“Ci alkyl”). In some embodiments, an alkyl group has 2 to 6 carbon atoms (“C2-6 alkyl”). Examples of C1-6 alkyl groups include, but are not limited to, methyl (Ci), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), and n-hexyl (Ce). Additional examples of alkyl groups include n-heptyl (C7), n-octyl (Cs) and the like. Unless otherwise specified, each instance of an alkyl group is unsubstituted (an “unsubstituted alkyl”) or substituted (a “substituted alkyl”) with one or more substituents (e.g., for instance from 1 to 6 substituents, 1 to 5 substituents, 1 to 4 substituents, 1 to 3 substituents, 1 to 2 substituents, or 1 substituent). In some embodiments, the alkyl group is unsubstituted C1-10 alkyl (e.g., -CH3). In some embodiments, the alkyl group is substituted C1-10 alkyl. Common alkyl abbreviations include -Me (-CH3), -Et (-CH2CH3), -nPr (-CH2CH2CH3), -Pr (-CH(CH3)2), -nBu (-CH2CH2CH2CH3), -'Bu (-CH2CH(CH3)2), -sBu (-CH(CH3)(CH2CH3)), and -‘Bu (-C(CH3))3).

[0029] As used herein, the term “alkenyl” refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 carbon-carbon double bonds), and optionally one or more carboncarbon triple bonds (e.g., 1, 2, 3, or 4 carbon-carbon triple bonds) (“C2-C20 alkenyl”). In some embodiments, alkenyl does not contain any triple bonds. In some embodiments, an alkenyl group has 2 to 10 carbon atoms (“C2-C10 alkenyl”). In some embodiments, an alkenyl group has 2 to 9 carbon atoms (“C2-C9 alkenyl”). In some embodiments, an alkenyl group has 2 to 8 carbon atoms (“C2-C8 alkenyl”). In some embodiments, an alkenyl group has 2 to 7 carbon atoms (“C2-C7 alkenyl”). In some embodiments, an alkenyl group has 2 to 6 carbon atoms (“C2-Ce alkenyl”). In some embodiments, an alkenyl group has 2 to 5 carbon atoms (“C2-C5 alkenyl”). In some embodiments, an alkenyl group has 2 to 4 carbon atoms (“C2-C4 alkenyl”). In some embodiments, an alkenyl group has 2 to 3 carbon atoms (“C2-C3 alkenyl”). In some Page 10 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO embodiments, an alkenyl group has 2 carbon atoms (“C2 alkenyl”). The one or more carboncarbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). Examples of C2-C4 alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like. Examples of C2-C6 alkenyl groups include the aforementioned C2-4 alkenyl groups as well as pentenyl (C5), pentadienyl (C5), hexenyl (Ce), and the like. Additional examples of alkenyl include heptenyl (C7), octenyl (Cs), octatrienyl (Cs), and the like. Unless otherwise specified, each instance of an alkenyl group is independently unsubstituted (an “unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents (e.g., for instance from 1 to 6 substituents, 1 to 5 substituents, 1 to 4 substituents, 1 to 3 substituents, 1 to 2 substituents, or 1 substituent). In some embodiments, the alkenyl group is unsubstituted C2-10 alkenyl. In some embodiments, the alkenyl group is substituted C2-C10 alkenyl.

[0030] As used herein, the term “alkynyl” refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 carbon-carbon triple bonds), and optionally one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 carbon-carbon double bonds) (“C2-C20 alkynyl”). In some embodiments, alkynyl does not contain any double bonds. In some embodiments, an alkynyl group has 2 to 10 carbon atoms (“C2-C10 alkynyl”). In some embodiments, an alkynyl group has 2 to 9 carbon atoms (“C2-C9 alkynyl”). In some embodiments, an alkynyl group has 2 to 8 carbon atoms (“C2-C8 alkynyl”). In some embodiments, an alkynyl group has 2 to 7 carbon atoms (“C2-C7 alkynyl”). In some embodiments, an alkynyl group has 2 to 6 carbon atoms (“C2-C6 alkynyl”). In some embodiments, an alkynyl group has 2 to 5 carbon atoms (“C2-C5 alkynyl”). In some embodiments, an alkynyl group has 2 to 4 carbon atoms (“C2-C4 alkynyl”). In some embodiments, an alkynyl group has 2 to 3 carbon atoms (“C2-C3 alkynyl”). In some embodiments, an alkynyl group has 2 carbon atoms (“C2 alkynyl”). The one or more carboncarbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl). Examples of C2-4 alkynyl groups include, without limitation, ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), and the like. Examples of C2-6 alkenyl groups include the aforementioned C2-C4 alkynyl groups as well as pentynyl (C5), hexynyl (C&), and the like. Additional examples of alkynyl include heptynyl (C7), octynyl (Cs), and the like. Unless otherwise specified, each instance of an alkynyl group is independently unsubstituted (an “unsubstituted alkynyl”) or substituted (a “substituted alkynyl”) with one or more substituents (e.g., for instance from 1 to 6 substituents, 1 to 5 substituents, 1 to 4 substituents, 1 to 3 substituents, 1 to 2 substituents, or 1 substituent). In some embodiments, the alkynyl Page 11 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO group is unsubstituted C2-C10 alkynyl. In some embodiments, the alkynyl group is substituted C2-C10 alkynyl.

[0031] The term “haloalkyl” refers to a straight or branched alkyl group that is substituted with one or more halogen atoms.

[0032] As used herein, the term “hydroxyalkyl” refers to alkyl, as defined above, substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6) hydroxy groups. Exemplary hydroxyalkyl groups include, but are not limited to, -CH2OH, -CH2CH2OH, and -C CFF OH.

[0033] The term “alkylene” refers to a bivalent alkyl group. An “alkylene chain” is a polymethylene group, i.e., -(CH2)n-, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent.

[0034] The term “alkenylene” refers to a bivalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent.

[0035] The term “halogen” means -F, -Cl, -Br, or -I.

[0036] The term “heteroatom” refers to oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen; and a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR+(as in N-substituted pyrrolidinyl)).

[0037] The term “unsaturated,” as used herein, means that a moiety has one or more units of unsaturation.

[0038] As used herein, the temi “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond. The term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.

[0039] The term “aryl” used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic or bicyclic ring systems having a total of six to fourteen ring members, wherein at least one ring in the system is a 6-carbon atom aromatic ring. The term “aryl” may be used interchangeably with the term “aryl ring.” In certain embodiments, “aryl” refers to an aromatic ring system which includes, but not limited to, phenyl, naphthyl, and the like, which may bear one or more substituents. Also included within the scope of the term “aryl,” as it is used herein, is a group in which an aromatic ring is fused to one or more cycloaliphatic (e.g., cycloalkyl or cycloalkenyl) rings, such as Page 12 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO indanyl, tetrahydronaphthyl, and the like. The term “arylenyl” refers to bivalent aryl groups (e.g., phenylenyl). Unless otherwise specified, an aryl is optionally substituted with one or more substituents.

[0040] As used herein, the terms “heterocycle," “heterocyclyl,” “heterocyclic radical," and “heterocyclic ring” are used interchangeably and refer to a stable monocyclic or bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, for example an oxygen atom, a sulfur atom or a nitrogen atom. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 1-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or+NR (as in TV-substituted pyrrolidinyl). A heterocyclyl may include one or more bridged bicyclic and / or spirocyclic rings.

[0041] Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, pyrrolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, oxazepinyl, and morpholinyl. The terms “heterocycle,” “heterocyclyl,” “heterocyclyl ring,” “heterocyclic group,” “heterocyclic moiety,” and “heterocyclic radical,” are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl or cycloaliphatic rings, such as indolinyl, chromanyl, or tetrahydroquinolinyl. A heterocyclic ring may include one or more oxo (=0) or thioxo (=S) substituent. The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.

[0042] I'he terms “heteroaryl” and “heteroar-,” used alone or as part of a larger moiety, e.g., “heteroaralkyl,” or “heteroaralkoxy,” refer to groups having 5 to 14 ring atoms having 6, 10, or 147t electrons shared in a cyclic array, preferably 5, 6, or 9 ring atoms having 6, 10, or 147t electrons shared in a cyclic array; and wherein in addition to carbon atom(s), at least one ring atom is a heteroatom. The term “heteroatom” refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quatemized form of a basic nitrogen. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms “heteroaryl” and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl Page 13 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO rings. Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, carbazolyl, acridinyl, phenazinyl, and phenothiazinyl. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted. The term “heteroaralkyl” refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted. The term “heteroarylenyl” refers to bivalent heteroaryl groups (e.g., pyridylenyl).

[0043] “Stereoisomers” refers to compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers.” Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that arc not mirror images of one another arc termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers.” When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture”.

[0044] “Tautomers” refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of n electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the aci- and nitro- forms of phenylnitromethane, that are likewise formed by treatment with acid or base. Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound disclosed herein.Other Definitions

[0045] The articles “a” and “an” may be used herein to refer to one or to more than one (i.e. at least one) of the grammatical objects of the article. By way of example “an analogue” means one analogue or more than one analogue.Page 14 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0046] The term “biological sample,” as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof. In some embodiments, the IRF5 is from a biological sample. In some embodiments, the biological sample is taken from a subject.

[0047] Disease, disorder, and condition are used interchangeably herein.

[0048] In general, the “effective amount” of a compound refers to an amount sufficient to elicit the desired biological response. As will be appreciated by those of ordinary skill in this art, the effective amount of a compound of the disclosure may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, weight, health, and condition of the subject.

[0049] As used herein, the term “inhibitor” is defined as a compound that binds to and / or inhibits IRF5 protein with measurable affinity.

[0050] As used herein, an “inhibitor compound" is a compound that binds a protein of interest. In some embodiments, an inhibitor compound binds a protein of interest and decreases its activity. In some embodiments, binding of an inhibitor compound to a protein of interest does not result in degradation of the protein of interest. In another embodiment, an inhibitor compound does not bind an E3 ligase in a manner that results in degradation of the protein of interest. In another embodiment, an inhibitor compound does not, in vivo or in vitro, bind an E3 ligase in a manner that results in degradation of the protein of interest. In some embodiments, an inhibitor compound binds IRF5. In some embodiments, an inhibitor compound binds IRF5 and decreases its activity. In some embodiments, binding of an inhibitor compound to IRF5 does not result in degradation of IRF5. In another embodiment, an inhibitor compound does not bind an E3 ligase in a manner that results in degradation of the IRF5. In some embodiments, an inhibitor compound binds a protein of interest (e.g., IRF5) but does not bind an E3 ligase. In some embodiments, an E3 ligase is selected from a cereblon E3 ubiquitin ligase, a VHL E3 ubiquitin ligase, a DCAF E3 ubiquitin ligase, (e.g., a DCAF1 E3 ubiquitin ligase, a DCAF15 E3 ubiquitin ligase, or a DCAF16 E3 ubiquitin ligase), an IAP E3 ubiquitin ligase, an MDM2 E3 ligase, or a KLHDC2 E3 ubiquitin ligase. It will be understood that, throughout this disclosure, reference to a “compound” or a “provided compound” refers to an inhibitor compound as defined above. In some embodiments, an E3 ligase is a cereblon E3 ubiquitin ligase. In certain embodiments, an inhibitor compound has an IC50 of less than about 50 nM, no greater than about 100 nM, no greater than about 1000 nM, no greater than about 10,000Page 15 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO nM, about 50-100 nM, greater than about 100 nM to about 1000 nM, or greater than about 1000 nM to about 10,000 nM.

[0051] The terms “measurable affinity” and “measurably inhibit,” as used herein, means a measurable change in IRF5 protein activity between a sample comprising a compound of the present disclosure, or composition thereof, and IRF5 protein, and an equivalent sample comprising IRF5 protein, in the absence of said compound, or composition thereof.

[0052] As used herein, the term “reference” describes a standard or control relative to which a comparison is performed. In some embodiments, a “reference” sample or subject is one that is sufficiently similar to a particular sample or subject of interest to pennit a relevant comparison. For example, in some embodiments, an agent, animal, individual, population, sample, sequence or value of interest is compared with a reference or control agent, animal, individual, population, sample, sequence or value. In some embodiments, a reference or control is tested and / or determined substantially simultaneously with the testing or determination of interest. In some embodiments, a reference or control is a historical reference or control, optionally embodied in a tangible medium. Typically, as would be understood by those skilled in the art, a reference or control is determined or characterized under comparable conditions or circumstances to those under assessment. Those skilled in the art will appreciate when sufficient similarities are present to justify reliance on and / or comparison to a particular possible reference or control.

[0053] As used herein, the term “IRF5-mediated” disorder, disease, and / or condition means any disorder, disease, or condition in which IRF5 plays a role. In some embodiments, the present disclosure relates to treating or lessening the severity of one or more diseases in which IRF5 plays a role.

[0054] As used herein, and unless otherwise specified, a “therapeutically effective amount” of a compound is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder or condition, or to delay or minimize one or more symptoms associated with the disease, disorder or condition. A therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the disease, disorder or condition. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of disease or condition, or enhances the therapeutic efficacy of another therapeutic agent.

[0055] As used herein, the temr “pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency inPage 16 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO countries other than the United States, or that is listed in the U. S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly, in humans.

[0056] As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds disclosed herein include those derived from suitable inorganic and organic acids and bases. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and NACi 4alkyl)4 salts. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions. In some embodiments, the provided compounds are purified in salt form for convenience and / or ease of purification, e.g., using an acidic or basic mobile phase during chromatography. Salts forms of the provided compounds formed during chromatographic purification are contemplated herein (e.g., diammonium salts).

[0057] As used herein, the terms “provided compound” and “disclosed compound” refers to any genus, subgenus, and / or species set forth herein.

[0058] A “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult or senior adult)) and / or a non-human animal, e.g., a mammal such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human animal.

[0059] As used herein, and unless otherwise specified, the terms “treat,” “treating” and “treatment” contemplate an action that occurs while a subject is suffering from the specified disease, disorder or condition, which reduces the severity of the disease, disorder or condition, or retards or slows the progression of the disease, disorder or condition (“therapeutic treatment”).Compounds

[0060] Compounds of the present disclosure include those described generally herein, and are further illustrated by the classes, subclasses, and species disclosed herein.Page 17 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0061] Compounds disclosed herein (e.g., compounds of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, and Formula E, and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof) are useful as inhibitors of IRF5 protein. In some embodiments, a compound disclosed herein modulates IRF5. In some embodiments, a compound disclosed herein inhibits IRF5.Formula Z

[0062] Disclosed herein, in some embodiments is a compound of Formula Z:Formula Z,or a pharmaceutically acceptable salt thereof, wherein:U1is -O- or -S-;RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- C6alkyl);Z1is — C(O)~, Z2is O, NRZ2, or CRZ3RZ4, and represents a single bond, or alternatively Z1is N or CRZ3, Z2is N or CRZ3, and represents a double bond;each of Z3, Z4, and Z5is, independently, CRZ5or N;RZ2is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-Ce alkyl)-O- (Ci-C6alkyl), -C(O)-(Ci-C6alkyl), -(Ci-C6alkyl)-RY, and RY;RZ3is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Ci-Ce alkyl)-RY, and RY;Page 18 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY; or alternativelyRZ3and RZ4are taken together with the carbon atom to which each is attached form 3- 8 membered monocyclic carbocyclylene;each Rz5is, independently, selected from the group consisting of H, halo, cyano, Ci-Ce alkyl, Ci-C6haloalkyl, and -ORza;each Rzais, independently, selected from the group consisting of H, Ci-C,6 alkyl, and Ci-C,6 haloalkyl;each of V1, V2, V3, and V4is, independently, CRVor N;each Rvis, independently, selected from the group consisting of H, halo, -NO2, -CN, Ci-Ce alkyl, Ci-Ce haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, -NRvaRvb, -ORVC, -(Ci-Ce alkylene)-NRvaRvb, -(Ci-C6alkylene) ORVC, -(Ci-C6alkylene)O(CH2)i.4ORvc, -NRva- (Ci-C6alkylene) -NRvaRvb, -O-(Ci-C6alkylene)-NRvaRvb, -(C2-C10 alkenylene)- NRvaRvb, -(C2-C10 alkynylene)-NRvaRvb, RVY, -NRva-(Co-C6alkylene)-RVY, -(Ci-C6alkylene) -RVY, -O-(Ci-Ce alkylene)-RVY, -(C2-C10 alkenylene)-RVY, -(C2-C10 alkynylene)-RVY, and RVY;each RVYis, independently, selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RVYis unsubstituted or substituted with 1-4 instances of Rvd;each Rvais, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each Rvbis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-Ce alkyl)-O-(Ci-Ce alkyl), and -C(O)-(Ci-Ce alkyl);each Rvcis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Ci-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each Rvdis, independently, selected from the group consisting of halo, -OH, -NO2, -CN, Ci- Ce alkyl, Ci-C6haloalkyl, -NRvaRvb, -ORVC, -(Ci-C6alkylene)-NRvaRvb, -(Ci-C6alkylene)ORvc, -(Ci-C6alkylene)O(CH2)i-4ORvc, -NRva-(Ci-C6alkylene)-NRvaRvb, - (C2-C10 alkenylene) -NRvaRvb, and -(C2-C10 alkynylene)-NRvaRvb;each of W1, W2, and W3is, independently, CRWor N;each Rwis, independently, selected from the group consisting of H, halo, -NO2, -CN, Ci-Ce alkyl, Ci-Ce haloalkyl, C2-Ce alkenyl, C2-C6 alkynyl, -NRwaRwb, -ORWC, -(Ci-Ce alkylene)-NRwaRwb, -(Ci-C6alkylene) ORWC, -(Ci-C6alkylene)O(CH2)i-4ORwc, -NRwa- Page 19 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO (C1-C6 alkylene)-NRwaRwb, -O-(Ci-C6alkylene) -NRwaRwb, -(C2-C10 alkenylene)- NRwaRwb, -(C2-C10 alkynylene)-NRwaRwb, -NRwa-(Co-C6 alkylene)-RWY, -(Ci-C6alkylene) -RWY, -0-(CI-C6 alkylene) -RWY, -(C2-C10 alkenylene)-RWY, and -(C2-C10 alkynylene) -RWY;each RWYis, independently, selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each Rwais, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each Rwbis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(C0-C6 alkyl)-O-(Ci-C6 alkyl), and -C(O)-(Ci-C6 alkyl);each Rwcis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Ci-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each of R11and R22is, independently, selected from a group consisting of H, halogen, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl; or alternativelyR11and R22are taken together with the carbon atom to which each is attached to formn is 0, 1, 2, 3, or 4;Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, 5-14 membered spirocyclic carbocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered bicyclic heteroaryl, 3-8 membered monocyclic heterocyclyl, 8-10 membered bicyclic heterocyclyl, and 5-14 membered spirocyclic heterocyclyl;each REis, independently, selected from the group consisting of-CN, -NO2, halo, Ci-C6 alkyl, Ci-Ce haloalkyl, -C(O)Rea, -OReb, -N(Rec)2, and REY;REYis selected from the group consisting of phenyl and 5-6 membered monocyclic heteroaryl, wherein REYis unsubstituted or substituted with 1-3 instances of Red;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -Ryaor -C(O)Rya;Page 20 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Recis, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Redis, independently, selected from the group consisting of halo, Ci-C.6 alkyl, and Ci-C,6 haloalkyl;each Ryais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl; ande is 0, 1, 2, 3, 4, 5, or 6.Formula A

[0063] Disclosed herein, in some embodiments is a compound of Formula A:Formula A,or a pharmaceutically acceptable salt thereof, wherein:RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- C6alkyl);Z1is — C(O)—, Z2is O, NRZ2, or CRZ’RZ4. and represents a single bond, or alternatively Z1is N or CRZ3, Z2is N or CRZ3, and represents a double bond;each of Z3, Z4, and Z? is, independently, CRZ5or N;Page 21 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO RZ2is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-Ce alkyl)-O- (Ci-Ce alkyl), -C(O)-(Ci-Ce alkyl), and RY;RZ3is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Ci-Ce alkyl)-RY, and RY;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY; or alternativelyRZ3and RZ4are taken together with the carbon atom to which each is attached form 3- 8 membered monocyclic carbocyclylene;each R75is, independently, selected from the group consisting of H, halo, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, and -ORza;each Rzais, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of V1, V2, V3, and V4is, independently, CRVor N;each Rvis, independently, selected from the group consisting of H, halo, -NO2, -CN, Ci-Ce alkyl, Ci-Ce haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, -NRvaRvb, -ORVC, -(Ci-Ce alkylene)-NRvaRvb, -(Ci-C6alkylene)ORvc, -(Ci-C6alkylene)O(CH2)i.4ORvc, -NRva- (Ci-C6alkylene)-NRvaRvb, -O-(Ci-C6alkylene)-NRvaRvb, -(C2-C10 alkenylene)- NRvaRvb, -(C2-C10 alkynylene)-NRvaRvb, RVY, -NRva-(Co-C6alkylene)-RVY, -(Ci-C6alkylene) -RVY, -O-(Ci-Ce alkylene) -RVY, -(C2-C10 alkenylene) -RVY, and -(C2-C10 alkynylene)-RVY;each RVYis, independently, selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RVYis unsubstituted or substituted with 1-4 instances of Rvd;each Rvais, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each Rvbis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each Rvcis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Ci-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each Rvdis, independently, selected from the group consisting of halo, -OH, -NO2, -CN, Ci- Ce alkyl. Ci-C6haloalkyl, -NRvaRvb, -ORVC, -(Ci-C6alkylene)-NRvaRvb, -(Ci-C6alkylene)ORvc, -(Ci-C6alkylene)O(CH2)i-4ORvc, -NRva-(Ci-C6alkylene)-NRvaRvb, - (C2-C10 alkenylene)-NRvaRvb, and -(C2-C10 alkynylene)-NRvaRvb;Page 22 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO each of W1, W2, and W3is, independently, CRWor N;each Rwis, independently, selected from the group consisting of H, halo, -NO2, -CN, Ci-Ce alkyl, Ci-C6haloalkyl, C2-C6alkenyl, C2-C6alkynyl, -NRwaRwb, -ORWC, -(Ci-C6alkylene)-NRwaRwb, -(Ci-C6alkylene) ORWC, -(Ci-C6alkylene)O(CH2)i-4ORwc, -NRwa- (Ci-C6alkylene)-NRwaRwb, -O-(Ci-C6alkylene) -NRwaRwb, -(C2-C10 alkenylene)- NRwaRwb, -(C2-C10 alkynylene)-NRwaRwb, -NRwa-(Co-C6alkylene)-RWY, -(Ci-C6alkylene)-RWY, -O-(Ci-C6alkylene)-RWY, -(C2-C10 alkenylene)-RWY, and -(C2-Cw alkynylene)-RWY;each RWYis, independently, selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each Rwais, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each Rwbis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-Ce alkyl)-O-(Ci-Ce alkyl), and -C(O)-(Ci-C6 alkyl);each Rwcis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Ci-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each of R” and R22is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;n is 1, 2, 3, or 4;Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, and 5-14 membered spirocyclic carbocyclyl;each REis, independently, selected from the group consisting of-CN, -NO2, halo, Ci-Ce alkyl, Ci-C6haloalkyl, -C(O)Rea, -OReb, and -N(Rec)2;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya;each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;Page 23 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO each Recis, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Ryais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl; ande is 0, 1, 2, 3, 4, 5, or 6.Formula I

[0064] Disclosed herein, in some embodiments is a compound of Formula I:Formula I,or a pharmaceutically acceptable salt thereof, wherein:RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- (, alkyl);Z2is NRZ2or CRZ'RZ4:each of Z3, Z4, and Z5is, independently, CRZ5or N;RZ2is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-Ce alkyl)-O- (Ci-C6alkyl), -C(O)-(Ci-C6alkyl), and RY;RZ3is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Ci-Ce alkyl)-RY, and RY;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl) -RY; or alternativelyPage 24 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO RZ3and RZ4are taken together with the carbon atom to which each is attached form 3- 8 membered monocyclic carbocyclylene;each RZ5is, independently, selected from the group consisting of H, halo, cyano, Ci-Ce alkyl, Ci-C6haloalkyl, and -ORza;each Rzais, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of V1, V2, V3, and V4is, independently, CRVor N;each Rvis, independently, selected from the group consisting of H, halo, -NO2, -CN, Ci-Ce alkyl, Ci-Ce haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, -NRvaRvb, -ORVC, -(Ci-Ce alkylene)-NRvaRvb, -(Ci-C6alkylene)ORvc, -(Ci-C6alkylene)O(CH2)i-4ORvc, -NRva- (C1-C6 alkylene)-NRvaRvb, -O-(Ci-C6alkylene)-NRvaRvb, -(C2-C10 alkenylene)- NRvaRvb, -(C2-C10 alkynylene)-NRvaRvb, RVY, -NRva-(Co-C6alkylene)-RVY, -(Ci-C6alkylene) -RVY, -O-(Ci-Ce alkylene) -RVY, -(C2-C10 alkenylene) -RVY, and -(C2-C10 alkynylene)-RVY;each RVYis, independently, selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RVYis unsubstituted or substituted with 1-4 instances of Rvd;each Rvais, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-Ce alkyl)-O-(Ci-Ce alkyl), and -C(O)-(Ci-Ce alkyl);each Rvbis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each Rvcis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Ci-Ce alkyl)-O-(Ci-Ce alkyl), and -C(O)-(Ci-Ce alkyl);each Rvdis, independently, selected from the group consisting of halo, -OH, -NO2, -CN, Ci- C6alkyl, Ci-C6haloalkyl, NRvaRvb, -ORVC, -(Ci-C6alkylene)-NRvaRvb, -(Ci-C6alkylene)ORvc, -(Ci-C6alkylene)O(CH2)i-4ORvc, -NRva-(Ci-C6alkylene)-NRvaRvb, - (C2-C10 alkenylene)-NRvaRvb, and -(C2-C10 alkynylene)-NRvaRvb;each of W1, W2, and W3is, independently, CRWor N;each Rwis, independently, selected from the group consisting of H, halo, -NO2, -CN, Ci-Ce alkyl, Ci-C6haloalkyl, C2-C6alkenyl, C2-C6alkynyl, -NRwaRwb, -ORWC, -(Ci-C6alkylene)-NRwaRwb, -(Ci-C6alkylene) ORWC, -(Ci-C6alkylene)O(CH2)i.4ORwc, -NRwa- (Ci-C6alkylene)-NRwaRwb, -O-(Ci-C6alkylene) -NRwaRwb, -(C2-C10 alkenylene)- NRwaRwb, -(C2-C10 alkynylene)-NRwaRwb, -NRwa-(Co-C6alkylene)-RWY, -(Ci-C6Page 25 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO alkylene)-RWY, -O-(Ci-C6alkylene) -RWY, -(C2-C10 alkenylene) -RWY, and -(C2-C10 alkynylene)-RWY;each RWYis, independently, selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each Rwais, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C,6 alkyl)-O-(Ci-Ce alkyl), and -C(O)-(Ci-Ce alkyl);each Rwbis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each Rwcis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(C1-C6 alkyl)-O-(Ci-C6 alkyl), and -C(O)-(Ci-C6 alkyl);each of R11and R22is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;nis 1, 2, 3, or 4;Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, and 5-14 membered spirocyclic carbocyclyl;each RFis, independently, selected from the group consisting of-CN, -NO2, halo, Ci-Ce alkyl, Ci-C6haloalkyl, -C(O)Rea, -OReb, and -N(Rec)2;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya;each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Recis, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Ryais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl; ande is 0, 1, 2, 3, 4, 5, or 6.Formula IIPage 26 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0065] Disclosed herein, in some embodiments is a compound of Formula II:Formula II,or a pharmaceutically acceptable salt thereof, wherein:RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- Ce alkyl);Z1is -C(O)-, Z2is O, and represents a single bond, or alternativelyZ1is N or CRZ3, Z2is N or CRZ3, and represents a double bond;each of Z3, Z4, and Z5is, independently, CRZ5or N;RZ2is selected from the group consisting of H, Ci-Cg alkyl, Ci-Ce haloalkyl, -(Co-Ce alkyl)-O- (Ci-C6alkyl), -C(O)-(Ci-C6alkyl), and RY;RZ3is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Ci-Ce alkyl)-RY, and RY;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY; orRZ3and RZ4are taken together with the carbon atom to which each is attached form 3- 8 membered monocyclic carbocyclylene;each Rz5is, independently, selected from the group consisting of H, halo, cyano, Ci-Ce alkyl, Ci-C6haloalkyl, and -ORza;each Rzais, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of V1, V2, V3, and V4is, independently, CRVor N;Page 27 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO each Rvis, independently, selected from the group consisting of H, halo, -NO2, -CN, Ci-Ce alkyl, Ci-Ce haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, -NRvaRvb, -ORVC, -(Ci-Ce alkylene)-NRvaRvb, -(Ci-C6alkylene) ORVC, -(Ci-C6alkylene)O(CH2)i-4ORvc, -NRva- (Ci-C6alkylene) -NRvaRvb, -O-(Ci-C6alkylene)-NRvaRvb, -(C2-C10 alkenylene)- NRvaRvb, -(C2-C10 alkynylene)-NRvaRvb, RVY, -NRva-(Co-C6alkylene)-RVY, -(Ci-C6alkylene) -RVY, -O-(Ci-Ce alkylene) -RVY, -(C2-C10 alkenylene) -RVY, and -(C2-C10 alkynylene)-RVY;each RVYis, independently, selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RVYis unsubstituted or substituted with 1-4 instances of Rvd;each Rvais, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each Rvbis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-Ce alkyl)-O-(Ci-Ce alkyl), and -C(O)-(Ci-Ce alkyl);each Rvcis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Ci-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each Rvdis, independently, selected from the group consisting of halo, -OH, -NO2, -CN, Ci- C6alkyl, Ci-C6haloalkyl, -NRvaRvb, -ORVC, -(Ci-C6alkylene)-NRvaRvb. -(Ci-C6alkylene)ORvc, -(Ci-C6alkylene)O(CH2)i-4ORvc, -NRva-(Ci-C6alkylene)-NRvaRvb, - (C2-C10 alkenylene)-NRvaRvb, and -(C2-C10 alkynylene)-NRvaRvb;each of W1, W2, and W3is, independently, CRWor N;each Rwis, independently, selected from the group consisting of H, halo, -NO2, -CN, Ci-Ce alkyl, Ci-Ce haloalkyl, C2-Ce alkenyl, C2-Ce alkynyl, -NRwaRwb, -ORWC, -(Ci-Ce alkylene)-NRwaRwb, -(Ci-C6alkylene) ORWC, -(Ci-C6alkylene)O(CH2)i-4ORwc, -NRwa- (Ci-C6alkylene)-NRwaRwb, -O-(Ci-C6alkylene) -NRwaRwb, -(C2-C10 alkenylene)- NRwaRwb, -(C2-C10 alkynylene)-NRwaRwb, -NRwa-(Co-C6alkylene) -RWY, -(Ci-C6alkylene) -RWY, -O-(CI-C6 alkylene) -RWY, -(C2-C10 alkenylene) -RWY, and -(C2-C10 alkynylene)-RWY;each RWYis, independently, selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each Rwais, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);Page 28 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO each Rwbis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-Ce alkyl)-O-(Ci-C6 alkyl), and -C(O)-(Ci-Ce alkyl);each Rwcis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Ci-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each of R11and R22is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;n is 1, 2, 3, or 4;Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, and 5-14 membered spirocyclic carbocyclyl;each REis, independently, selected from the group consisting of-CN, -NO2, halo, C1-C6 alkyl, Ci-C6haloalkyl, -C(O)Rea, -OReb, and -N(Rec)2;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya;each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Recis, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Ryais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl; ande is 0, 1, 2, 3, 4, 5, or 6.Variables - Formula Z, Formula A, Formula I, and Formula II, and Subformulas Thereof

[0066] It should be understood that the variables described herein can be combined in a variety of ways without departing from the spirit and scope of the present disclosure, whether explicit or implicit herein. For example, where reference is made to a particular variable (e.g., in any one of Formula Z, Formula A, Formula I, and Formula II, and subformulas thereof), that variable can be used in various embodiments of compositions of the present disclosure and / or in methods of the present disclosure, unless otherwise understood from the context. Where Page 29 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO variables are presented as lists, each subgroup of the variable(s) is also disclosed, and any variable(s) can be removed from the group. In other words, within this disclosure, embodiments have been described and depicted in a way that enables a clear and concise disclosure to be written and drawn, but it is intended and will be appreciated that embodiments may be variously combined or separated without parting from the present teachings and disclosure(s). For example, it will be appreciated that all variables described and depicted herein can be applicable to all aspects and embodiments of the disclosure(s) described and depicted herein. As used herein, “in some embodiments” refers to any of the aspects and embodiments of the disclosure(s) described and depicted herein.

[0067] In some embodiments, Z1is -C(O)-, Z2is O, NRZ2, or CRZ3RZ4, and represents a single bond, or Z1is N or CRZ3, Z2is N or CRZ3, and represents a double bond.

[0068] In some embodiments, Z1is -C(O)-, Z2is O, NRZ2, or CRZ3RZ4, and represents a single bond.

[0069] In some embodiments, Z1is N or CRZ3, Z2is N or CRZ3, and represents a double bond.

[0070] In some embodiments, RZ1is H.

[0071] In some embodiments, RZ1is selected from the group consisting of Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci-C6alkyl).

[0072] In some embodiments, RZ1is selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl.

[0073] In some embodiments, RZ1is Ci-Ce alkyl.

[0074] In some embodiments, RZ1is selected from the group consisting of H and Ci-Ce alkyl.

[0075] In some embodiments, RZ1is H, -Me, -Et, -nPr, - Pr, -nBu, -Bu, -sBu, or -‘Bu.

[0076] In some embodiments, RZ1is H, -Me, or -Et.

[0077] In some embodiments, RZ1is H or -Me.

[0078] In some embodiments, Z2is NRZ2.

[0079] In some embodiments, RZ2is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-Ce alkyl)-O-(Ci-Ce alkyl), and -C(O)-(Ci-Ce alkyl).

[0080] In some embodiments, RZ2is H.

[0081] In some embodiments, RZ2is selected from the group consisting of Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci-C6alkyl).

[0082] In some embodiments, RZ2is selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl.

[0083] In some embodiments, RZ2is Ci-Ce alkyl.Page 30 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0084] In some embodiments, RZ2is selected from the group consisting of H and Ci-Ce alkyl.

[0085] In some embodiments, RZ2is H, -Me, -Et, -nPr, -‘Pr, -nBu, -‘Bu, -sBu, or -‘Bu.

[0086] In some embodiments, RZ2is H, -Me, or -Et.

[0087] In some embodiments, RZ2is H or -Me.

[0088] In some embodiments, RZ2is -(Ci-Ce alkyl)-RYor RY.

[0089] In some embodiments, RZ2is -(Ci-Ce alkyl)-RY.

[0090] In some embodiments, RZ2is RY.

[0091] In some embodiments, RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl, wherein RYis unsubstituted or substituted with one or more instances of-C(O)Rya.

[0092] In some embodiments, RYis selected from the group consisting of 3-8 membered monocyclic heterocyclyl having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of-C(O)Rya.

[0093] In some embodiments, RYis selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya.

[0094] In some embodiments, RYis selected from the group consisting of 3-6 membered monocyclic carbocyclyl, wherein RYis unsubstituted or substituted with one or more instances of-C(O)Rya.

[0095] In some embodiments, RYis selected from the group consisting of 3-6 membered monocyclic heterocyclyl having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of-C(O)Rya.

[0096] In some embodiments, each Ryais, independently, -Me, -Et, -nPr, -‘Pr, -nBu, -‘Bu, -sBu, -‘Bu, -CF3, -CHF2, -CH2F, -CF2CH3, -CF(CH3)2, -CF2CF3, or-CH2CF3.

[0097] In some embodiments, RZ2is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen and oxygen.

[0098] In some embodiments, RZ2is selected from the group consisting of 3-5 membered monocyclic carbocyclyl and 3-5 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen and oxygen.

[0099] In some embodiments, RZ2is 3-4 membered monocyclic carbocyclyl and 3-4 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen and oxygen.Page 31 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0100] In some embodiments, RZ2is 3-4 membered monocyclic carbocyclyl and 3-4 membered monocyclic heterocyclyl having 1-2 oxygen atoms.

[0101] In some embodiments, RZ2is cyclopropyl, cyclobutyl, or oxetanyl.

[0102] In some embodiments,

[0103] In some embodiments,

[0104] In some embodiments,

[0105] In some embodiments,

[0106] In some embodiments, Z2is CRZ3RZ4.

[0107] In some embodiments, RZ3is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-C6haloalkyl, and -(Ci-C6alkyl)-RY.

[0108] In some embodiments, RZ3is selected from the group consisting of H, Ci-Ce alkyl, and -(Ci-C6alkyl)-RY.

[0109] In some embodiments, RZ3is selected from the group consisting of H and Ci-Ce alkyl.

[0110] In some embodiments, RZ3is H, -Me, -Et, -“Pr, -‘Pr, -nBu, -Bu, -sBu, or -‘Bu.

[0111] In some embodiments, RZ3is H, -Me, or -Et.

[0112] In some embodiments, RZ3is H or -Me.

[0113] In some embodiments, R74is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-C6haloalkyl, and -(Ci-C6alkyl)-RY.

[0114] In some embodiments, RZ4is selected from the group consisting of H, Ci-Ce alkyl, and -(Ci-C6alkyl)-RY.

[0115] In some embodiments, R74is selected from the group consisting of H and Ci-Ce alkyl.

[0116] In some embodiments, RZ4is H, -Me, -Et, -nPr, - Pr, -nBu, - Bu, -sBu, or -‘Bu.

[0117] In some embodiments, R74is H, -Me, or -Et.

[0118] In some embodiments, R74is H or -Me.

[0119] In some embodiments, RZ3and RZ4are taken together with the carbon atom to which each is attached form 3-8 membered monocyclic carbocyclylene.

[0120] In some embodiments, RZ3and RZ4are taken together with the carbon atom to which each is attached form 3-6 membered monocyclic carbocyclylene.

[0121] In some embodiments, RZ3and RZ4are taken together with the carbon atom to which each is attached form cyclopropylene or cyclobutylene.Page 32 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0122] In some embodiments, RZ3is RY.

[0123] In some embodiments, RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl, wherein RYis unsubstituted or substituted with one or more instances of-C(O)Rya.

[0124] In some embodiments, RYis selected from the group consisting of 3-8 membered monocyclic heterocyclyl having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of-C(O)Rya.

[0125] In some embodiments, RYis selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya.

[0126] In some embodiments, RYis selected from the group consisting of 3-6 membered monocyclic carbocyclyl, wherein RYis unsubstituted or substituted with one or more instances of-C(O)Rya.

[0127] In some embodiments, RYis selected from the group consisting of 3-6 membered monocyclic heterocyclyl having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of-C(O)Rya.

[0128] In some embodiments, each Ryais, independently, -Me, -Et, -nPr, -'Pr, -nBu, -'Bu, -sBu, -‘Bu, -CF3, -CHF2, -CH2F, -CF2CH3, -CF(CH3)2, -CF2CF3, or-CH2CF3.

[0129] In some embodiments, RZ3is selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen and oxygen.

[0130] In some embodiments, RZ3is selected from the group consisting of 3-5 membered monocyclic carbocyclyl and 3-5 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen and oxygen.

[0131] In some embodiments, RZ3is selected from the group consisting of 3-4 membered monocyclic carbocyclyl and 3-4 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen and oxygen.

[0132] In some embodiments, RZ3is selected from the group consisting of 3-4 membered monocyclic carbocyclyl and 3-4 membered monocyclic heterocyclyl having 1-2 oxygen atoms.

[0133] In some embodiments, RZ3is cyclopropyl, cyclobutyl, or oxetanyl.

[0134] In some embodiments,Page 33 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0135] In some embodiments,

[0136] In some embodiments,

[0137] In some embodiments,

[0138] In some embodiments, Z3is CRZ5.

[0139] In some embodiments, Z4is CRZ5.

[0140] In some embodiments, Z’’ is CRZ5.

[0141] In some embodiments, Z3is N.

[0142] In some embodiments, Z4is N.

[0143] In some embodiments, Z5is N.

[0144] In some embodiments, each RZ5is, independently, selected from the group consisting of H, Ci-C6alkyl, and Ci-Ce haloalkyl.

[0145] In some embodiments, each RZ5is, independently, selected from the group consisting of H and Ci-Ce alkyl.

[0146] In some embodiments, each RZ5is, independently, H, -Me, -Et, -nPr, - Pr, -nBu, -Bu, -sBu, or - Bu.

[0147] In some embodiments, each RZ5is, independently, H, -Me, or -Et.

[0148] In some embodiments, each RZ5is, independently, H or -Me.

[0149] In some embodiments, the structureselected from the groupconsisting of:Page 34 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0150] In some embodiments, the structureselected from the group consisting of:

[0151] In some embodiments, the structureselected from the group consisting of:

[0152] In some embodiments, the structureselected from the groupPage 35 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0153] In some embodiments, the structureselected from the groupPage 36 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0154] In some embodiments, the structureselected from the group

[0155] In some embodiments, the structureselected from the groupPage 37 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0157] In some embodiments, the structureselected from the group

[0158] In some embodiments, V1is CRV. In some embodiments, V1is N.

[0159] In some embodiments, V2is CRV. In some embodiments, V2is N.

[0160] In some embodiments, V3is CRV. In some embodiments, V3is N.

[0161] In some embodiments, V4is CRV. In some embodiments, V4is N.

[0162] each Rvis, independently, selected from the group consisting of H, halo, -NO2, -CN, Ci-C6alkyl, Ci-C6haloalkyl, C2-C6alkenyl, C2-C6alkynyl, -NRvaRvb, -ORVC, -(Ci-C6alkylene)-NRvaRvb, -(Ci-C6alkylene)ORvc, -(Ci-C6alkylene)O(CH2)i.4ORvc, -NRva-(Ci-C6alkylene)-NRvaRvb, -O-(Ci-C6alkylene)-NRvaRvb, -(C2-Cw alkenylene)-NRvaRvb, -(C2-C10Page 38 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO alkynylene)-NRvaRvb, RVY, -NRva-(Co-C6alkylene)-RVY, -(Ci-C6alkylene)-RVY, -O-(Ci-C6alkylene)-RVY, -(C2-C10 alkenylene)-RVY, and -(C2-C10 alkynylene)-RVY;

[0163] each RVYis, independently, selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RVYis unsubstituted or substituted with 1-4 instances of Rvd;

[0164] each Rvais, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-C6haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);

[0165] each Rvbis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);

[0166] each Rvcis, independently, selected from the group consisting of H, Ci-C6alkyl, Ci-Ce haloalkyl, -(Ci-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);

[0167] each Rvdis, independently, selected from the group consisting of halo, -OH, -NO2, - CN, Ci-C6alkyl, Ci-C6haloalkyl, -NRvaRvb, -ORVC, -(Ci-C6alkylene)-NRvaRvb. -(Ci-C6alkylene)ORvc, -(Ci-Ce alkylene)O(CH2)i-4ORvc, -NRva-(Ci-Cs alkylene)-NRvaRvb, -(C2-C10 alkenylene)-NRvaRvb, and -(C2-C10 alkynylene)-NRvaRvb;

[0168] In some embodiments, each Rvis, independently, selected from the group consisting of H and Ci-Ce alkyl.

[0169] In some embodiments, each Rvis, independently, H, -Me, -Et, -nPr, - Pr, -nBu, -‘Bu, -sBu, or - Bu.

[0170] In some embodiments, each Rvis, independently, H, -Me, or-Et.

[0171] In some embodiments, each Rvis, independently, H or -Me.

[0172] In some embodiments, each Rvis H.

[0173] In some embodiments, W1is CRW. In some embodiments, W1is N.

[0174] In some embodiments, W2is CRW. In some embodiments, W2is N.

[0175] In some embodiments, W3is CRW. In some embodiments, W3is N.

[0176] In some embodiments, each Rwis, independently, selected from the group consisting of H, halo, -NO2, -CN, Ci-Ce alkyl, Ci-Ce haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, -NRwaRwb, -ORWC, -(Ci-C6alkylene)-NRwaRwb, -(Ci-C6alkylene)ORwc, -(Ci-C6alkylene)O(CH2)i-4ORwc, -NRwa-(Ci-C6alkylene)-NRwaRwb, -O-(Ci-C6alkylene) -NRwaRwb, -(C2-C10 alkenylene)- NRwaRwb, -(C2-C10 alkynylene)-NRwaRwb, -NRwa-(Co-C6alkylene) -RWY, -(Ci-C6alkylene)-alkylene)-RWY, -(C2-C10 alkenylene) -RWY, and -(C2-C10 alkynylene)-RWY.Page 39 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0177] In some embodiments, each Rwis, independently, selected from the group consisting of H, halo, -NO2, -CN, Ci-Ce alkyl, Ci-Ce haloalkyl, C2-C6 alkyne, -ORWC, -O-(Ci-C6 alkylene)-NRwaRwb, and -O-(Ci-C6alkylene)-RWY.

[0178] In some embodiments, each RWYis, independently, selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0179] In some embodiments, each Rwais, independently, selected from the group consisting of H, Ci-C6alkyl, Ci-C6haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl).

[0180] In some embodiments, each Rwbis, independently, selected from the group consisting of H, Ci-C6alkyl, Ci-C6haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl).

[0181] In some embodiments, each Rwcis, independently, selected from the group consisting of H, Ci-C6alkyl, Ci-C6haloalkyl, -(Ci-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl).

[0182] In some embodiments, each Rwis, independently, H, -F, -Cl, -CN, -Me, -Et, -nPr, -

[0183] In some embodiments, each Rwis, independently, H, -F, -Cl, -CN, -Me, -Et, -CF3, -C=CCH3, or -OMe.

[0184] In some embodiments, each Rwis, independently, H, -F, -Cl, -CN, -Me, -CF3, -C=CCH3, or -OMe.

[0185] In some embodiments, each Rwis, independently, selected from the group consisting of H and Ci-Ce alkyl.

[0186] In some embodiments, each Rwis, independently, H, -Me, -Et, -nPr, -‘Pr, -nBu, -‘Bu, -sBu, or -‘Bu.

[0187] In some embodiments, each Rwis, independently, H, -Me, or -Et.

[0188] In some embodiments, each Rwis, independently, H or -Me.

[0189] In some embodiments, each Rwis H.

[0190] In some embodiments, each R11is, independently, selected from the group consisting of H and Ci-Ce alkyl.

[0191] In some embodiments, each R11is, independently, H, -Me, -Et, -nPr, -‘Pr, -nBu, - Bu, -sBu, or - Bu.Page 40 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0192] In some embodiments, each R11is, independently, H, -Me, or-Et.

[0193] In some embodiments, each R11is, independently, H or -Me.

[0194] In some embodiments, each R22is, independently, selected from the group consisting of H and Ci-Ce alkyl.

[0195] In some embodiments, each R22is, independently, H, -Me, -Et, -nPr, -‘Pr, -nBu, -‘Bu, -sBu, or -Bu.

[0196] In some embodiments, each R22is, independently, H, -Me, or -Et.

[0197] In some embodiments, each R22is, independently, H or -Me.

[0198] In some embodiments, n is 1, 2, or 3.

[0199] In some embodiments, n is 1 or 2.

[0200] In some embodiments, n is 1.

[0201] In some embodiments, Ring E is phenyl.

[0202] In some embodiments, Ring E is 3-8 membered monocyclic carbocyclyl.

[0203] In some embodiments, Ring E is 3-6 membered monocyclic carbocyclyl.

[0204] In some embodiments, Ring E is 6 membered monocyclic carbocyclyl.

[0205] In some embodiments, Ring E is cyclohexanyl.

[0206] In some embodiments, Ring E is 5-14 membered bridged bicyclic carbocyclyl.

[0207] In some embodiments, Ring E is 5-10 membered bridged bicyclic carbocyclyl.

[0208] In some embodiments, Ring E is 8-14 membered bridged bicyclic carbocyclyl.

[0209] In some embodiments, Ring E is 5-14 membered spirocyclic carbocyclyl.

[0210] In some embodiments, Ring E is 5-10 membered spirocyclic carbocyclyl.

[0211] In some embodiments, Ring E is 8-14 membered spirocyclic carbocyclyl.

[0212] In some embodiments, each REis, independently, selected from the group consisting of halo, Ci-C6alkyl, and Ci-Ce haloalkyl.

[0213] In some embodiments, each REis, independently, -F, -Cl, -Br, -Me, -Et, -nPr, -‘Pr, -nBu, -‘Bu,sBu, -‘Bu, CF3, CHF2, CH2F, CF2CH3, CF(CH3)2, CF2CF3, or CH2CF3.

[0214] In some embodiments, each REis, independently, -F, -Cl, -Br, -Me, -Et, -nPr, -‘Pr, -CF3, -CHF2, -CH2F, -CF2CH3, -CF(CH3)2. -CF2CF3, or -CH2CF3.

[0215] In some embodiments, e is 0, 1, 2, 3, or 4.

[0216] In some embodiments, e is 2.Page 41 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0217] In some embodiments,selected from the group consisting ofPage 42 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula B

[0221] Disclosed herein, in some embodiments is a compound of Formula B:Formula B,or a pharmaceutically acceptable salt thereof, wherein:RZ11is selected from the group consisting of H and Ci-Ce alkyl;Page 43 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO RZ12is selected from the group consisting of H and Ci-Ce alkyl;each of Z13, Z14, and Z15is, independently, CRZ15or N;each RZ15is, independently, selected from the group consisting of H, halo, -NO2, cyano, Ci- C6alkyl, Ci-C6haloalkyl, and -ORzb;Rzbis selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;V12is CRV1or N;RV1is selected from the group consisting of H, halo, -NO2, -CN, Ci-C,6 alkyl, Ci-Ce haloalkyl, and -ORve;Rveis selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each RW1is, independently, selected from the group consisting of halo, -NO2, -CN, Ci-Ce alkyl, Ci-C6haloalkyl, and-ORwd;Rwdis selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of R111and R122is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;nl is 1, 2, 3, or 4;Ring El is 3-8 membered monocyclic carbocyclyl;each RE1is, independently, selected from the group consisting of-CN, -NO2, halo, Ci-Ce alkyl, Ci-C6haloalkyl, -C(O)Rea, -OReh, and -N(Rec)2;each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Recis, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;Page 44 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO el is 0, 1, 2, 3, 4, 5, or 6: andfl is 0, 1, 2, or 3.Variables - Formula B, and Subformulas Thereof

[0222] It should be understood that the variables described herein can be combined in a variety of ways without departing from the spirit and scope of the present disclosure, whether explicit or implicit herein. For example, where reference is made to a particular variable (e.g., in any one of Formula B, and subformulas thereof), that variable can be used in various embodiments of compositions of the present disclosure and / or in methods of the present disclosure, unless otherwise understood from the context. Where variables are presented as lists, each subgroup of the variable(s) is also disclosed, and any variable(s) can be removed from the group. In other words, within this disclosure, embodiments have been described and depicted in a way that enables a clear and concise disclosure to be written and drawn, but it is intended and will be appreciated that embodiments may be variously combined or separated without parting from the present teachings and disclosure(s). For example, it will be appreciated that all variables described and depicted herein can be applicable to all aspects and embodiments of the disclosure(s) described and depicted herein. As used herein, “in some embodiments” refers to any of the aspects and embodiments of the disclosure(s) described and depicted herein.

[0223] In some embodiments, RZ11is H, -Me, -Et, -nPr, -‘Pr, -nBu, -‘Bu, -sBu, or-’Bu.

[0224] In some embodiments, RZ11is H or -Me.

[0225] In some embodiments, RZ11is H.

[0226] In some embodiments, RZ11is -Me.

[0227] In some embodiments, RZ12is H, -Me, -Et, -nPr, -‘Pr, -nBu, - Bu, -sBu, or - Bu.

[0228] In some embodiments, RZ12is Ci-Cs alkyl.

[0229] In some embodiments, RZ12is -Me, -Et, -nPr, -’Pr, -nBu, -’Bu, -sBu, or -’Bu.

[0230] In some embodiments, RZ12is H or -Me.

[0231] In some embodiments, RZ12is H.

[0232] In some embodiments, RZ12is -Me.

[0233] In some embodiments, Z13is CRZ13.

[0234] In some embodiments, Z14is CRZ13.

[0235] In some embodiments, Z15is CRZ15.

[0236] In some embodiments, Z13is N.

[0237] In some embodiments, Z14is N.

[0238] In some embodiments, Z15is N.Page 45 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0239] In some embodiments, each RZ15is, independently, selected from the group consisting of H, halo, Ci-C6alkyl, Ci-Ce haloalkyl, and -ORzb.

[0240] In some embodiments, each RZ15is, independently, selected from the group consisting of H and Ci-Ce alkyl.

[0241] In some embodiments, each RZ15is, independently, H, -Me, -Et, -nPr, -Pr, -nBu, -Bu, -sBu, or -lBu.

[0242] In some embodiments, each RZ15is, independently, H, -Me, or -Et.

[0243] In some embodiments, each RZ15is, independently, H or -Me.

[0244] In some embodiments, each RZ15is H.

[0245] In some embodiments, V12is CRV1.

[0246] In some embodiments, each RV1is, independently, H or Ci-C6alkyl.

[0247] In some embodiments, each RV1is, independently, H, -Me, -Et, -nPr, -Pr, -nBu, - Bu, -sBu, or -lBu.

[0248] In some embodiments, each RV1is, independently, H, -Me, or -Et.

[0249] In some embodiments, each RV1is, independently, H or -Me.

[0250] In some embodiments, each RV1is H.

[0251] In some embodiments, each RV1is -Me.

[0252] In some embodiments,is selected from the group consisting of

[0253] In some embodiments, nl is 1.

[0254] In some embodiments, Ring El is 6 membered monocyclic carbocyclyl.

[0255] In some embodiments, el is 0.

[0256] In some embodiments, fl is 0 or 1.

[0257] In some embodiments, fl is 0.

[0258] In some embodiments, fl is 1.Formula C

[0259] Disclosed herein, in some embodiments is a compound of Formula C:Page 46 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula C,or a pharmaceutically acceptable salt thereof, wherein:RZ21is selected from the group consisting of H and Ci-Ce alkyl;RZ22is selected from the group consisting of H, Ci-C.6 alkyl, -(Co-C,6 alkyl)-O-(Ci-C,6 alkyl), - (Co-C6alkyl)-O-(Ci-C6alkyl)-O-(Ci-C6alkyl), and -(Ci-C6alkyl)-RY;each of Z23, Z24, and Z25is, independently, CH or N;V22is CRV2or N;each RV2is, independently, selected from the group consisting of H, halo, and Ci-Ce alkyl;Ring W2 is selected from the group consistingeach RW2is, independently, selected from the group consisting of halo, -NO2, -CN, Ci-Ce alkyl, Ci-C6haloalkyl, and-ORwd;or alternatively, two RW2groups, together with the single carbon atom on Ring W2 that they each commonly attach to, form a cyclopropyl;Rwdis selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;Ring E2 is selected from the group consisting of phenyl and 3-8 membered monocyclic carbocyclyl;each RE2is, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected Page 47 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -Ryaor -C(O)Rya;each Ryais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl;e2 is 0, 1, 2, 3, 4, 5, or 6; andf2 is 0, 1, 2, or 3.

[0260] In some embodiments, the compound of Formula C is notpharmaceutically acceptable salt thereof.Variables - Formula C, and Subformulas Thereof

[0261] It should be understood that the variables described herein can be combined in a variety of ways without departing from the spirit and scope of the present disclosure, whether explicit or implicit herein. For example, where reference is made to a particular variable (e.g., in any one of Formula C, and subformulas thereof), that variable can be used in various embodiments of compositions of the present disclosure and / or in methods of the present disclosure, unless otherwise understood from the context. Where variables are presented as lists, each subgroup of the variable(s) is also disclosed, and any variable(s) can be removed from the group. In other words, within this disclosure, embodiments have been described and depicted in a way that enables a clear and concise disclosure to be written and drawn, but it is intended and will be appreciated that embodiments may be variously combined or separated without parting from the present teachings and disclosure(s). For example, it will be appreciated that all variables described and depicted herein can be applicable to all aspects and embodiments of the disclosure(s) described and depicted herein. As used herein, “in some embodiments” refers to any of the aspects and embodiments of the disclosure(s) described and depicted herein.

[0262] In some embodiments, RZ21is H, -Me, -Et, -nPr, -Pr, -nBu, -Bu, -sBu, or-‘Bu.

[0263] In some embodiments, RZ21is H or -Me.

[0264] In some embodiments, RZ21is H.

[0265] In some embodiments, RZ21is -Me.

[0266] In some embodiments, RZ22is H or Ci-Ce alkyl.

[0267] In some embodiments, RZ22is H, -Me, -Et, -nPr, -Pr, -nBu, - Bu, -sBu, or - Bu.Page 48 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0268] In some embodiments, RZ22is Ci-Ce alkyl.

[0269] In some embodiments, RZ22is -Me, -Et, -nPr, -Pr, -nBu, -'Bu, -sBu, or - Bu.

[0270] In some embodiments, RZ22is H or -Me.

[0271] In some embodiments, RZ22is H.

[0272] In some embodiments, RZ22is -Me.

[0273] In some embodiments, RZ22is H, Ci-Cg alkyl, -(Co-Ce alkyl)-O-(Ci-C6 alkyl), or — (Ci-C6alkyl)-O-(Ci-C6alkyl)-O-(Ci-C6alkyl).

[0274] In some embodiments, RZ22is -(Ci-Ce alkyl)-RY.

[0275] In some embodiments, RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl, wherein RYis unsubstituted or substituted with one or more instances of-C(O)Rya.

[0276] In some embodiments, RYis selected from the group consisting of 3-8 membered monocyclic heterocyclyl having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of-C(O)Rya.

[0277] In some embodiments, RYis selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya.

[0278] In some embodiments, RYis selected from the group consisting of 3-6 membered monocyclic carbocyclyl, wherein RYis unsubstituted or substituted with one or more instances of-C(O)Rya.

[0279] In some embodiments, RYis selected from the group consisting of 3-6 membered monocyclic heterocyclyl having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of-C(O)Rya.

[0280] In some embodiments, each Ryais, independently, -Me, -Et, -nPr, -'Pr, -nBu, -'Bu, -sBu, -‘Bu, CF3, CHF2, CH2F, CF2CH3, CF(CH3)2, CF2CF3, or CH2CF3.

[0281] In some embodiments, RZ22is H, -Me, -Et, -nPr, -'Pr, -nBu, -'Bu, -sBu, -Bu,Page 49 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0283] In some embodiments, Z23is CH.

[0284] In some embodiments, Z24is CH.

[0285] In some embodiments, Z25is CH.

[0286] In some embodiments, Z23is N.

[0287] In some embodiments, Z24is N.

[0288] In some embodiments, Z25is N.

[0289] In some embodiments, V22is CRV2.

[0290] In some embodiments, each RV2is, independently, H or Ci-Ce alkyl.

[0291] In some embodiments, each RV2is, independently, H, -Me, -Et, -nPr, -‘Pr, -nBu, -‘Bu, -sBu, or -‘Bu.

[0292] In some embodiments, each RV2is, independently, H, -Me, or -Et.

[0293] In some embodiments, each RV2is, independently, H or -Me.

[0294] In some embodiments, each RV2is H.

[0295] In some embodiments, each RV2is -Me.

[0296] In some embodiments, Ring E2 is selected from the group consisting of phenyl and 3-6 membered monocyclic carbocyclyl.

[0297] In some embodiments, Ring E2 is selected from the group consisting of phenyl and 6 membered monocyclic carbocyclyl.

[0298] In some embodiments, each RE2is, independently, selected from the group consisting of halo and Ci-Ce alkyl.

[0299] In some embodiments, each RE2is, independently, -F, -Cl, -Br, -Me, -Et, -nPr, -‘Pr, -“Bu, -'Bu, -sBu, or -‘Bu.

[0300] In some embodiments, each RE2is, independently, -F, -Cl, -Me, or-Et.

[0301] In some embodiments, each RE2is, independently, -F or -Me.

[0302] In some embodiments, each RE2is -F.

[0303] In some embodiments, each RE2is -Me.

[0304] In some embodiments, e2 is 0, 1, or 2.

[0305] In some embodiments, e2 is 0.

[0306] In some embodiments, e2 is 1.Page 50 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0307] In some embodiments, e2 is 2.

[0308] In some embodiments, Ring

[0309] In some embodiments, Ring W2 is

[0310] In some embodiments, f2 is 0, 1, or 2.

[0311] In some embodiments, f2 is 0.

[0312] In some embodiments, f2 is 1.

[0313] In some embodiments, f2 is 2.

[0314] In some embodiments, two RW2groups, together with the single carbon atom on Ring W2 that they each commonly attach to, form a cyclopropyl.Formula D

[0315] Disclosed herein, in some embodiments is a compound of Formula D:Formula D,or a pharmaceutically acceptable salt thereof, wherein:Q1is selected from the group consisting of a covalent bond, C1-C4 alkyl, and C2-C4 alkenyl; each Rzis, independently, selected from the group consisting of halo, NH2, Ci-Ce alkyl, Ci-Ce haloalkyl,-0-(Co-C4)-RYZ, and RYZ; or alternativelyPage 51 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO two Rzgroups that are connected to two adjacent carbon atoms on Ring Z, which is a phenyl, together with the two adjacent carbon atoms on Ring Z, form a Ring Z1 that is fused to Ring Z;Ring Z1 is 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur or a 6-membered heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring Z1 is unsubstituted or substituted with 1 -4 instances of Rzc;RYZis selected from the group consisting of phenyl, 5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Rzbis selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rzcis, independently, selected from the group consisting of halo, C1-C3 alkyl, C1-C3 alkoxy, and C1-C3 haloalkyl;z is 0, 1, 2, 3, or 4;V32is CRV3or N;RV3is selected from the group consisting of H, halogen, and Ci-Ce alkyl;each of W31, W32, and W33is, independently, CRW3or N;each RW3is, independently, selected from the group consisting of H, halogen, and Ci-Ce alkyl; each of R311and R322is, independently, selected from a group consisting of H, halogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;n3 is 1, 2, 3, or 4;Ring E3 is selected from the group consisting of phenyl and 3-8 membered monocyclic carbocyclyl;each RE3is, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl; ande3 is 0, 1, 2, 3, 4, 5, or 6.Variables - Formula D, and Subformulas Thereof

[0316] It should be understood that the variables described herein can be combined in a variety of ways without departing from the spirit and scope of the present disclosure, whether explicit or implicit herein. For example, where reference is made to a particular variable (e.g., in any one of Formula D, and subformulas thereof), that variable can be used in various embodiments of compositions of the present disclosure and / or in methods of the present disclosure, unless Page 52 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO otherwise understood from the context. Where variables are presented as lists, each subgroup of the variable(s) is also disclosed, and any variable(s) can be removed from the group. In other words, within this disclosure, embodiments have been described and depicted in a way that enables a clear and concise disclosure to be written and drawn, but it is intended and will be appreciated that embodiments may be variously combined or separated without parting from the present teachings and disclosure(s). For example, it will be appreciated that all variables described and depicted herein can be applicable to all aspects and embodiments of the disclosure(s) described and depicted herein. As used herein, “in some embodiments” refers to any of the aspects and embodiments of the disclosure(s) described and depicted herein.

[0317] In some embodiments, wherein Q1is a covalent bond.

[0318] In some embodiments, Q1is C1-C4 alkyl or C2-C4 alkenyl.

[0319] In some embodiments,

[0320] In some embodiments, z is 0, 1, or 2.

[0321] In some embodiments, each Rzis, independently, selected from the group consisting of Ci-C6alkyl, -O-(Ci-C4)-Rzb, -C(O)-(CI-C4)-RYZ, and RYZ.

[0322] In some embodiments, RYZis selected from the group consisting of phenyl, pyridinonyl, pyrrolidinonyl, imidazolyl, thiazolyl, pyridinyl, tetrahydrofuranyl, and piperidinyl.

[0324] In some embodiments, V32is CRV3.

[0325] In some embodiments, each RV3is, independently, H or Ci-Ce alkyl.Page 53 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0326] In some embodiments, each RV3is, independently, H, -Me, -Et, -nPr, - Pr, -nBu, - Bu, -sBu, or -lBu.

[0327] In some embodiments, n3 is 1.

[0328] In some embodiments, Ring E3 is phenyl.

[0329] In some embodiments, Ring E3 is 6 membered monocyclic carbocyclyl.Formula E

[0330] Disclosed herein, in some embodiments is a compound of Formula E:Formula E,or a pharmaceutically acceptable salt thereof, wherein:RZ41is selected from the group consisting of H and Ci-Ce alkyl;RZ42is selected from the group consisting of H, Ci-Ce alkyl, and -(Ci-Ce alkyl)-RY;RV4ais selected from the group consisting of Ci-Ce alkyl and 3-6 membered monocyclic carbocyclyl;Q2is a covalent bond or N, wherein:when Q2is N, then:Q3is Ci-Ce alkyl,alkyl, and Q2and RVYare taken together with the carbon atom to which each is attached to form 5-6 membered heterocyclyl, andwhen Q2is a covalent bond, then:Page 54 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO Q3is selected from the group consisting of a covalent bond, Ci-Ce alkyl,Rqnis selected from the group consisting of H, Ci-Ce alkyl and phenyl optionally substituted with one or more groups selected from halo, C1-C3 alkyl, and C1-C3 haloalkyl; each of R?and R66is, independently, selected from a group consisting of H, halogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;ql is 0, 1, 2, 3, or 4;Ring E4 is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, 5-14 membered spirocyclic carbocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered bicyclic heteroaryl, and 8-10 membered bicyclic heterocyclyl;each RE4is, independently, selected from the group consisting of-CN, -NCh, halo, Ci-C6 alkyl, Ci-Ce haloalkyl, -C(O)Rea, -OR*. -N(Rec)2, and REY:REYis selected from the group consisting of phenyl and 5-6 membered monocyclic heterocyclyl, wherein REYis unsubstituted or substituted with 1-3 instances of Red;each Redis, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl; ande4 is 0, 1, 2, 3, 4, 5, or 6.Variables - Formula E, and Subformulas Thereof

[0331] It should be understood that the variables described herein can be combined in a variety of ways without departing from the spirit and scope of the present disclosure, whether explicit or implicit herein. For example, where reference is made to a particular variable (e.g., in any one of Formula E, and subformulas thereof), that variable can be used in various embodiments of compositions of the present disclosure and / or in methods of the present disclosure, unless otherwise understood from the context. Where variables are presented as lists, each subgroup of the variable(s) is also disclosed, and any variable(s) can be removed from the group. In other Page 55 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO words, within this disclosure, embodiments have been described and depicted in a way that enables a clear and concise disclosure to be written and drawn, but it is intended and will be appreciated that embodiments may be variously combined or separated without parting from the present teachings and disclosure(s). For example, it will be appreciated that all variables described and depicted herein can be applicable to all aspects and embodiments of the disclosure(s) described and depicted herein. As used herein, “in some embodiments” refers to any of the aspects and embodiments of the disclosure(s) described and depicted herein.

[0332] In some embodiments, R241is H, -Me, -Et, -nPr, -Pr, -nBu, -Bu, -sBu, or -‘Bu.

[0333] In some embodiments, R741is H or -Me.

[0334] In some embodiments, R241is H.

[0335] In some embodiments, R241is -Me.

[0336] In some embodiments, R242is selected from the group consisting of H, Ci-Ce alkyl, and -(Ci-C6alkyl)-RY.

[0337] In some embodiments, R242is H, -Me, -Et, -nPr, -Pr, -nBu, - Bu, -sBu, or - Bu.

[0338] In some embodiments, R242is H or -Me.

[0339] In some embodiments, R242is H.

[0340] In some embodiments, R242is -Me.

[0341] In some embodiments, R242is -(Ci-Ce alkyl)-RY.

[0342] In some embodiments, RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl, wherein RYis unsubstituted or substituted with one or more instances of-C(O)Rya.

[0343] In some embodiments, RYis selected from the group consisting of 3-8 membered monocyclic heterocyclyl having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of-C(O)Rya.

[0344] In some embodiments, RYis selected from the group consisting of 3-6 membered monocyclic carbocyclyl and 3-6 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya.

[0345] In some embodiments, RYis selected from the group consisting of 3-6 membered monocyclic carbocyclyl, wherein RYis unsubstituted or substituted with one or more instances of-C(O)Rya.

[0346] In some embodiments, RYis selected from the group consisting of 3-6 membered monocyclic heterocyclyl having 1 -3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya.Page 56 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0347] In some embodiments, each Ryais, independently, -Me, -Et, -nPr, -Pr, -nBu, -‘Bu, -sBu, -‘Bu, -CF3, -CHF2, -CH2F, -CF2CH3, -CF(CH3)2, -CF2CF3, or-CH2CF3.

[0349] In some embodiments, RV4ais -Me, -Et, -nPr, -‘Pr, -nBu, - Bu, -sBu, or -‘Bu.

[0351] In some embodiments, Q2is N, Q3is Ci-Ce alkyl,alkyl, and Q2and RVYare taken together with the carbon atom to which each is attached to form 5-6 membered heterocyclyl.

[0352] In some embodiments, Q2is a covalent bond, Q3is selected from the group consisting

[0353] In some embodiments, Q3is a covalent bond.

[0354] In some embodiments, Q3is Ci-Ce alkyl,

[0355] In some embodiments, Q4is hydrogen.Page 57 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0356] In some embodiments,

[0357] In some embodiments, Ring E4 is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, or 5-14 membered spirocyclic carbocyclyl.

[0358] In some embodiments, Ring E4 is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, or 5-6 membered monocyclic heteroaryl.

[0359] In some embodiments, Ring E4 is phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl.

[0360] In some embodiments, Ring E4 is phenyl or 3-8 membered monocyclic carbocyclyl.

[0361] In some embodiments, Ring E4 is phenyl.

[0362] In some embodiments, Ring E4 is 3-8 membered monocyclic carbocyclyl.

[0363] In some embodiments, Ring E4 is 5 membered monocyclic carbocyclyl.

[0364] In some embodiments, Ring E4 is 6 membered monocyclic carbocyclyl.

[0365] In some embodiments, each RE4is, independently, selected from the group consisting of halo and Ci-Ce alkyl.

[0366] In some embodiments, each RE4is, independently, -F, -Cl, -Br, -Me, -Et, -nPr, -Pr, -nBu, - Bu, -sBu, or -*Bu.

[0367] In some embodiments, each RE4is, independently, -F, -Cl, -Me, or -Et.

[0368] In some embodiments, each RE4is, independently, -F or -Me.

[0369] In some embodiments, each RE4is -F.

[0370] In some embodiments, each RE4is -Me.

[0371] In some embodiments, e4 is 0, 1, or 2.

[0372] In some embodiments, e4 is 0.

[0373] In some embodiments, e4 is 1.

[0374] In some embodiments, e4 is 2.Exemplary Compounds of the Disclosure

[0375] In some embodiments, the compound is of Formula LA:Page 58 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula I-A,or a pharmaceutically acceptable salt thereof,

[0376] In some embodiments, the compound is of any one of Formula I-B to Formula I-I:Page 59 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 60 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOor a pharmaceutically acceptable salt thereof.

[0377] In some embodiments, the compound is of Formula I-A-i:Formula I-A-i,or a pharmaceutically acceptable salt thereof.

[0378] In some embodiments, the compound is of any one of Formula I-B-i to Formula I-I-i:Page 61 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 62 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 63 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOor a pharmaceutically acceptable salt thereof.

[0380] In some embodiments, the compound is of any one of Formula I-J-i to Formula I-K-or a pharmaceutically acceptable salt thereof.

[0381] In some embodiments, the compound is of any one of Formula I-B-l to Formula I-B-6:Page 64 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula I-B-3, Formula I-B-4,Page 65 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOor a pharmaceutically acceptable salt thereof.

[0382] In some embodiments, the compound is of any one of Formula I-B-l-i to Formula I- B-6 -i:Page 66 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 67 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 68 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula I-C-5,or a pharmaceutically acceptable salt thereof.

[0384] In some embodiments, the compound is of any one of Formula I-C-l-i to Formula I- C-5-i:Page 69 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula I-C-5-i,or a pharmaceutically acceptable salt thereof.

[0385] In some embodiments, the compound is of any one of Formula I-D-l to Formula I- D-5:Page 70 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 71 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula I-D-5,or a pharmaceutically acceptable salt thereof.

[0386] In some embodiments, the compound is of any one of Formula I-D-l-i to Formula I- D-5-i:Page 72 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula I-D-5-i,or a pharmaceutically acceptable salt thereof.

[0387] In some embodiments, the compound is of any one of Formula I-H-l to Formula I- H-4:Page 73 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula I-H-3, Formula I-H-4,or a pharmaceutically acceptable salt thereof.

[0388] In some embodiments, the compound is of any one of Formula I-H-l-i to Formula I- H-4-i:Page 74 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula I-H-3-i, Formula I-H-4-i,or a pharmaceutically acceptable salt thereof.

[0389] In some embodiments, the compound is any one of Formula I-G-l to Formula I-G-7:Page 75 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula I-G-3, Formula I-G-4,Page 76 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula I-G-7,or a pharmaceutically acceptable salt thereof.

[0390] In some embodiments, the compound is of any one of Formula I-G-l-i to Formula I- G-7-i:Page 77 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 78 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula I-G-7-i,or a pharmaceutically acceptable salt thereof.

[0391] In some embodiments, the compound is of Formula A-l:Page 79 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula A-l,or a pharmaceutically acceptable salt thereof.

[0392] In some embodiments, the compound is of Formula II-A:Formula II- A,or a pharmaceutically acceptable salt thereof.

[0393] In some embodiments, the compound is of any one of Formula II-B to Formula II -J:Page 80 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 81 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 82 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula II- J,or a pharmaceutically acceptable salt thereof.

[0394] In some embodiments, the compound is of any one of Formula ILK to Formula ILL:Formula ILK, Formula ILL,or a pharmaceutically acceptable salt thereof.

[0395] In some embodiments, the compound is of any one of Formula ILK-i to Formula II- L-i:Page 83 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0396] Disclosed herein, in some embodiments, is a compound of Table 1. or a pharmaceutically acceptable salt thereof.Table 1. Exemplary CompoundsPage 84 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 85 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 86 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 87 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 88 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 89 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 90 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 91 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 92 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 93 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 94 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 95 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 96 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 97 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 98 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 99 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 100 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 101 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 102 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 103 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 104 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 105 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 106 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 107 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 108 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 109 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 110 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 111 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 112 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 113 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 114 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 115 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 116 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 117 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 118 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 119 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 120 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 121 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 122 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 123 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 124 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 125 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 126 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 127 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 128 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 129 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 130 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 131 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 132 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 133 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 134 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 135 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 136 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 137 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 138 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 139 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 140 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 141 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0397] In some embodiments, one or more hydrogen atoms of the compound is replaced by deuterium.

[0398] In some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, adjuvant, or vehicle. For example, in some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, adjuvant, or vehicle. In some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, or Formula E, or a subformula thereof, as defined above, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, adjuvant, or vehicle. In some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound set forth in Table 1 above, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, adjuvant, or vehicle. In some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound set forth in Table 1 above, together with a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[0399] In some embodiments, the present disclosure provides a compound of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, or Formula E, or a subformula thereof, as defined above, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, or Formula E, or a subformula thereof, as defined above, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle for use as a medicament.

[0400] In some embodiments, the present disclosure also provides a compound described herein, or pharmaceutical compositions described herein, for use in a method for modulating IRF5 as described herein and / or in a method for treating an IRF5-mediated disorder as described herein. In some embodiments, the present disclosure also provides a compound described herein, or pharmaceutical compositions described herein, for use in a method for modulating IRF5 as described herein. In some embodiments, the present disclosure also provides a compound described herein, or pharmaceutical compositions described herein, for use in a method for treating an IRF5-mediated disorder as described herein.

[0401] Disclosed herein, in some embodiments, is a pharmaceutical composition comprising a compound disclosed herein, and a pharmaceutically acceptable excipient thereof.Page 142 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0402] Disclosed herein, in some embodiments, is a method of modulating IRF5 in a subject or a biological sample, wherein the method comprises administering to the subject or the biological sample a compound disclosed herein, or a pharmaceutical composition disclosed herein.

[0403] Disclosed herein, in some embodiments, is a method of treating an IRF5-mediated disease or disorder in a subject in need thereof, wherein the method comprises administering to the subject a compound disclosed herein, or a pharmaceutical composition disclosed herein.

[0404] In some embodiments, the IRF5-mediated disease or disorder is an autoimmune disease.Pharmaceutical Compositions

[0405] Compounds disclosed herein (e.g., compounds of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, and Formula E, and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof) are administered alone or as pharmaceutical compositions comprising the compounds disclosed herein and one or more pharmaceutically acceptable excipients.

[0406] Disclosed herein, in some embodiments, is a pharmaceutical composition comprising a compound disclosed herein (e.g., compounds of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, and Formula E, and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof) and a pharmaceutically acceptable excipient (i.e., one or more pharmaceutically acceptable excipients).

[0407] The compounds disclosed herein are used in free base forms, salt forms, or solvate forms, or as prodrugs. All forms are within the compositions (e.g., pharmaceutical compositions) described herein. The disclosed compounds, or salts, solvates, or prodrugs thereof, are administered to a subject in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art.

[0408] Pharmaceutical compositions described herein are preferably formulated for administration to a subject (e.g., a human) in a biologically compatible form suitable for administration in vivo. Pharmaceutical compositions comprising compounds disclosed herein (e.g., compounds of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, and Formula E, and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof) are useful for treating a disease or disorder, or symptoms thereof, described herein.

[0409] The dosage of the compounds disclosed herein (e.g., compounds of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, and Formula E,Page 143 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof) in the pharmaceutical compositions, as well as the amount of the pharmaceutical composition administered to a subject, can vary depending on factors such characteristics of the subject (e.g., age, health, weight, and gender); the nature and extent of the symptoms; the frequency of treatment; the mode of administration of the pharmaceutical compositions; the solubility of the compounds in the pharmaceutical compositions; the potency and activity of the compounds; and the pharmacodynamic properties of the compound. The dosage of the compounds disclosed here (e.g., compounds of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, and Formula E, and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof) or compositions comprising compounds disclosed herein are varied to achieve a desired therapeutic response for a particular subject, composition, or mode of administration, without being toxic to the subject.

[0410] The present disclosure also provides kits including pharmaceutical compositions comprising compounds disclosed herein (e.g., compounds of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, and Formula E, and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof) and package inserts with instructions to perform any of the methods described herein.

[0411] Disclosed herein, in some embodiments, is a process for providing a pharmaceutical composition comprising a compound disclosed herein (e.g., compounds of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, and Formula E, and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof).Methods of Use and Treatment

[0412] Compounds disclosed herein (e.g., compounds of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, and Formula E, and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof) and compositions comprising said compounds as described herein are generally useful for modulating IRF5 (e.g., inhibiting IRF5).

[0413] Disclosed herein, in some embodiments, is a method of modulating (e.g., inhibiting) IRF5, or a mutant thereof, in a subject, the method comprising administering to said subject a compound disclosed herein, or a pharmaceutical acceptable salt thereof (e.g., a compound of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, or Page 144 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO Formula E, or a subformula thereof, or a compound of Table 1, or a pharmaceutically acceptable salts thereof), or pharmaceutically acceptable composition thereof.

[0414] Also disclosed herein, in some embodiments, is a method of modulating (e.g., inhibiting) IRF5, or a mutant thereof, in a biological sample, the method comprising contacting said biological sample with a compound disclosed herein, or a pharmaceutical acceptable salt thereof (e.g., a compound of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, or Formula E, or a subformula thereof, or a compound of Table 1, or a pharmaceutically acceptable salts thereof), or pharmaceutically acceptable composition thereof.

[0415] The term “biological sample”, as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof. In some embodiments, the IRF5 is from a biological sample. In some embodiments, the biological sample is taken from a subject (e.g., a patient).

[0416] Modulation (e.g., inhibition) of IRF5, or a mutant thereof, activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, blood transfusion, organ-transplantation, biological specimen storage, and biological assays.

[0417] Also disclosed herein, in some embodiments, is a method of modulating (e.g., inhibiting) IRF5, or a mutant thereof, activity in a subject, the method comprising administering to said subject a compound disclosed herein, or a pharmaceutical acceptable salt thereof (e.g., a compound of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, or Formula E, or a subformula thereof, or a compound of Table 1, or a pharmaceutically acceptable salts thereof), or pharmaceutically acceptable composition thereof.

[0418] Also disclosed herein, in some embodiments, is a method for treating a disease or disorder mediated by IRF5, or a mutant thereof, in a subject (e.g., a patient) in need thereof, the method comprising administering to said subject a compound disclosed herein, or a pharmaceutical acceptable salt thereof (e.g., a compound of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, or Formula E, or a subformula thereof, or a compound of Table 1, or a pharmaceutically acceptable salts thereof), or pharmaceutically acceptable composition thereof.

[0419] Disclosed herein, in some embodiments, is a method of modulating (e.g., inhibiting) IRF5 in a subject (e.g., a patient), wherein the method comprises administering to said subject a compound disclosed herein, or a pharmaceutical acceptable salt thereof, (e.g., compounds of Page 145 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, and Formula E, and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof), wherein the method results in the subject having a reduced IRF5 level relative to the subject prior to administering the compound described herein, or a pharmaceutical acceptable salt thereof. In some embodiments, the IRF5 is from a biological sample. In some embodiments, the biological sample is taken from the subject.

[0420] Disclosed herein, in some embodiments, is a method of modulating (e.g., inhibiting) IRF5 in a subject in need thereof (e.g., a patient), wherein the method comprises administering to said subject a compound described herein, or a pharmaceutical acceptable salt thereof, (e.g., compounds of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, and Formula E, and subformulas thereof, and compounds of Table 1, and pharmaceutically acceptable salts thereof); and wherein the method results in the subject having a reduced IRF5 level relative to an untreated subject with the same IRF5-mediated disorder, disease, or condition. In some embodiments, the IRF5 is from a biological sample. In some embodiments, the biological sample is taken from the subject.

[0421] Also disclosed herein, in some embodiments, is a method for treating an IRF5-mediated disease or disorder in a subject (e.g., a patient) in need thereof, the method comprising administering to said subject a compound disclosed herein, or a pharmaceutical acceptable salt thereof (e.g., a compound of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, or Formula E, or a subformula thereof, or a compound of Table 1, or a pharmaceutically acceptable salts thereof), or pharmaceutically acceptable composition thereof. Exemplary diseases and disorders are described in herein.

[0422] Also disclosed herein, in some embodiments, is a method of treating an IRF5-mediated disorder, disease, or condition in a subject in need thereof, wherein the method comprises administering to said subject a compound described herein, or a pharmaceutical acceptable salt thereof (e.g., a compound of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, or Formula E, or a subformula thereof, or a compound of Table 1, or a pharmaceutically acceptable salts thereof), or pharmaceutically acceptable composition thereof; and wherein the method results in the subject having a reduced IRF5 level relative to the subject prior to administering the compound described herein, or a pharmaceutical acceptable salt thereof. In some embodiments, the IRF5 is from a biological sample. In some embodiments, the biological sample is taken from the subject.

[0423] Also disclosed herein, in some embodiments, is a method of treating an IRF5-mediated disorder, disease, or condition in a subject in need thereof, wherein the method comprises Page 146 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO administering to said subject a compound described herein, or a pharmaceutical acceptable salt thereof (e.g., a compound of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, or Formula E, or a subformula thereof, or a compound of Table 1, or a pharmaceutically acceptable salts thereof), or pharmaceutically acceptable composition thereof; and wherein the method results in the subject having a reduced IRF5 level relative to an untreated subject with the same IRF5-mediated disorder, disease, or condition. In some embodiments, the IRF5 is from a biological sample. In some embodiments, the biological sample is taken from the subject.

[0424] The activity of a compound disclosed herein as an inhibitor of IRF5 may be assayed in vitro, in vivo, or in a cell line. Detailed conditions for assaying a compound disclosed herein as an inhibitor of IRF5 proteins are set forth in the Examples below.

[0425] Compounds disclosed herein are inhibitors of IRF5 protein and are therefore useful for treating one or more disorders associated with activity of IRF5 protein. Thus, in some embodiments, disclosed herein is a method for treating an IRF5 -mediated disorder comprising the step of administering to a subject in need thereof a compound disclosed herein, or a pharmaceutically acceptable salt thereof (e.g., a compound of Formula Z, Formula A, Formula I, Formula II, Formula B, Formula C, Formula D, or Formula E, or a subformula thereof, or a compound of Table 1, or a pharmaceutically acceptable salts thereof), or pharmaceutically acceptable composition thereof.

[0426] Disclosed herein, in some embodiments, is a method for treating one or more disorders, diseases, and / or conditions wherein the disorder, disease, or condition is an autoimmune disease.

[0427] Diseases and conditions treatable or treated according to the methods disclosed herein include, but are not limited to, ankylosing spondylitis, arthritis, asthma, autoimmune hepatitis, chronic obstructive pulmonary disease, Crohn’s disease, dermatomyositis, vasculitis, inflammatory bowel disease, juvenile idiopathic arthritis, lupus nephritis, myositis, polymyositis, psoriasis, rheumatoid arthritis, psoriatic arthritis, sclerosing cholangitis, Sjogren syndrome, cutaneous lupus erythematosus (CLE), discoid lupus erythematosus (DLE), systemic lupus erythematosus (SLE), systemic scleroderma, Type 1 diabetes mellitus, ulcerative colitis, macrophage activation syndrome (MAS), multiple sclerosis (MS), primary biliary cirrhosis (PBC), myocardial inflammation, and atherosclerosis. In some embodiments, the disease or condition treatable according to the methods disclosed herein is selected from the group consisting of ankylosing spondylitis, arthritis, asthma, autoimmune hepatitis, chronic obstructive pulmonary disease, Crohn’s disease, dermatomyositis, inflammatory bowel disease,Page 147 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO juvenile idiopathic arthritis, lupus nephritis, myositis, polymyositis, psoriasis, rheumatoid arthritis, sclerosing cholangitis, Sjogren syndrome, systemic lupus erythematosus, systemic scleroderma, Type 1 diabetes mellitus, and ulcerative colitis. In some embodiments, the disease or condition treatable or treated according to the methods disclosed herein is systemic lupus erythematosus (SLE). In some embodiments, the disease or condition treatable or treated according to the methods disclosed herein is cutaneous lupus erythematosus (CLE). In some embodiments, the disease or condition treatable or treated according to the methods disclosed herein is discoid lupus erythematosus (DLE). In some embodiments, the disease or condition treatable or treated according to the methods disclosed herein is Sjogren syndrome. In some embodiments, the disease or condition treatable or treated according to the methods disclosed herein is lupus nephritis. In some embodiments, the disease or condition treatable or treated according to the methods disclosed herein is ulcerative colitis. In some embodiments, the disease or condition treatable or treated according to the methods disclosed herein is rheumatoid arthritis. In some embodiments, the disease or condition treatable or treated according to the methods disclosed herein is systemic scleroderma.EXAMPLES

[0428] The compounds disclosed may be prepared or isolated in general by synthetic and / or semi-synthetic methods known to those skilled in the art for analogous compounds.General Synthetic Methods

[0429] The following examples are intended to illustrate the invention and are not to be construed as being limitations thereon. Temperatures are given in degrees centigrade. If not mentioned otherwise, all evaporations are performed under reduced pressure, preferably between about 15 mm Hg and 100 mm Hg (= 20-133 mbar). The structure of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g., microanalysis and spectroscopic characteristics, e.g., MS, IR, NMR. Abbreviations used are those conventional in the art.

[0430] All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents, and catalysts utilized to synthesis the compounds of the present invention are either commercially available or can be produced by organic synthesis methods known to one of ordinary skill in the art (Houben-Weyl 4th Ed. 1952, Methods of Organic Synthesis, Thieme, Volume 21). Further, the compounds of the present invention can be produced by organic synthesis methods known to one of ordinary skill in the art as shown in the following examples.

[0431] All reactions are carried out under nitrogen or argon unless otherwise stated.Page 148 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0432] Proton NMR (’ll NMR) is conducted in deuterated solvent. In certain compounds disclosed herein, one or more ’ll shifts overlap with residual proteo solvent signals; these signals have not been reported in the experimental provided hereinafter.Table 2. Analytical instruments

[0433] For acidic LCMS data: LCMS was recorded on an Agilent 1200 Series LC / MSD or Shimadzu LCMS2020 equipped with electro-spray ionization and quadruple MS detector [ES+ve to give MH+] and equipped with Chromolith Flash RP-18e 25*2.0 mm, eluting with 0.0375 vol% TFA in water (solvent A) and 0.01875 vol% TFA in acetonitrile (solvent B). Other LCMS was recorded on an Agilent 1290 Infinity RRLC attached with Agilent 6120 Mass detector. The column used was BEH C18 50*2.1 mm, 1.7 micron. Column flow was 0.55 ml / min and mobile phase were used (A) 2 mM Ammonium Acetate in 0.1 % Formic Acid in Water and (B) 0.1 % Formic Acid in Acetonitrile.

[0434] For basic LCMS data: LCMS was recorded on an Agilent 1200 Series LC / MSD or Shimadzu LCMS 2020 equipped with electro-spray ionization and quadruple MS detector [ES+ve to give MH+] and equipped with Xbridge C18, 2.1X50 mm columns packed with 5 mm C18-coated silica or Kinetex EVO C18 2.1X30mm columns packed with 5 mm CIS-coated silica, eluting with 0.05 vol% NH₃·H₂O in water (solvent A) and acetonitrile (solvent B).

[0435] HPLC Analytical Method: HPLC was carried out on X Bridge C18 150*4.6 mm, 5 micron. Column flow was 1.0 ml / min and mobile phase were used (A) 0.1 % Ammonia in water and (B) 0.1 % Ammonia in Acetonitrile.

[0436] Prep HPLC Analytical Method: The compound was purified on Shimadzu LC-20AP and UV detector. The column used was X-BRIDGE C18 (250*19)mm, 5p. Column flow was 16.0 ml / min. Mobile phase were used (A) 0.1% Formic Acid in Water and (B) Acetonitrile Page 149 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO Basic method used (A) 5mM ammonium bicarbonate and 0.1% NH3 in Water and (B) Acetonitrile or (A) 0.1% Ammonium Hydroxide in Water and (B) Acetonitrile. The UV spectra were recorded at 202nm & 254nm.

[0437] NMR Method: The 1H NMR spectra were recorded on a Bruker Ultra Shield Advance 400 MHz / 5 mm Probe (BBFO). The chemical shifts are reported in part-per-million.

[0438] In some instances, intermediates and compounds described in the examples comprise one or more stereocenters and more than one enantiomer / diastereomer was produced. In some embodiments, these enantiomers / diastereomers were separated and isolated, although stereochemistry was not resolved. Unless otherwise stated, stereochemistry was assigned arbitrarily. For intermediates, each enantiomer / diastereomer with arbitrarily assigned stereochemistry may result in a final compound (e.g., assigned a “I-” number), which also maintains the arbitrarily assigned stereochemistry. Accordingly, any compound with arbitrarily assigned stereochemistry or produced from an intermediate with arbitrarily assigned stereochemistry may be depicted herein as a certain stereoisomer, but it is understood that such compound may be the other stereoisomer (i.e., enantiomer or diastereomer).

[0439] As depicted in the Examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures. It will be appreciated that, although the general methods depict the synthesis of certain compounds of the present invention, the following general methods, and other methods known to one of ordinary skill in the art, can be applied to all compounds and subclasses and species of each of these compounds, as described herein.Page 150 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO Example 1. General Scheme - General Synthesis of IRF5 InhibitorsGeneral Scheme 1

[0440] Unless specifically defined otherwise within the schemes themselves, all variables in General Scheme 1 are as defined in any one of Formula Z, and subformulas thereof.Page 151 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0441] In General Scheme 1, the reactions N-alkylation, palladium-catalyzed coupling, etherification / copper-mediated cross-coupling, and ring formation are indicated with dotted lines. Each of these reactions is expanded within the scheme and is described in the following accompanying text.Etherification or copper-mediated cross-coupling

[0442] The C-0 bond of the ether linkage between the 6-membered heteroaryl and the 9-membered heteroaryl was formed by either etherification or with copper-mediated crosscoupling between a phenol on the 6-membered heteroaryl and an aryl halide on the 9-membered heteroaryl or alternatively, between a phenol on the 9-membered heteroaryl and an aryl halide on the 6-membered heteroaryl. These types of methodologies are exemplified in the Intermediate B, Intermediate L and Intermediate O syntheses.Palladium-catalyzed coupling or copper catalyzed amination

[0443] Synthesizing the C-C bond between the 6-membered heteroaryl and the 5-membered heteroaryl was achieved using palladium-catalyzed coupling of an aryl (pseudo)halide on the 6-membered heteroaryl with a tributyl tin reagent on the 5-membered heteroaryl via Stille coupling. These reactions were performed as described in Example 1-1 (Method 1). Alternatively, this bond was formed via a Suzuki coupling of an aryl (pseudo)halide on the 6-membered heteroaryl with a boronic acid or ester reagent on the 5-membered heteroaryl. These reactions were performed as described in Example 1-14 (Method 2). When a C-N bond exists between the 6-membered heteroaryl and the 5 -membered heteroaryl, copper catalyzed amination between an aryl (pseudo)halide on the 6-membered heteroaryl with the amine on the 5 -membered heteroaryl was employed, as described in Example 1-207 (Method 3).5-Membered heteroaryl ring formation

[0444] The 5-membered heteroaryl ring was formed using palladium and copper catalyzed cyclization of an azide on the alkyl group moiety and an alkyne on the 6-membered heteroaryl, as described in the Example 1-26 synthesis.N-Alkylation, etherification and alkylation

[0445] The C-N bond between the 5-membered heteroaryl and Ring E was accomplished via an N-alkylation between an amine on the 5-membered heteroaryl and a halide or an alcohol on Ring E, as seen in the methodology described for Intermediate D and Intermediate G. The C-O bond between the 5-membered heteroaryl and Ring E was accomplished via coupling an alkyl alcohol and a heteroaromatic alcohol using triphenylphosphine and diisopropyl azodicarboxylate, as seen in Intermediate AD and Intermediate AF syntheses. The 5 -membered heteroaryl ring was also further substituted by etherification of an alcohol on the 5-membered Page 152 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO ring with an alkyl halide, as exemplified in Intermediate V and Intermediate X syntheses. A further alkyl group was also added to the 5 membered heteroaryl group via alkylation with a leaving group (such as tosylate) on the alkyl portion with a halide on the heteroaryl ring, as described in the Intermediate Z synthesisN -alkylation, palladium-catalyzed coupling, and ring formation

[0446] Ring Z was alkylated with various groups via an N-alkylation between an amine and a halide on Ring Z, as exemplified in Intermediate F synthesis. Alternatively, a C-C bond could be formed via Pd-catalyzed coupling of a boronic acid or ester with the halide on Ring Z. Furthermore, The C-C bond was formed via photochemistry between a halide on Ring Z and a phenol on the alkyl group, as described in Intermediate J synthesis. Ring fomration was subsequently achieved by reacting the amines on Ring Z with an activating agent, such as phosgene or CDI, as exemplified in Intermediate F synthesis.Example 2. Synthesis of Intermediates4-Hydroxy-l-(2-methoxyethyl)-l,3-dihydro-2H-benzo[d]imidazol-2-one (Intermediate A)Step 1 - l-fluoro-3-(methoxymethoxy)-2-nitrobenzene

[0447] To a solution of 3-fluoro-2-nitrophenol (10 g, 60 mmol) in DMF (50 mL) was added K2CO3 (17.6 g, 127 mmol) and bromo(methoxy)methane (11.9 g, 95.5 mmol, 7.79 mL, CAS# 13057-17-5) and the mixture was stirred at 25 °C for 12 h. Upon completion, the reaction mixture was quenched with water (100 mL) at 20 °C, and extracted with EtOAc (300 mL x 2). The combined organic layers were washed with brine (200 mL x 2), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column Page 153 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO chromatography (S1O2, Petroleum ether / Ethyl acetate=l / O to 10 / 1) to afford the title compound (11.8 g, 79% yield) as a light yellow liquid. LC-MS (ESI+) m / z 155.9 (M-46H)’;1H NMR (400 MHz, DMSO-d6) 3 = 7.62 (dt, J = 6.8, 8.8 Hz, 1H), 7.27 (d, 7 = 8.8 Hz, 1H), 7.19 (t, 7= 9.2 Hz, 1H), 5.38 (s, 2H), 3.39 (s, 3H).Step 2 - N-(2-methoxyethyl)-3-(methoxymethoxy)-2-nitroaniline

[0448] To a solution of l-fhioro-3-(methoxymethoxy)-2-nitro-benzene (3.53 g, 14.9 mmol) and 2-methoxyethanamine (1.68 g, 22.3 mmol, 1.94 mL, CAS# 109-85-3) in DMF (30 mL) was added K2CO3 (6.18 g, 44.7 mmol). Then the mixture was stirred at 60 °C for 12 h. Upon completion, the reaction mixture was poured into H2O (60 mL) and extracted with EtOAc (100 mL x3). The combined organic layers were washed with brine (200 mL x 2), dried over Na2SC>4 filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiCL, Petroleum ether: Ethyl acetate=O:l to Petroleum ether: Ethyl acetate=3:l) followed by a further column chromatography (SiCh, Petroleum ether: Ethyl acetate=5:l to Petroleum ether: Ethyl acetate=l:l) to afford the title compound (2.78 g, 73% yield) as a white solid. LC-MS (ESI+) m / z 225.3[M+H]+; ’ll NMR (400 MHz, DMSO-d6) 8 = 7.26 (br t, 7 = 8.4 Hz, 1H), 6.57 - 6.46 (m, 2H), 5.98 (br s, 1H), 5.22 (s, 2H), 3.50 - 3.45 (m, 2H), 3.36 (s, 3H), 3.30 (br s, 2H), 3.27 (s, 3H).Step 3 - NI-(2-methoxyethyl)-3-(methoxymethoxy)benzene-l,2-diamine

[0449] To a solution of N-(2-methoxyethyl)-3-(methoxymethoxy)-2-nitro-aniline (2.78 g, 10.8 mmol) in EtOH (20 mL) and H2O (10 mL) was added Fe (3.03 g, 54.2 mmol) and NH4CI (5.80 g, 108 mmol). The mixture was then stirred at 80 °C for 1 h. Upon completion, the reaction mixture was filtered and to the filtrate was added water (30 mL) at 20 °C, and the mixture was extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (60 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to afford the title compound (2.30 g) as a white solid. LC-MS (ESI+) m / z 195.1 [M+H]+.Step 4 - 1-(2 -methoxyethyl )-4-( methoxymethoxy ) -1, 3-dihydro-2H-benzo[ d ]imidazol-2 -one

[0450] To a solution of Nl-(2-methoxyethyl)-3-(methoxymethoxy)benzene-l,2-diamine (2.30 g, 10.1 mmol) in DMF (25 mL) was added CDI (2.47 g, 15.2 mmol) and DIEA (3.94 g, 30.4 mmol, 5.31 mL). The mixture was then stirred at 60 °C for 12 h. Upon completion, the reaction mixture was poured into H2O (50 mL) and extracted with EtOAc (100 mL x3). The combined organic layers were washed with brine (200 mL x 2), dried over Na2SO4 filtered and Page 154 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiCL, Petroleum ether: Ethyl acetate=5:l to Petroleum ether: Ethyl acetate=O:l) to afford the title compound (2.30 g, 90% yield) as a white solid. LC-MS (ESI+) m / z 253.0[M+H]+; 'll NMR (400 MHz, DMSO-d6) 5 = 10.98 (s, 1H), 6.94 - 6.88 (m, 1H), 6.85 - 6.80 (m, 1H), 6.77 (d, J = 8.4 Hz, 1H), 5.22 (s, 2H), 3.92 (t, J = 5.6 Hz, 2H), 3.57 (t, J = 5.2 Hz, 2H), 3.42 (s, 3H), 3.22 (s, 3H).Step 5 - 4-Hydroxy-l-(2-methoxyethyl)-l,3-dihydro-2H-benzo[d]imidazol-2-one

[0451] To a solution of 3-(2-methoxyethyl)-7-(methoxymethoxy)-lH-benzimidazol-2-one (2.30 g, 9.12 mmol) in MeOH (40 mL) was added HC1 (4 M, 8 mL). The mixture was then stirred at 40 °C for 12 h. Upon completion, the reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiCh, Petroleum ether: Ethyl acetate=5:l to Petroleum ether: Ethyl acetate=O:l) to afford the title compound (2.00 g, HO) as a white solid. LC-MS (ESI+) m / z 208.9 [M+H]+4-((2-Chloro-6-methylpyrimidin-4-yl)oxy)-l-(2-methoxyethyI)-l,3-dihydro-2H-benzo[d]imidazol-2-one (Intermediate B)

[0452] To a solution of 7-hydroxy-3-(2-methoxyethyl)-lH-benzimidazol-2-one (1.00 g, 4.09 mmol, HO, Intermediate A) and 2,4-dichloro-6-methyl-pyrimidine (999 mg, 6.13 mmol, CAS# 5424-41-5) in DMF (10 mL) was added K2CO3 (2.82 g, 20.4 mmol). The mixture was then stirred at 25 °C for 2 h. Upon completion, the reaction mixture was poured into H2O (200 mL) and extracted with EtOAc (100 mL x3). The combined organic layers were washed with brine (200 mL x 2), dried over Na2SC>4 filtered and concentrated under reduced pressure to give a residue. The crude product was triturated with EtOH (3ml) at 40 °C for 12 h to afford the title compound (600 mg, 44% yield) as a white solid. LC-MS (ESI+) m / z 335.0 [M+H]+.(3S)-3-(3,4-difluorophenoxy)pyrrolidine (Intermediate C)Page 155 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOStep 1 - Tert-butyl (S)-3-(3,4-difluorophenoxy)pyrrolidine-l-carboxylate

[0453] To a solution of 3,4-difluorophenol (1 g, 8 mmol), PPh3 (2.22 g, 8.46 mmol) and tertbutyl (R)-3-hydroxypyrrolidine-l-carboxylate (1.44 g, 7.69 mmol, CAS# 103057-44-9) in THF (10 mL) was added dropwise DIAD (1.71 g, 8.46 mmol, 1.64 niL) in THF (2 niL) at 0 °C under N2. Then the mixture was stirred at 60 °C for 12 h under N2. Upon completion, the reaction mixture concentrated under reduced pressure to give a residue. The crude oil was diluted with PE (10 mL) and then 1 M aqueous sodium hydroxide (40 mL) was added. The aqueous layer was extracted with PE (60 mL x 2). The combined organic layers were dried over Na2SC>4, filtered and concentrated in vacuo. The residue was purified by column chromatography (SiCL, Petroleum ether / Ethyl acetate=l / 0 to 10 / 1) to afford the title compound (900 mg, 38% yield) as a yellow solid. LC-MS (ESI+) m / z 243.9 (M+1H)+.Step 2 - (S)-3-(3,4-difluorophenoxy)pyrrolidine

[0454] To a solution of tert-butyl (S)-3-(3,4-difluorophenoxy)pyrrolidine-l-carboxylate (200 mg, 668 pmol) in DCM (2 mL) was added HCl / dioxane (4 M, 0.5 mL) and the mixture was stirred at 20 °C for 12 h. Upon completion, the reaction mixture was concentrated under reduced pressure to afford the title compound (173 mg, HC1)) as a white oil. LC-MS (ESI+) m / z 200.1 (M+1H)+.l-((4,4-DifluorocyclohexyI)methyl)-4-(tributylstannyl)-lH-imidazole (Intermediate D)Step 1 - l,l-difluoro-4-(iodomethyl)cyclohexanePage 156 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0455] To a solution of triphenylphosphane (9.61 g, 36.6 mmol) and imidazole (3.85 g, 56.6 mmol) in DCM (50 mL) was added dropwise I2 (9.30 g, 36.6 mmol) at 0 °C. Then the mixture was stirred at 25 °C for 10 min. Next, (4,4-difluorocyclohexyl)methanol (5 g, 33 mmol, CAS# 178312-48-6) in DCM (20 mL) was added at 0 °C and the mixture was stirred at 25 °C for 12 h. Upon completion, the reaction mixture was quenched with water (100 mL) and extracted with dichloromethane (3x100 mL). The extracts were washed by brine (100 mL) and dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to get the crude residue. The residue was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate= 1 / 0 to 10 / 1) to give the title compound (8 g, 92% yield) as a yellow solid. ’H NMR (400 MHz, DMSO-d6) 5 = 3.28 (d, J = 6.0 Hz, 2H), 2.05 - 1.95 (m, 2H), 1.92 - 1.78 (m, 4H), 1.56 (br s, 1H), 1.31 - 1.21 (m, 2H).Step 2 - 1 -((4,4-difluorocyclohexyl)methyl)-4-iodo-l H-imidazole

[0456] To a solution of Ll-difhioro-4-(iodomethyl)cyclohexane (8 g, 31 mmol) and 4-iodo-IH-imidazole (2.98 g, 15.3 mmol, CAS# 71759-89-2) in DMF (20 mL) was added CS2CO3 (15.0 g, 46.1 mmol). Then the mixture was stirred at 25 °C for 12 hrs. Upon completion, the reaction mixture was filtered and concentrated in vacuo to give the crude residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18 (250*70mm, 10 um);mobile phase:[water(FA)-ACN];gradient:12%-42% B over 30 min ) to give the title compound (1.5 g, 30% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d6) δ = 8.15 (s, 1H), 7.72 (s, 1H), 7.41 (s, 1H), 3.91 (d, J = 7.2 Hz, 2H), 2.07 - 1.94 (m, 2H), 1.89 - 1.67 (m, 3H), 1.57 (br d, J = 13.4 Hz, 2H), 1.25 - 1.12 (m, 2H).Step 3 - 1 -((4,4-Difluorocyclohexyl)methyl)-4-(tributylstannyl)-l H-imidazole

[0457] To a solution of l-[(4,4-difluorocyclohexyl)methyl]-4-iodo-imidazole (6 g, 18 mmol) in THF (60 mL) was added dropwise i-PrMgCl (2 M, 18.4 mL) at -10 °C under N2 atmosphere and the mixture was stirred at -10 °C for 1 h. Next, tributyl(chloro) stannane (7.19 g, 22.0 mmol, 5.94 mL) was added drop wise at -10 °C, then the mixture was stirred at 25 °C for 1 h under N2 atmosphere. Upon completion, the reaction mixture was quenched with aq. NH4CI (20 mL) and extracted with ethyl acetate (3x20 mL). The extracts were washed with brine (20 mL) and dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give the crude residue. The residue was purified by column chromatography (AI2O3, Petroleum ether / Ethyl acetate=100 / l to 2 / 1) to give the title compound (9 g, 84% yield) as a yellow oil. LC-MS (ESI+) m / z 491.1(M+H)+.Page 157 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO l-[(3,4-Difluorophenyl)methyl]-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazole (Intermediate E)

[0458] To a solution of 4-(4,4,5,5-tctramcthyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazolc (562 mg, 2.90 mmol, CAS# 269410-08-4) and 4-(bromomethyl)-l,2-difluorobenzene (500 mg, 2.42 mmol, 309 pL, CAS# 85118-01-0) in ACN (5 mL) was added CS2CO3 (2.75 g, 8.45 mmol). The mixture was stirred at 80 °C for 3 h. Upon completion, the reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiCh, PE / EA=4 / 1) to afford the title compound (509 mg, 63% yield) as a yellow oil. ’ll NMR (400 MHz, DMSO-d6) 5 = 8.08 (s, 1H), 7.61 (s, 1H), 7.44 - 7.30 (m, 2H), 7.09 (ddd, 7= 2.4, 4.4, 6.4 Hz, 1H), 5.33 (s, 2H), 1.24 (s, 12H).4-[2-[4-[(6-Bromo-4-methyl-2-pyridyl)oxy]-2-oxo-3H-benzimidazol-l-yl]ethyl]piperidine-l-carboxylate (Intermediate F)Step 1 - l-(Benzyloxy)-3-fluoro-2-nitrobenzenePage 158 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0459] To a solution of 3-fluoro-2-nitro-phenol (165 g, 1.05 mol, CAS# 385-01-3) and K2CO3 (290 g, 2.10 mol) in DMF (1600 mL) was added BnBr (269 g, 1.58 mol, 187 mL) at 0 °C. Then the mixture was stirred at 25 °C for 10 h. Upon completion, the reaction mixture was poured into ice water (1.6 L) and extracted with EtOAc (1 L x 4). The combined organic layers were washed with brine (1 L x 8), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiC>2, Petroleum ether / Ethyl acetate=l / 0 to 10 / 1) to afford the title compound (240 g, 92% yield) as a yellow oil.NMR (400 MHz, DMSO-d6) 5 = 7.65 - 7.58 (m, 1H), 7.44 - 7.32 (m, 5H), 7.29 (d, J = 8.8 Hz, 1H), 7.13 (t, J = 9.2 Hz, 1H), 5.33 (s, 2H).Step 2 - Tert-butyl 4-(2-((3-(benzyloxy)-2-nitrophenyl)amino)ethyl)piperidine-l-carboxylate

[0460] To a solution of l-(benzyloxy)-3-fhioro-2-nitrobenzene (28.5 g, 76.1 mmol) and tertbutyl 4-(2-aminoethyl) piperidine- 1 -carboxylate (15.8 g, 69.2 mmol, CAS# 146093-46-1) in DMF (200 mL) was added K2CO3 (28.7 g, 208 mmol). Then the mixture was stirred at 100 °C for 12 h. Upon completion, the reaction mixture was quenched with water (400 mL) at 25 °C, and extracted with EtOAc (600 mL x 3). The combined organic layers were washed with brine (320 mL x 6), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO; 220 g SepaFlash Silica Flash Column, Eluent of 0~7% Ethyl acetate / Petroleum ether gradient @ lOOmL / min) to afford the title compound (16.4 g, 52% yield) as a yellow oil. LC-MS (ESI+) m / z 478.2 (M+23H)+; ’H NMR (400 MHz, DMSO-d6) 5 = 7.39 (d, J = 4.4 Hz, 4H), 7.35 - 7.22 (m, 2H), 6.46 (t, J = 8.8 Hz, 2H), 6.04 (br t, J = 5.6 Hz, 1H), 5.16 (s, 2H), 3.90 (br d, J = 12.0 Hz, 2H), 3.16 (q, 7 = 6.4 Hz, 2H), 2.73 - 2.61 (m, 2H), 1.65 (brd,. / = 12.4 Hz, 2H), 1.47 (br s, 3H), 1.38 (s, 9H), 1.05 - 0.93 (m, 2H).Step 3 - Tert-butyl 4-(2-((2-amino-3 -(benzyloxy )phenyl)amino)ethyl)piperidine-l-carboxylate

[0461] To a solution of tert-butyl 4-(2-((3-(benzyloxy)-2-nitrophenyl)amino)ethyl)piperidine-1-carboxylate (16.4 g, 36.0 mmol) in EtOH (160 mL) and H2O (80 mL) was added Fe (10.1 g, 180.0 mmol) and NH4CI (19.3 g, 360 mmol). Then the mixture was stirred at 80 °C for 4 h. Upon completion, the reaction mixture was filtered and obtained filter liquor. To the filter liquor was added water (400 mL) at 20 °C, and the mixture was extracted with EtOAc (700 mL x 3). The combined organic layers were washed with brine (400 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to afford the title compound (17.2 g) as a Page 159 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO black brown oil. LC-MS (ESI+) m / z 426.2 (M+23H)+; ’ll NMR (400 MHz, DMSO-de) 5 = 7.48 - 7.44 (m, 2H), 7.38 (t, J= 7.6 Hz, 2H), 7.33 - 7.29 (m, 1H), 6.49 - 6.44 (m, 1H), 6.35 (d, 7= 8.0 Hz, 1H), 6.17 (d, 7 = 8.0 Hz, 1H), 5.05 (s, 2H), 4.41 (t, 7 = 5.2 Hz, 1H), 4.11 (s, 2H), 3.92 (br d, 7= 12.4 Hz, 2H), 3.04 (q, 7= 6.4 Hz, 2H), 2.81 - 2.59 (m, 2H), 1.67 (br d, 7= 12.8 Hz, 2H), 1.61 - 1.49 (m, 3H), 1.39 (s, 9H), 1.04 - 0.95 (in, 2H).Step 4 - 4-(benzyloxy)-l -(2-(piperidin-4-yl)ethyl)-l,3-dihydro-2H-benzo[d]imidazol-2-one

[0462] To a solution of tert-butyl 4-(2-((2-amino-3-(benzyloxy)phenyl)amino)ethyl)piperidine-l -carboxylate (17.2 g, 40.4 mmol) in THF (200 mL) was added bis(trichloromethyl) carbonate (18.4 g, 62.1 mmol, CAS# 32315-10-9) and TEA (4.91 g, 48.5 mmol, 6.75 mL) at 0 °C under N2. The mixture was then stirred at 25 °C for 1 h under N2. Upon completion, the reaction mixture was concentrated under reduced pressure to give a residue. The crude product was triturated with EtOAc (20 ml) at 25 °C for 30 min to afford the title compound (18 g, 89% yield) as a white solid. LC-MS (ESI+) m / z 352.1 (M+lH^ H NMR (400 MHz, DMSO-de) 5 = 11.05 (s, 1H), 10.15 (br d, 7= 4.4 Hz, 1H), 7.53 (d, J = 7.2 Hz, 2H), 7.41 - 7.35 (m, 2H), 7.34 - 7.29 (m, 1H), 6.96 - 6.90 (m, 1H), 6.77 (dd, 7 = 4.4, 8.0 Hz, 2H), 5.21 (s, 2H), 3.80 (t, 7 = 6.8 Hz, 2H), 3.21 (br d, 7 = 12.8 Hz, 2H), 2.83 -2.72 (m, 2H), 1.89 (br d, 7= 14.0 Hz, 2H), 1.58 (q, 7 = 6.8 Hz, 2H), 1.53 - 1.45 (m, 1H), 1.40 - 1.28 (m, 2H).Step 5 - Tert-butyl 4-(2-(4-(benzyloxy)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl )ethyl)piperidine-l -carboxylate

[0463] To a solution of 4-(benzyloxy)-l-(2-(piperidin-4-yl)ethyl)-l,3-dihydro-2H-benzo[d]imidazol-2-one (18 g, 36 mmol) and TEA (9.07 g, 89.6 mmol, 12.5 mL) in DCM (250 mL) was added BOC2O (8.61 g, 39.4 mmol, 9.06 mL) at 0 °C under N2. The mixture was then stirred at 25 °C for 1 h. Upon completion, the reaction mixture was quenched with water (300 mL) at 25 °C, and extracted with DCM (300 mL x 2). The combined organic layers were washed with brine (200 mL x 2), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The crude product was triturated with EtOAc at 25 °C for 30 min to afford the title compound (10.1 g, 62% yield,) as a pink solid. LC-MS (ESI+) m / z 474.2 (M+23H)+; ’ll NMR (400 MHz, DMSO-de) 5 = 11.09 - 10.94 (m, 1H), 7.53 (br d, 7 = 7.6 Hz, 2H), 7.41 - 7.35 (m, 2H), 7.34 - 7.27 (m, 1H), 6.96 - 6.90 (m, 1H), 6.76 (dd, 7 = 6.0, 8.0 Hz, 2H), 5.21 (s, 2H), 3.89 (br d, J= 12.0 Hz, 2H), 3.79 (br t, 7 = 7.2 Hz, 2H), 2.63 (br d, 7= 1.2Page 160 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO Hz. 2H), 1.77 - 1.65 (m, 2H), 1.55 (q. J = 6.8 Hz, 2H). 1.38 (s, 10H), 1.00 (dq, J = 4.0, 12.0 Hz, 2H).Step 6 - Tert-butyl 4-(2-(4-hydroxy-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl)ethyl)piperidine-l -carboxylate

[0464] To a solution of tert-butyl 4-(2-(4-(benzyloxy)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl)ethyl)piperidine-l -carboxylate (10.1 g, 22.4 mmol) in MeOH (200 mb) was added Pd / C (9 g, 8.46 mmol, 10 wt%). The mixture was then stirred at 25 °C for 12 h under H2. Upon completion, the reaction mixture was filtered and concentrated under reduced pressure to afford the title compound (7.5 g, 93% yield) as a white solid. LC-MS (ESI+) m / z 262.2 (M-100 H)+; ¹H NMR (400 MHz, DMSO-d₆) 5 = 11.47 - 8.30 (m, 1H), 6.84 - 6.74 (m, 1H), 6.57 (d, 7= 8.0 Hz, 1H), 6.49 (d, J= 8.0 Hz, 1H), 3.89 (brd, 7= 12.0 Hz, 2H), 3.76 (br t, 7= 7.2 Hz, 211), 2.62 (br s, 211), 1.70 (br d, 7= 12.0 Hz, 211), 1.54 (q, 7= 6.8 Hz, 211), 1.38 (s, 10H), 0.99 (dq, 7 = 4.0, 12.0 Hz, 2H).

[0465] Step 7 - Tert-butyl 4-(2-(4-((6-bromo-4-methylpyridin-2-yl)oxy)-2-oxo-2,3-dihydro-1 H-benzo [d]imidazol- 1 -yl)ethyl)piperidine- 1 -carboxylate

[0466] To a solution of tert -butyl 4-(2-(4-hydroxy-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl)ethyl)piperidine-l -carboxylate (5 g, 10 mmol) and 2-bromo-6-fluoro-4-methylpyridine (2.89 g, 15.2 mmol. CAS# 180608-37-1) in NMP (50 mL) was added K2CO3 (5.74 g, 41.5 mmol). Then the mixture was stirred at 100 °C for 12 h. Upon completion, the reaction mixture was quenched with water (100 mL) at 25 °C, and extracted with EtOAc (200 mL x 3). The combined organic layers were washed with brine (200 mL x 5), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiCh, Petroleum ether / DCM / Ethyl acetate=3.3 / 1.7 / l to 1 / 1 / 2) to afford the title compound (4.8 g, 55% yield) as a pink solid. LC-MS (ESI+) m / z 433.1(M-100H)’; ¹H NMR (400 MHz, DMSO-d₆) 5 = 11.07 (s, 1H), 7.24 (s, 1H), 7.06 - 7.01 (m, 2H), 6.85 (s, 1H), 6.80 - 6.76 (m, 1H), 3.91 (br d, 7 = 12.0 Hz, 2H), 3.84 (br t, 7 = 7.2 Hz, 2H), 2.69 - 2.59 (m, 2H), 2.31 (s, 3H), 1.73 (brd, 7= 12.0 Hz, 2H), 1.60 (q, 7 = 7.2 Hz, 2H), 1.43 (br d, 7 = 3.2 Hz, 1H), 1.38 (s, 9H), 1.08 - 0.98 (m, 2H).l-((4,4-DifluorocycIohexyl)methyI)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaboroIan-2-yl)-lH-pyrazole (Intermediate G)Page 161 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0467] To a solution of (4,4-difhiorocyclohexyl)rnethanol (50 g, 330 mmol, CAS# 178312-48-6) in toluene (200 mL) was added 2-(tributyl-phosphanylidene)acetonitrile (80.36 g, 333.0 mmol) and 4-(4, 4,5, 5-tetramethyl- 1,3, 2-dioxaborolan-2-yl)-lH-pyrazole (83.99 g, 432.9 mmol, CAS# 269410-08-4). The mixture was then stirred at 100 °C for 12 h. Upon completion, the mixture was concentrated under reduced pressure to obtain a residue. The crude product was purified by reversed-phase HPLC (column: Phenomenex luna cl8 250mm* 100mm* 10um;mobile phase: [water(FA)-ACN];gradient:40%-75% B over 20 min) to give the title compound (62 g, 49% yield) as a white solid. LC-MS (ESI+) m / z 327.0 (M+H)+.l-(Bicyclo[2.2.1]heptan-2-ylmethyl)-4-(tributylstannyl)-lH-imidazole (Intermediate H)Step 1 - bicyclo[2.2.1 ]heptan-2-ylmethyl 4-methylbenzenesulfonate

[0468] To a solution of TosCI (75.5 g, 396 mmol) and TEA (120 g, 1.19 mol) in DCM (200 mL) was added [(lR,4S)-norbornan-2-yl]methanol (50.0 g, 396 mmol, CAS# 5240-72-2) slowly at 0 °C and stirred at 25 °C for 20 hr. Upon completion, the reaction mixture was partitioned between DCM (200 mL) and H2O (200 mL). The organic phase was separated, washed with aqueous NaCl (100 ml,), dried over NajSOj, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiCL, Petroleum ether / Ethyl acetate=l / O to 10 / 1) to afford title compound (107 g, 96% yield) as a colorless oil. ’ll NMR (400 MHz, CDCh-d) 5 = 7.80 (dd, J = 3.0, 8.3 Hz, 2H), 7.35 (br d, J = 8.0 Hz, 2H), 4.06 - 3.70 (m, 2H), 2.46 (s, 3H), 2.25 - 2.11 (m, 2H), 1.54 - 1.40 (m, 2H), 1.40 -1.22 (m, 3H), 1.17 - 1.06 (m, 2H), 1.00 - 0.56 (m, 2H).Page 162 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO Step 2 - 2-(Bromomethyl)bicyclo[2.2.1 Jheptane

[0469] To a solution of bicyclo[2.2.1]heptan-2-ylmethyl 4-methylbenzenesulfonate (50.0 g, 178 mmol) in ACN (500 mL) was added LiBr (92.9 g, 1.07 mol) and the mixture was stirred at 60 °C for 3 hr. Upon completion, the reaction mixture was quenched with H2O (100 mL) and extracted with EA ( 100 mL x 3). The organic layer was washed with brine and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiC>2, Petroleum ether / Ethyl acetate=l / O to 1 / 1) to afford the title compound (25 g, 74% yield) as a colorless oi H NMR (400 MHz, CDCl3-d) 5 = 3.52 - 3.10 (m, 2H), 2.35 - 2.23 (m, 2H), 1.94 - 1.78 (m, 1H), 1.63 - 1.06 (m, 8H).Step 3 - 1 -(Bicyclo [2.2.1 ]heptan-2-ylmethyl)-4-iodo-lH-imidazole

[0470] To a solution of [(lR,4S)-norboman-2-yl]methanol (5 g, 40 mmol) and 4-iodo-lH-imidazole (7.69 g, 39.6 mmol) in toluene (20 mL) was added 2-(tributyl-phosphanylidene)acetonitrile (9.56 g, 39.6 mmol) and stirred at 100 °C for 5 hr. Upon completion, the reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18 (250*70mm,10 um);mobile phase: [water(FA)-ACN];gradient:10%-40% B over 25 min) to afford the title compound (8 g, 67% yield) as a yellow oil. 'H NMR (400 MHz, DMSO-d6) 5 = 7.62 (d, J = 1.3 Hz, 1H), 7.38 (dd, J = 1.3, 11.1 Hz, 1H), 3.93 (dd, J = 2.9, 8.1 Hz, 1H), 3.82 - 3.66 (m, 1H), 2.17 - 2.10 (m, 2H), 1.30 - 1.20 (m, 5H), 1.10 (hr d, J = 6.1 Hz, 2H), 1.06 - 0.98 (m, 2H).Step 4 - l-(Bicyclo[2.2.1 ]heptan-2-ylmelhyl)-4-(tribulylstannyl)- 1 H-imidazole

[0471] To a solution of tributyl(chloro)stannane (8.00 g, 25.8 mmol) in THF (50 mL) was added i-PrMgCl (2 M, 16.1 mL) at -15 °C under N2. The mixture was then stirred at -15 °C for 1 hr under N2. Then l-(bicyclo[2.2.1]heptan-2-ylmethyl)-4-iodo-lH-imidazole (6.50 g, 21.5 mmol) was added to the reaction at -15 °C under N2. The mixture was then stirred at 25 °C for 1 hr. Upon completion, the reaction mixture was quenched with aq. NIECl (50 mL) and extracted with ethyl acetate (3 x 50 mL). The extracts were washed with brine (40 mL) and dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford the title compound (12 g) as a yellow gum. LC-MS (ESI+) m / - 467.1 (M+H)+.4-(Azidomethyl)-l,l-difluorocyclohexane (Intermediate I)Page 163 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0472] To a solution of (4,4-difhrorocyclohexyl)methyl 4-methylbenzenesulfonate (500 mg, 1.64 mmol, CAS# 178310-99-1) in DMF (2.5 mL) was added NaNs (0.26 g, 4.00 mmol), them the mixture was stirred at 90 °C for 1.5 h. Upon completion, the mixture was quenched by adding it to Na2COa aq. (5 mL) to keep the pH> 10, then diluted with dichloromethane (5 mL). The organic layer was separated and washed with water (2x5 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to provide the title compound (200 mg) as yellow gum.l-(4-(2-(7-Hydroxy-lH-indazol-3-yl)ethyl)piperidin-l-yl)ethan-l-one (Intermediate J)Step 1 - 7-(Benzyloxy)-3-bromo-l H-indazole

[0473] To a solution of 7 -benzyloxy- 177-indazole (2.00 g, 8.92 mmol, CAS# 351210-09-8) in DMF (20 mL) was added NBS (1.75 g, 9.81 mmol), and the mixture was stirred at 20°C for 5 h. Upon completion, the mixture was diluted with water (50 mL) and extracted with EA (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried over Na2SC>4, and concentrated in vacuo to give a residue. The residue was purified by columnPage 164 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO chromatography (S1O2, Petroleum ether / Ethyl acetate=100 / l to 10 / 1) to give the title compound (2.70 g, 100% yield) as a white solid. LC-MS (ESI+) m / z 302.8 (M+H)+.Step 2 - Tert-butyl 7-(benzyloxy)-3-bromo-lH-indazole-l -carboxylate

[0474] To a solution of 7-benzyloxy-3-bromo- 1 / / -indazole (3.6 g, 12 mmol) and tert-butoxycarbonyl tert-butyl carbonate (3.11 g, 14.2 mmol, 3.27 mL) in DCM (30 mL) was added DMAP (145 mg, 1.19 mmol) and TEA (2.40 g, 23.7 mmol, 3.31 mL), then the mixture was stirred at 20 °C for 2 h. Upon completion, the mixture was quenched with water (100 mL) and extracted with EA (100 mL x 2). The combined organic layer was dried over NaeSCh, and concentrated in vacuo to give a residue. The residue was purified by column chromatography (SiC>2, Petroleum ether / Ethyl acetate=100 / l to 10 / 1) to give the title compound (4.50 g, 90% yield) as a white solid. LC-MS (ESI+) m / z 302.7 (M+H-Boc)+; ’ll NMR (400 MHz, DMSO-d6) 5 = 7.57 - 7.51 (m, 211), 7.45 - 7.31 (m, 511), 7.25 (dd, J = 0.8, 8.0 IIz, III), 5.31 (s, 211), 1.48 (s, 9H).Step 3 - Tert-butyl 7-(benzyloxy)-3-(2-(l-(tert-butoxycarbonyl)piperidin-4-yl)ethyl)-IH-indazole-l -carboxylate

[0475] To an 15 mL vial equipped with a stir bar was added tert-butyl 4-(2-hydroxyethyl)piperidine- 1 -carboxylate (2.99 g, 13.0 mmol, CAS# 89151-44-0), 5,7-ditert-butyl-3-phenyl-l,3-benzoxazol-3-ium tetrafluoroborate (4.70 g, 11.9 mmol) and MTBE (5 mL). Then pyridine (941 mg, 11.9 mmol, 960 pL) in DMA (20 mL) was added dropwise. The vial was sealed and placed under glovebox and stirred at 25 °C for 10 mins then filtered to get the filter liquor. Next, bis[2-(2-pyridyl)phenyl]iridium(l+) 4-tert-butyl-2-(4-tert-butyl-2-pyridyl)pyridine hexafluorophosphate (101 mg, 111 pmol), 4-tert-butyl-2-(4-tert-butyl-2-pyridyl)pyridine dibromonickel (181 mg, 372 pmol), quinuclidine (1.45 g, 13.0 mmol) and tert-butyl 7-benzyloxy-3-bromo-indazole-l -carboxylate (3.00 g, 7.44 mmol) in MTBE (5 mL) was added to the above filter liquor. The reaction was stirred and irradiated with a 10 W [455 nm] blue LED lamp (3 cm away), with cooling water to keep the reaction temperature at 25 °C for 2 h. Upon completion, the mixture was quenched with water (100 mL) and extracted with EA (100 mL x 2). The combined organic layers was dried over Na2SC>4, and concentrated in vacuo to give a residue. The residue was purified by column chromatography GS i O2, Petroleum ether / Ethyl acetate=100 / l to 10 / 1) to give the title compound (1.50 g, 30% yield) as a yellow oil. LC-MS (ESI+) m / z 558.4 (M+Na)+.Step 4 - 7-(benzyloxy)-3-(2-(piperidin-4-yl)ethyl)-lH-indazolePage 165 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0476] To a solution of tert-butyl 7-benzyloxy-3-[2-(l-tert-butoxycarbonyl-4-piperidyl)ethyl]indazole- 1 -carboxylate (1.50g, 2.80 mmol) in DCM (10 mL) was added HCl / dioxane (2 M, 1.40 mL) and the mixture was stirred at 30 °C for 5 h. Upon completion, the mixture was concentrated in vacuo to give the title compound (1.50 g, HC1 salt) as a white solid. LC-MS (ESI+) m / z 336.1 (M+H)+.Step 5 - l-(4-(2-(7-(benzyloxy)-lH-indazol-3-yl)ethyl)piperidin-l-yl)ethan-l-one

[0477] To a solution of 7-benzyloxy-3-[2-(4-piperidyl)ethyl]-lH-indazole (1.50 g, 2.35 mmol, 2HC1 salt) in DCM (20 mL) was added TEA (713 mg, 7.05 mmol, 981 pL) and AC2O (240 mg, 2.35 mmol, 220 pL) at 20°C, the mixture was stirred at 20°C for 1 h. The mixture was quenched with water (100 mL) and extracted with EA (100 mL x 2). The combined organic layer was dried over Na2SC>4, and concentrated in vacuo to give a residue. The residue was triturated with EA (10 mL) at 20 °C for 10 min to give the title compound (850 mg, 91% yield) as a white solid. LC-MS (ESI+) m / z 400.3 (M+Na)+; ’ll NMR (400 MHz, DMSO-d6) 5 = 12.87 (s, 1H), 7.56 ( d, J = 7.2 Hz, 2H), 7.41 (t, J = 7.2 Hz, 2H), 7.35 ( d, J = 7.2 Hz, 1H), 7.26 (d, J = 8.0 Hz, 1H), 6.99 - 6.93 (m, 1H), 6.92 - 6.86 (m, 1H), 5.33 - 5.21 (m, 2H), 4.44 - 4.27 (m, 1H), 3.77 ( d, J = 13.6 Hz, 1H), 3.04 - 2.84 (m, 4H), 2.54 (s, 2H), 1.82 - 1.62 (m, 4H), 1.50 ( d, J= 6.4 Hz, 1H), 1.21 - 0.90 (m, 3H).Step 6 - l-(4-(2-(7-Hydroxy-lH-indazol-3-yl)ethyl)piperidin-l-yl)ethan-l-one

[0478] To a solution of l-[4-[2-(7 -benzyloxy- 177-indazol-3-yl)ethyl]- 1 -piperidyl ]ethanone (850 mg, 2.25 mmol) in MeOH (20.0 mL) was added Pd / C (2.40 g, 2.25 mmol, 10 wt%), and the mixture was stirred at 40 °C for 5 h under H2 atmosphere (15 psi). Upon completion, the mixture was concentrated in vacuo to give a residue. The residue was purified by column chromatography (S1O2. DCM / MeOI 1= 100 / 1 to 10 / 1) to give the title compound (600 mg, 93% yield) as a white solid. LC-MS (ESI+) m / z 288.0 (M+H)+.Step 7 - l-(4-(2-(7-((6-bromo-4-methylpyridin-2-yl)oxy)-lH-indazol-3-yl)ethyl )piperidin-l -yl )ethan-l -one

[0479] To a solution of l-[4-[2-(7-hydroxy-lH-indazol-3-yl)ethyl]-l-piperidyl]ethanone (450 mg, 1.57 mmol) and 2-bromo-6-fhioro-4-methyl-pyridine (327 mg, 1.72 mmol, CAS# 180608-37-1) in DMF (5.00 mL) was added CS2CO3 (1.53 g, 4.70 mmol) and CsF (237 mg, 1.57 mmol), then the mixture was stirred at 100 °C for 0.5 h. Upon completion, the mixture was quenched with water (50.0 mL) and extracted with EA (50 mL x 2). The combined organic layer was dried over Na2SC>4, and concentrated in vacuo to give a residue. The residue was purified by Page 166 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO column chromatography (S1O2, EA / MeOH=100 / l to 10 / 1) to give the title compound (300 mg, 42% yield) as a yellow oil. LC-MS (ESI+) m / z. 459.2 (M+H)+.4-(l-AzidoethyI)-l,l-difluorocyclohexane (Intermediate K)

[0480] To a solution of l-(4,4-difluorocyclohexyl)ethanol (500 mg, 3.05 mmol) in toluene (10 mL) was added DPPA (1.02 g, 3.65 mmol, 788 pL) and DBU (556 mg, 3.65 mmol, 550 pL). The mixture was then stirred at 20 °C for 12 h. Upon completion, the reaction mixture was poured into ice water (50 mL) and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL x 3), dried over sodium sulfate, filtered and concentrated under reduced pressure to afford the title compound (620 mg) as a yellow oil.NMR (400 MHz, CDCh) 5 = 4.68-4.41 (m, 1H), 3.45-3.23 (m, 3H), 2.75 (s, 1H), 2.13-2.00 (m, 2H), 1.95-1.86 (m, 1H), 1.77-1.63 (m, 4H), 1.46-1.29 (m, 2H).4-((6-bromo-4-methylpyridin-2-yl)oxy)-l-methyl-3-((2- (trimethylsilyl)ethoxy)methyl)-l,3-dihydro-2H-benzo[d]imidazol-2-one (Intermediate L)Step 1 - 4-((6-Bromo-4-methylpyridin-2-yl)oxy)-l-methyl-3-((2- (trimethylsilyl)ethoxy)methyl)-l,3-dihydro-2H-benzo[d]imidazol-2-one

[0481] A solution of 2-bromo-6-fluoro-4-methylpyridine (10 g, 50 mmol, CAS# 180608-37- 1), 4-hydroxy-l-methyl-3-((2-(trimethylsilyl)ethoxy)methyl)-l,3-dihydro-2H-benzo[d]imidazol-2-one (15.4 g, 52.6 mmol, Intermediate Y), and K2CO3 (21.8 g, 157 mmol) in DMF (100 mL) was stirred at 100 °C for 12 h. Upon completion, the mixture was poured into water (500 mL) and filtered. The filter cake was dried under reduced pressure to afford the title compound (15 g, 57% yield) as a gray solid. LC-MS (ESI+) m / z 466.0 (M+H)+; ’ll NMR Page 167 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO (400 MHz, DMSO-d6) 5 = 7.24 (s, 1H), 7.17 - 7.08 (m, 2H), 6.87 - 6.82 (m, 2H), 5.14 (s, 2H), 3.37 (s, 3H), 3.31 (s, 2H), 2.29 (s, 3H), 0.57 - 0.51 (m, 2H), -0.13 (s, 9H).2,6-Dichloro-4-(l-fluorocyclobutyl)pyridine (Intermediate M)Step 1 - l-(2,6-Dichloropyridin-4-yl)cyclobutanol

[0482] To a solution of 2,6-dichloro-4-iodopyridine (10 g, 40 mmol, CAS# 98027-84-0) in THF (10 mL) was added i-PrMgCl (2 M, 18.2 mL) at -45 °C and the mixture was stirred for 1 h. Then cyclobutanone (2.56 g, 36.5 mmol, 2.73 mL, CAS# 1191-95-3) was added and the mixture was stirred at 25 °C for 11 h. Upon completion, the reaction mixture was quenched with aqueous ammonium chloride (50 mL) at 25 °C, and then diluted with water (50 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (20 mLx3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO; 120 g SepaFlash Silica Flash Column, Eluent of 0~25 % Ethyl acetate / Petroleum ether gradient @ 100 mL / min) to give the title compound (5 g, 63% yield) as a colorless oil. LC-MS (ESI+) m / z 217.9 (M+H)+.Step 2 - 2,6-Dichloro-4-( 1 -fluorocyclobutyl)pyridine

[0483] To a solution of l-(2,6-dichloropyridin-4-yl)cyclobutanol (2 g, 10 mmol) in DCM (15 mL) was added DAST (1.77 g, 11.0 mmol, 1.45 mL) and the mixture was stirred at 0 °C for 1 hr. On completion, the reaction mixture was quenched with aqueous ammonium chloride (20 mL) at 25 °C, and then diluted with water (30 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (20 mL x 3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO; 12 g SepaFlash Silica Flash Column, Eluent of 0-30% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to give the title compound (1 g, 50% yield) as a colorless oil. LC-MS (ESI+) m / z 220.0 (M+H)+; ’ll NMR (400 MHz, DMSO-d6) 5 = 7.65 (s, 2H), 2.65 - 2.55 (m, 4H), 2.11 - 2.00 (m, 1H), 1.93 - 1.81 (m, 1H).Page 168 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO l-(2-(l-Acetylpiperidin-4-yl)ethyl)-4-hydroxy-3-((2- (trimethylsilyl)ethoxy)methyl)-lH-benzo[d]imidazol-2(3H)-one (Intermediate N)Step 1 - l-(2-(l-Ac.etylpiperidin-4-yl)ethyl)-4-(benzyloxy)-l,3-dihydro-2H-benzo[d]imidazol-2-one

[0484] To a solution of 4-(benzyloxy)-l-(2-(piperidin-4-yl)ethyl)-l,3-dihydro-2H-benzo[d]imidazol-2-one (16 g, 46 mmol, synthesized via Steps 1-4 of Intermediate F) in EtOAc (160 mL) was added TEA (4.61 g, 45.5 mmol) and AC2O (9.30 g, 91.0 mmol) at 20 °C under nitrogen flow. Then the reaction was stirred at 20 °C for 1 h under nitrogen atmosphere. Upon completion, the reaction was concentrated to give the tittle compound (20 g) as a yellow solid, ’ll NMR (400 MHz, DMSO-d6) 5 = 11.03 (s, 1H), 7.53 (br d, J = 7.2 Hz, 2H), 7.43 - 7.35 (m, 2H), 7.34 - 7.26 (m, 1H), 6.97 - 6.88 (m, 1H), 6.76 (t, J = 7.2 Hz, 2H), 5.21 (s, 2H), 3.79 (br d, 7 = 7.2 Hz, 2H), 2.93 (br t, J = 11.6 Hz, 1 H), 2.48 - 2.37 (m, 1 H), 1.96 (s, 3H), 1.74 (br t, J = 14.4 Hz, 2H), 1.56 (q, 7 = 6.8 Hz, 2H), 1.50 - 1.41 (m, 1H), 1.15 - 0.90 (m, 3H), 0.89 - 0.77 (m, 1H).Step 2 - l-(2-(l-Acetylpiperidin-4-yl)ethyl)-4-(benzyloxy)-3-((2-(trimethylsilyl)ethoxy)methyl)-l,3-dihydro-2H-benzo[d]imidazol-2-one

[0485] To a solution of l-(2-(l-acetylpiperidin-4-yl)ethyl)-4-(benzyloxy)-l,3-dihydro-2H-benzo[d]imidazol-2-one (20 g, 50.8 mmol) in DMF (200 mL) was added NaH (6.10 g, 152 mmol, 60% dispersion in mineral oil) and SEM-C1 (21.1 g, 127 mmol) at 0 °C under nitrogen flow. Then the reaction was stirred at 20 °C for 10 h under nitrogen atmosphere. Upon completion, the reaction was poured into NH4CI (sat.aq, 300 mL) and extracted with EtOAc (200 mL x 2). The combined organic phase was washed with brine (100 mL x 2), dried over Na2SO4, filtered, and the filtrate was concentrated to give a residue. The residue was purified by column chromatography on silica gel (eluted with petroleum ether: ethyl acetate = 100: 1 to 100: 17) to give the tittle compound (7.6 g, 29% yield) as a yellow oil. ’ll NMR (400 MHz, CDCL) 5 = 7.51 (d, 7= 7.2 Hz, 2H), 7.44 - 7.30 (m, 3H), 7.08 - 6.98 (m, 1H), 6.74 (d, 7= 8.4Page 169 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO Hz, 1H), 6.64 (d, J = 7.6 Hz, 1H), 5.49 (s, 2H), 5.19 (s, 2H), 4.59 (br d, J= 9.6 Hz, 1H), 3.92 (br t, J = 7.2 Hz, 2H), 3.86 - 3.71 (m, 1H), 3.65 - 3.50 (m, 2H), 3.07 - 2.96 (m, 1H), 2.62 - 2.43 (m, 1H), 2.11 - 2.06 (m, 3H), 1.96 - 1.77 (m, 2H), 1.75 - 1.64 (m, 2H), 1.55 (tddd, 7= 3.2, 7.2, 10.8, 14.4 Hz, 1H), 1.16 (q, J = 11.2 Hz, 2H), 0.94 - 0.83 (m, 2H), -0.06 (s, 9H).Step 3 - l-(2-(l-acetylpiperidin-4-yl)ethyl)-4-hydroxy-3-((2- (trimethylsilyl)ethoxy)methyl)-l,3-dihydro-2H-benw[d]imidawl-2-one

[0486] To a solution of Pd / C (15.44 g, 14.5 mmol, 10 wt%) in MeOH (150 mL) was added 1-(2-(l-acetylpiperidin-4-yl)ethyl)-4-(benzyloxy)-3-((2-(trimethylsilyl)ethoxy)methyl)-l,3-dihydro-2H-benzo[d]imidazol-2-on (7.6 g, 14.5 mmol) at 20 °C under nitrogen flow. Then the reaction was stirred at 20 °C for 10 h under hydrogen atmosphere (15 psi). Upon completion, the reaction was filtered, and the filtrate was concentrated to give the tittle compound (5.6 g, 89% yield) as a white solid. Ul NMR (400 MHz, CDCh) 5 = 8.05 (br s, III), 7.02 (t, 7 = 8.0 Hz, 1H), 6.72 (d, 7 = 8.0 Hz, 1H), 6.56 (d, 7 = 7.6 Hz, 1H), 4.60 (br d, 7 = 13.2 Hz, 1H), 3.89 (t, 7= 7.2 Hz, 2H), 3.83 - 3.77 (m, 1H), 3.77 - 3.70 (m, 2H), 3.48 (s, 1H), 3.07 - 2.97 (m, 1H), 2.53 (dt, 7= 2.4, 12.8 Hz, 1H), 2.08 (s, 3H), 1.95 - 1.77 (m, 3H), 1.76 - 1.64 (m, 2H), 1.56 (dtd, 7= 3.2, 7.2, 14.4 Hz, 1H), 1.27 - 1.10 (m, 2H), 1.07 - 0.96 (m, 2H), 0.00 (s, 9H).l-(2-(l-Acetylpiperidin-4-yl)ethyl)-4-((6-chloro-4-(l-fhiorocyclobutyl)pyridin-2-yl)oxy)-lH-benzo[d]imidazol-2(3H)-one (Intermediate O)Page 170 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO Step 1 - l-(2-(l-Acetylpiperidin-4-yl)ethyl)-4-((6-chloro-4-(l-fluorocyclobutyl)pyridin-2-yl)oxy)-3-( (2-( trimethylsilyl)ethoxy)methyl)-lH-benzo[ d Jimidazol- 2(3H)-one

[0487] To a solution of 2,6-dichloro-4-(l-fluorocyclobutyl)pyridine (1 g, 5 mmol, Intermediate M) and l-(2-(l-acetylpiperidin-4-yl)elhyl)-4-hydroxy-3-((2-(trimethylsilyl)ethoxy)melhyl)- lH-benzo[d]imidazol-2(3H)-one (1.79 g, 4.13 mmol, Intermediate N) in DMSO (10 mL) was added MNBO (1 1 mg, 413 pmol), K3PO4 (1.14 g, 5.37 mmol) and C. U2O (118 mg, 826 pmol, 84.4 pL). The mixture was then stirred at 100 °C for 12 hr under N2. Upon completion, the reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (20 mL x 3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (FA condition) to give the title compound (1.5 g, 58% yield) as a yellow oil. NMR (400 MHz, CDCh-d) 5 = 7.42 (s, 1H), 7.27 - 7.23 (m, 1H), 7.07 (s, 1H), 7.01 (dd, J = 5.3, 8.0 Hz, 2H), 5.49 (s, 2H), 4.77 (br d, J = 13.4 Hz, 1H), 4.11 (t, J = 7.1 Hz, 2H), 3.96 (br d, J = 13.6 Hz, 1H), 3.65 - 3.53 (m, 2H), 3.24 - 3.13 (m, 1H), 2.93 - 2.76 (m, 2H), 2.73 - 2.60 (m, 3H), 2.37 - 2.28 (m, 1H), 2.24 (s, 3H), 2.08 (br d, I = 13.6 Hz, 1H), 2.04 - 1.97 (m, 2H), 1.91 - 1.84 (m, 2H), 1.73 (ddd, J = 3.8, 7.1, 10.9 Hz, 1H), 1.40 - 1.28 (m, 2H), 0.85 - 0.73 (m, 2H), 0.05 (s, 9H); LC-MS (ESI+) m / z 617.2 (M+H)+,Step 2 - 1 -(2-(l -Acetylpiperidin-4-yl)ethyl)-4-((6-chloro-4-(l -fluorocyclobutyl)pyridm-2-yl)oxy)-lH-benzo[d]imidazol-2(3H)-one

[0488] To a solution of l-(2-(l-acetylpiperidin-4-yl)ethyl)-4-((6-chloro-4-(l- fluorocyclobutyl)pyridin-2-yl)oxy)-3-((2-(trimethylsilyl)ethoxy)methyl)-lH- benzo[d]imidazol-2(3H)-one (0.3 g, 490 pmol) in DCM (1 mL) was added TEA (363 mg, 3.59 mmol, 0.5 mL). The mixture was then stirred at 25 °C for 2 h. Then NI F / MeOH (2 M, 3 mL) was added at 25 °C and the mixture was stirred for 2 h. Upon completion, the reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (20 mL x 3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The crude product was purified by reversed-phase HPLC (neutral condition) to give the title compound (0.17 g, 72% yield) as a yellow solid. LC-MS (ESI+) m / z 487.1 (M+H)+.l-(l-(4,4-Difluorocyclohexyl)ethyl)-4-(tributylstannyl)-lH-imidazole (Intermediate P)Page 171 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOStep 1 - 4,4-Difluoro-N-methoxy-N-methylcyclohexanecarboxamide

[0489] To a solution of N, O-dimethylhydroxylamine hydrochloride (163 g, 1.68 mol, CAS# 6638-79-5), HATU (637 g, 1.68 mol) and DIEA (394 g, 3.05 mol) were added in a solution of 4,4-difluorocyclohexanecarboxylic acid (250 g, 1.52 mol, CAS# 122665-97-8) in DMF (2 L) at 20 °C, and the mixture was stirred for 1 h. Upon completion, the reaction mixture was poured into water (4000 mL), and then extracted with EtOAc (1000 mL x 3). The combined organic layers were washed with brine (500 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO; 5000 g SepaFlash Silica Flash Column, Eluent of 0-30% Ethyl acetate / Petroleum ethergradient @ 400 mL / min) to give the title compound (680 g, 97 % yield) as a yellow oil.Step 2 - l-(4,4-Difluorocyclohexyl)ethanone

[0490] A mixture of 4,4-difluoro-N-methoxy-N-methylcyclohexanecarboxamide (220 g, 956 mmol) in THF (2 L) was added bromo(methyl)magnesium (3 M, 414 mL) at 0 °C under N2, and the mixture was stirred at 25 °C for 2 h. Upon completion, the reaction mixture was poured into water (2000 mL), and then extracted with EtOAc (1000 mL x 3). The combined organic layers were washed with brine (1000 mL x 3), dried over NasSC, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO; 4000 g SepaFlash Silica Flash Column, Eluent of 0-30% Ethyl acetate / Petroleum ether gradient @ 400 mL / min) to give the title compound (258 g, 83% yield) as a yellow oil.Step 3 - l-(4,4-Difluorocyclohexyl)ethanol

[0491] A mixture of l-(4,4-difhrorocyclohexyl)ethanone (258 g, 1.59 mol) in EtOH (2.5 L) was added NaBEU (77.1 g, 2.04 mol) at 0 °C under N2. The mixture was stirred at 0 °C for 1 h.Page 172 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO Upon completion, the reaction mixture was poured into NH4CI solution (1000 mL), and then extracted with EtOAc (500 mL x 3). The combined organic layers were washed with brine (500 mL x 3), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (S1O2, Petroleum ether / Ethyl acetate=20 / l-3 / l) to give the title compound (208 g, 80% yield) as a yellow oil.1! I NMR (400 MHz, CDCL-d) 6 = 3.64 (quin, J = 5.6 Hz, 1H), 2.18 - 2.06 (m, 2H), 2.02 - 1.90 (m, 1H), 1.80 - 1.59 (m, 3H), 1.42 - 1.32 (m, 3H), 1.20 (dd, J = 1.2, 6.4 Hz, 3H).Step 4 - 1 -(1 -(4,4-Difluorocyclohexyl)elhyl)-4-iodo-l H-imidazole

[0492] A mixture of 4-iodo-l H-imidazole (11.8 g, 60.9 mmol, CAS# 71759-89-2), l-(4,4-difluorocyclohexyl)ethanol (10 g, 60.9 mmol) and 2-(tributyl-phosphanylidene)acetonitrile (14.7 g, 60.9 mmol) in toluene (100 mL) was degassed and purged with N2 three times, and then the mixture was stirred at 100 °C for 12 h under N2 atmosphere. Upon completion, the reaction mixture was poured into water (200 mL), and then extracted with EtOAc (300 mL x 3). The combined organic layers were washed with brine (300 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (SiO2, Petroleum ether / Ethyl acetate=20 / 1-3 / 1). Then the residue was purified by prep-HPLC (column: Phenomenex luna C18 (250*70mm,10 urn); mobile phase: [water(FA)-ACN];gradient:20%-50% B over 20 min ) to give desired compound. Next, the residue was purified by flash silica gel chromatography (SiO2, Petroleum ether / Ethyl acetate=3 / l) to give the title compound (3.5 g, 17% yield) as yellow oil. LC-MS (ESI+) m / z 340.9 (M+H)+; 'll NMR (400 MHz, DMSO-d6) 5 =7.70 (s, 1H), 7.46 (s, 1H), 4.18 - 4.07 (m, 1H), 2.06 - 1.91 (m, 3H), 1.86 - 1.66 (m, 4H), 1.40 (d, J= 6.8 Hz, 3H), 1.22 - 1.15 (m, 2H).Step 5 - l-(l- 4,4-Difluorocyclohexyl)ethyl)-4-(tributylstannyl)-lH-imidazole

[0493] To a solution of l-(l-(4,4-difluorocyclohexyl)ethyl)-4-iodo-lH-imidazole (7.5 g, 22.0 mmol) in THF (20 mL) was added chloro(isopropyl)magnesium (2 M, 22.1 mL) and the mixture was degassed and purged with N2 three times. Then the mixture was stirred at 0 °C for 1 h under N2 atmosphere. Next, tributyl(chloro)stannane (8.61 g, 26.5 mmol, 7.12 mL) was added and the mixture was stirred at 0 °C under N2 atmosphere for 1 h. Upon completion, the reaction mixture was quenched with aq. NH4C1 (20 mL) and extracted with EtOAc (3x20 mL). The combined organic extracts were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo to give the title compound (16.3 g) as yellow oil. LC-MS (ESI+) m / z 505.1 (M+H)+.Page 173 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO (S)-l-( l-(4,4-difluorocyclohexyl)ethyl)-4-(tributylstannyl)-lH-imidazole (Intermediate Q)Step 1 - (S)-l-(l-(4,4-difluorocyclohexyl)ethyl)-4-iodo-lH-imidaz.ole

[0494] l-(l-(4,4-difluorocyclohexyl)ethyl)-4-iodo-lH-imidazole (synthesized via Steps 1-4 of Intermediate P, 35 g) was purified by SFC (column: DAICEL CHIRALPAK IC (250mm*50mm,10um);mobile phase: [CO2-MeOH(0.1%NH3H2O)];gradient:30%-% B over 3.5 min) to afford the first eluting peak as (S)-l-(l-(4,4-difluorocyclohexyl)ethyl)-4-iodo-lH-imidazole (17.1 g, 46% yield) as a white solid.Step 2 - (S)-l-(l-(4,4-difluorocyclohexyl)ethyl)-4-(tributyistannyl)-lH-imidazole

[0495] To a solution of (S)-l-(l-(4,4-difluorocyclohexyl)ethyl)-4-iodo-lH-imidazole (24.5 g, 72.0 mmol) in THF (200 mL) was added chloro(isopropyl)magnesium (2 M, 72.03 mL) and the mixture was degassed and purged with N2 three times. Then the mixture was stirred at 0 °C for 2 h under N2 atmosphere. Next, tributyl(chloro)stannane (28.1 g, 86.4 mmol, 23.3 mL) was added and the mixture was stirred at 0 °C under N2 atmosphere for 2 h. Upon completion, the reaction mixture was quenched with aq. NH4C1 (20 mL) and extracted with EtOAc (3x20 mL). The extracts were washed with brine (20 mL), dried over Na2SC>4, filtered and concentrated in vacuo to give the title compound (34.5 g) as yellow oil. LC-MS (ESI+) m / z 505.1 (M+H)+.4-Butyl-2,6-dichloropyridine (Intermediate R)Step 1 - Butylzinc(Il) bromidePage 174 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0496] A schlenk flask was charged Zn (3.60 g, 55.1 mmol) and heated at 70 °C under high vacuum for 1 h. Then the reaction was cooled to 20 °C and I2 (463 mg, 1.82 mmol, 367 giL) in DMA (19 mL) was added under N2, and the mixture was stirred until the mixture was colorless. Next, 1-bromobutane (5 g, 36.5 mmol, 3.94 mL) in DMA (19 mL) was added at 20 °C, and the mixture was stirred at 70 °C for 12 h. Upon completion, the mixture was concentrated in vacuo to give the title compound (7.39 g) as an orange oil.Step 2 - 4-Buty 1-2, 6- dichloropyridine

[0497] To a solution of 2,6-dichloro-4-iodo-pyridine (2.50 g, 9.13 mmol, CAS# 98027-84-0), bromo(butyl)zinc (7.39 g, 36.5 mmol), and Pd(PPh3)4 (527 mg, 456 pmol) in THF (5 mL) was degassed and purged with N2 three times. Then the mixture was stirred at 20 °C for 12 h under N2 atmosphere. Upon completion, the reaction mixture was quenched with NH4CI (20 mL), and then extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (20 mL x 3), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The crude product was triturated with Petroleum ether (10 mL) at -20 °C for 10 min and purified by column chromatography (SiCL, Petroleum ether / Ethyl acetate=100 / 0 to 99 / 1) to give the title compound (620 mg, 32% yield) as a white oil.JH NMR (400 MHz, DMSO-de) 5 = 7.46 (s, 2H), 2.66 - 2.60 (m, 2H), 1.61 - 1.52 (m, 2H), 1.28 (d, J = 7.6 Hz, 2H), 0.88 (t, J = 7.2 Hz, 3H).l-(2-(l-Acetylpiperidin-4-yl)ethyI)-4-((4-butyl-6-chloropyridin-2-yl)oxy)-lH-benzo[d]imidazol-2(3H)-one (Intermediate S)Page 175 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOStep 1 - l-(2-(l -Acetylpiperidin-4-yl)ethyl)-4- ( 4-butyl-6-chloropyridin-2-yl)oxy)-3-((2-(trimethylsilyl)ethoxy)methyl)-lH-benzo[d]imidazol-2(3H)-one

[0498] To a solution of l-(2-(l-acetylpiperidin-4-yl)ethyl)-4-hydroxy-3-((2-(trimethylsilyl)ethoxy)methyl)-lH-benzo[d]imidazol-2(3H)-one (1.10 g, 2.53 mmol, Intermediate N), 4-butyl-2,6-dichloro-pyridine (620 mg, 3.04 mmol, Intermediate R), CU2O (72.4 mg, 506 pmol), MNBO (80.6mg, 253 pmol) and K3PO4 (698 mg, 3.29 mmol) in DMSO (11 mL) was degassed and purged with N2 three times. Then the mixture was stirred at 120 °C for 12 h under N2 atmosphere. Upon completion, the reaction mixture was quenched with H2O (20 mL), and then extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (20 mL x 3), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiCh, Petroleum ether / Ethyl acetate=l / l to 0 / 1) to give the title compound (1.1 g, 72% yield) as a white solid. LC-MS (ESI+) m / z 601.5(M+II)+.Step 2 - l-(2-(l-Acetylpiperidin-4-yl)ethyl)-4-((4-butyl-6-chloropyridin-2-yl)oxy)-3- (hydroxymethyl)-lH-benzo[ d ]imidazol-2( 3H)-onePage 176 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0499] To a solution of l-(2-(l-acetylpiperidin-4-yl)ethyl)-4-((4-butyl-6-chloropyridin-2-yl)oxy)-3-((2-(trimethylsilyl)ethoxy)methyl)-lH-benzo[d]imidazol-2(3H)-one (1.1 g, 1.8 mmol) TFA (4.61 g, 40.4 mmol, 3 mL) in DCM (9 mL) was degassed and purged with N2 three times, and then the mixture was stirred at 20 °C for 1 h under N2 atmosphere. Upon completion, the mixture was quenched with Nal ICO? (20 mL), and then extracted with DCM (20 mL x 3). The combined organic layers were washed with brine (10 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate=O / l to DCM: MeOH = 10:1) to give the title compound (1.2 g) as an orange oil. LC-MS (ESI+) m / z 501.1 (M+H)+.Step 3 - l-(2-(l-Acetylpiperidin-4-yl)ethyl)-4-((4-butyl-6-chloropyridin-2-yl)oxy)-lH-benzo[d]imidazol -2(3 H)-one

[0500] To a solution of l-(2-(l-acetylpiperidin-4-yl)ethyl)-4-((4-butyl-6-chloropyridin-2-yl)oxy)-3-(hydroxymethyl)-lH-benzo[d]imidazol-2(3H)-one (1.2 g, 2.4 mmol), in NI L / MeOI I (20 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 20 °C for 1 h under N2 atmosphere. Upn completion, the reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiCL, Ethyl acetate to Ethyl acetate / THF= 95 / 5) to give the title compound (470 mg, 42% yield) as a white solid. LC-MS (ESI+) m / z 471.1 (M+H)+.4-(3-(l,3-Dioxolan-2-yI)propyl)-2,6-dichloropyridine (Intermediate T)Step 1 - (3-(l,3-dioxolan-2-yl)propyl)zinc(II) bromide

[0501] A schlenk flask was charged Zn (20.3 g, 310 mmol, CAS# 62563-07-9) and heated at 70 °C under high vacuum for 1 h. Then the flask was cooled to 20 °C and I2 (2.60 g, 10.3 mmol) in DMA (100 mL) was added under N2, and the mixture was stirred until the mixture was colorless. Next, 2-(3-bromopropyl)-l,3-dioxolane (40 g, 200 mmol, CAS# 62563-07-9) in DMA (100 mL) was added at 20 °C, and the mixture was stirred at 70 °C for 12 h. Upon completion, the reaction mixture was the title compound (53 g) as a yellow oil.Page 177 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO Step 2 - 4-(3-(l,3-Dioxolan-2-yl)propyl)-2,6-dichloropyridine

[0502] To a solution of bromo-[3-(l,3-dioxolan-2-yl)propyl]zinc (1 M, 175 mL), 2,6-dichloro-4-iodo-pyridine (12 g, 43.8 mmol, CAS# 98027-84-0), and Pd(PPh3)4 (2.53 g, 2.19 mmol) in THF (24 mL) was degassed and purged with N2 three times. Then the mixture was stirred at 25 °C for 12 h under N2 atmosphere. Upon completion, the reaction mixture was quenched with NH4CI (200 mL), and then extracted with EtOAc (200 mL x 3). The combined organic layers were washed with brine (100 mL x 3), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiC>2, Petroleum ether / Ethyl acetate=20 / l to 5 / 1) to give the title compound (11.3 g, 98% yield) as a yellow oil. ’ll NMR (400 MHz, DMSO-d6) 5 = 7.47 (s, 2H), 4.79 (t, J = 4.6 Hz, 1H), 3.89 - 3.72 (m, 4H), 2.67 (t, 7 = 7.6 Hz, 2H), 1.71 - 1.63 (m, 2H), 1.59 - 1.52 (m, 2H).4-((4-(3-(l,3-Dioxolan-2-yI)propyl)-6-chloropyridin-2-yI)oxy)-l-(2-(l-acetylpiperidin-4-yl)ethyl)-lH-benzo[d]imidazol-2(3H)-one (Intermediate U)Step 1 - 4-((4-(3-(l,3-Dioxolan-2-yl)propyl)-6-chloropyridin-2-yl)oxy)-l-(2-(l-acetylpiperidin-4-yl)ethyl)-3- (2- trimethylsilyl)ethoxy)methyl)-lH-benzo[d]imidazol-2(3H)-one

[0503] To a solution of l-(2-(l-acetylpiperidin-4-yl)ethyl)-4-hydroxy-3-((2-(trimethylsilyl)ethoxy)methyl)-lH-benzo[d]imidazol-2(3H)-one (2 g, 5 mmol, Intermediate N),Page 178 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO 4-(3-(L3-dioxolan-2-yl)propyl)-2,6-dichloropyridine (1.45 g, 5.53 mmol, Intermediate T), C112O (132 mg, 922 pmol, 94.3 pL), MNBO (146 mg, 461 pmol) and K3PO4 (1.27 g, 6.00 mmol) in DMSO (20 mL) was degassed and purged with N2 three times. Then the mixture was stirred at 120 °C for 6 h under N2 atmosphere. Upon completion, the reaction mixture was quenched with H2O (20 mL), and then extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (20 mL x 3), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (FA condition; 50%-55%) to give the title compound (2.8 g, 92% yield) as a brown solid. LC-MS (ESI+) m / z 659.3(M+H)+.Step 2 - 4-((4-(3-(l,3-Dioxolan-2-yl)propyl)-6-chlompyridin-2-yl)oxy)-l-(2-(l-acetyipiperidin-4-yl)ethyl)-3-(hydroxymethyi)-lH-benzo[d]imidazol-2(3H)-one

[0504] A solution of 4-((4-(3-(l,3-dioxolan-2-yl)propyl)-6-chloropyridin-2-yl)oxy)-l-(2-(l-acetylpiperidin-4-yl)ethyl)-3-((2-(trimethylsilyl)ethoxy)methyl)-lH-benzo[d]imidazol-2(3H)-one (2.7 g, 4.1 mmol) in TFA (18.4 g, 161 mmol, 12mL) and DCM (12 mL) was degassed and purged with N2 three times, and then the mixture was stirred at 20 °C for 1 h under N2 atmosphere. Upon completion, the reaction mixture was concentrated under reduced pressure to give a residue. The residue was quenched with NaHCCh (10 mL), and then extracted with DCM (20 mL x 3). The combined organic layers were washed with brine (20 mL x 3), dried over Na2SC>4, filtered and concentrated under reduced pressure to give the title compound (2.2 g) as an orange oil. LC-MS (ESI+) m / z 559.1(M+H)+.Step 3 - 4-((4-(3-(l,3-Dioxolan-2-yl)propyl)-6-chloropyridin-2-yl)oxy)-l-(2-(l-acetydpiperidin-4-yl )ethyl)-lH-benzo[ d]imidazol-2(3H)-one

[0505] A solution of 4-((4-(3-(l,3-dioxolan-2-yl)propyl)-6-chloropyridin-2-yl)oxy)-l-(2-(l-acetylpiperidin-4-yl)ethyl)-3-(hydroxymethyl)-HI-benzo[d]imidazol-2(3II)-one (2 g, 4 mmol) in NI L / MeOI I (25 mL) was degassed and purged with N2 three times, and then the mixture was stirred at 20 °C for 1 h under N2 atmosphere. Upon completion, the reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (HC1 condition) to give the title compound (1 g, 53% yield) as a white solid. LC-MS (ESI+) m / z 529.2(M+H)+.Tert-butyl (4-((l-((4,4-difluorocyclohexyI)methyl)-4-(4,4,5,5-tetramethyI-l,3,2-dioxaborolan-2-yl)-lH-pyrazol-3-yl)oxy)butyl)carbamate (Intermediate V)Page 179 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOStep 1 - l-(3-Hydroxy-lH-pyrazol-l-yl)ethan-l-one

[0506] To a solution of lH-pyrazol-3-ol (90 g, 1.07 mol) in pyridine (450 mL) was added AC2O (120 g, 1.18 mol, 110 mL) and the mixture was stirred at 95 °C for 10 hrs. Upon completion, the reaction mixture was quenched with H2O (500 mL), and then diluted with EA (500 mL) and extracted with EA (1000 mL x 2). The combined organic layers were washed with NaCl (500 mL x 2), dried over NaCl, filtered and concentrated under reduced pressure to give a residue. The crude product was triturated with MeOH at 25 °C for 30 mins, to give the title compound (98.5 g, 73% yield) as a white solid.rH NMR (400 MHz, DMSO-d6) 5 = 10.96 (br s, 1H), 8.12 (d, J = 3.0 Hz, 1H), 6.00 (d. J = 2.9 Hz. 1H), 2.47 (s, 3H).Step 2 - Tert-butyl (4-( l-acetyTlH-pyrazoT3-yl)oxy)butyl)carbamate

[0507] To a solution of l-(3-hydroxypyrazol-l-yl)ethanone (11.9 g, 94.4 mmol) and tert-butyl N-(4-bromobutyl)carbamate (25 g, 99.2 mmol, 20.4 mL) in DMF (150 mL) was added K2CO3 (26.1 g, 189 mmol). Then the mixture was stirred at 80 °C for 12 hrs. Upon completion, the reaction mixture was quenched with H2O (100 mL), and then diluted with EA (100 mL) and extracted with EA (300 mL x 2). The combined organic layers were washed with NaCl (100 mL x 2), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue.Page 180 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO The residue was purified by column chromatography (SiC>2, Petroleum ether / Ethyl acetate=20 / l to 5 / 1) to give the title compound (18 g, 62% yield) as a white solid. LC-MS (ESI+) m / z 320.1 (M+H)+.Step 3 - Tert-butyl (4-((lH-pyrazol-3-yl)oxy)butyl)carbamate

[0508] To a solution oftert-butyl N-[4-(l-acetylpyrazol-3-yl)oxybutyl]carbamate (17.8 g, 59.9 mmol) in MeOH (150 mL) was added NaOH (6 M, 9.98 mL) and the mixture was stirred at 25 °C for 12 hrs. Upon completion, the reaction mixture was quenched with H2O (50 mL), and then diluted with EA (100 mL) and extracted with EA (400 mL x 2). The combined organic layers were washed with NaCl (200 mL x 2), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The crude product was triturated with PE at 25 °C for 30 mins to give the title compound (15 g, 98% yield) as a white solid. LC-MS (ESI+) m / z 278.0 (M+H)+.Step 4 - Tert-butyl (4-((4-bromo-lH-pyrazol-3-yl)oxy)butyl)carbamate

[0509] To a solution of tert-butyl N-[4-(lH-pyrazol-3-yloxy)butyl]carbamate (12.1 g, 47.4 mmol) in ACN (100 mL) was added NBS (9.28 g, 52.1 mmol) and the mixture was stirred at 25 °C for 12 hrs. Upon completion, the reaction mixture was quenched with H2O (50 mL), and then diluted with EA (50 mL) and extracted with EA (100 mL x 2). The combined organic layers were washed with NaCl (50 mL x 2), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiCL, Petroleum ether / Ethyl acetate=10 / l to 1 / 1) to give the title compound (11 g, 60% yield) as a white solid. LC-MS (ESI+) z 234.0 (M+H)+.Step 5 - Tert-butyl (4-((4-bromo-l-((4,4-difluorocyclvhexyl)methyl)-lH-pyrazol-3-yl)oxy )butyl)carbamate

[0510] To a solution of tert-butyl N-[4-[(4-bromo- lH-pyrazol-3-yl)oxy]butyl]carbamate (5.10 g, 10.7 mmol) l,l-difluoro-4-(iodomethyl)cyclohexane (5 g, 20 mmol) in DMSO (50 mL) was added CS2CO3 (10.4 g, 32.0 mmol) and the mixture was stirred at 60 °C for 12 hrs. Upon completion, the reaction mixture was quenched with II2O (20 mL), and then diluted with EA (20 mL) and extracted with EA (100 mL x 2). The combined organic layers were washed with NaCl (30 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiCh, Petroleum ether / Ethyl acetate=10 / l to 4 / 1) to give the title compound (3.3 g, 53% yield) as a white solid.JH NMR (400 MHz, DMSO-d6) 5 = 7.77 (s, 1H), 6.81 (br s, 1H), 4.09 (br t, J = 6.4 Hz, 2H), 3.84 (br d,Page 181 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO J = 7.0 Hz, 2H), 2.99 - 2.91 (m, 2H), 2.02 - 1.89 (m, 3H), 1.81 - 1.71 (m. 2H), 1.69 - 1.63 (m, 2H), 1.57 (br d, J = 13.1 Hz, 2H), 1.51 - 1.44 (m, 2H), 1.37 (s, 9H), 1.18 (br d, J = 12.9 Hz, 2H); LC-MS (ESI+) m / z 410.0 (M+H)+.Step 6 - Tert-butyl (4-((l-((4,4-difluorocyclohexyl)methyl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazol-3-yl)oxy)butyl)carbamate

[0511] To a solution of tert-butyl N-[4-[4-bromo-l-[(4,4-difluorocyclohexyl)methyl]pyrazol-3-yl]oxybutyl]carbamate (3.2 g, 6.86 mmol) and B2Pin2 (17.4 g, 68.6 mmol) in dioxane (50 mL) was added KOAc (2.02 g, 20.6 mmol) and XPhos Pd G3 (581 mg, 686 pmol) and the mixture was stirred at 100 °C for 2 hrs. Upon completion, the reaction mixture was quenched with H2O (10 mL), and then diluted with EA (20 mL) and extracted with EA (50 mL x 2). The combined organic layers were washed with NaCl (30 mL x 2), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography CS1O2. Petroleum ether / Ethyl acetate=10 / l to 3 / 1) to give the title compound (3.2 g, 42% yield) as a white solid. LC-MS (ESI+) m / z. 514.0 (M+H)+.7-[(6-Bromo-4-methyl-2-pyridyl)oxy]-3-methyl-lH-benzimidazol-2-one (Intermediate W)Step 1 - 4-Hydroxy-l-methyl-l,3-dihydro-2H-benzo[d]imidazol-2-one

[0512] To a solution of 4-(benzyloxy)-l-methyl-l,3-dihydro-2H-benzo[d]imidazol-2-one (50 g, 200 mmol, synthesized via Steps 1-4 of Intermediate Y) in DCM (500 mL) was added BBr3 (148 g, 590 mmol, 56.8 mL) dropwise. Then the mixture was stirred at 25 °C for 12 h. Upon completion, the reaction mixture was quenched with MeOH (1200 mL) at 0 °C and concentrated under reduced pressure to give a residue. The crude product was triturated with MeOH: DCM=10 / l(100 ml) at 40 °C for 30 min to afford the title compound (26 g, 74% yield) as an off-white solid. LC-MS (ESI+) m / z 165.0 (M+1H)+; ’ll NMR (400 MHz, DMSO-d6) 5 = 10.58 (s, 1H), 10.12 - 8.75 (m, 1H), 6.85 - 6.76 (m, 1H), 6.53 (dd, J = 8.0, 18.0 Hz, 2H), 3.22 (s, 3H)Page 182 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO Step 2 - 4-((6-Bromo-4-methylpyridin-2-yl)oxy)-l-methyl-l,3-dihydro-2H-benzo[dJimidazol-2-one

[0513] To a solution of 4-hydroxy-l-methyl-l,3-dihydro-2H-benzo[d]imidazol-2-one (5 g, 30.5 mmol) and 2-bromo-6-fluoro-4-methylpyridine (6.08 g, 32.0 mmol, CAS# 180608-37-1) in DMF (50 niL) was added K2CO3 (12.6 g, 91.4 mmol). Then the mixture was stirred at 100 °C for 12 h. Upon completion, the reaction mixture was quenched with water 150 mL at 20 °C, and extracted with EtOAc (200 mL x 4). The combined organic layers were washed with brine (60 mL x 2), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The crude product was triturated with EtOAc at 45 °C for 30 min to afford the title compound (4.4 g, 43% yield) as a white solid. LC-MS (ESI+) m / z 336.0 (M+1H)+; ’ll NMR (400 MHz, DMSO-dfi) 8 = 11.07 (br d, J= 3.6 Hz, 1H), 7.24 (s, 1H), 7.06 - 6.98 (m, 2H), 6.85 - 6.76 (m, 2H), 3.30 (s, 3H), 2.31 (s, 3H).Tert-butyl 4-(((l-((4,4-difluorocyclohexyl)methyl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazol-3-yl)oxy)methyl)piperidine-l-carboxylate (Intermediate X)Step 1 - 4-Bromo-l-((4,4-difluorocyclohexyl)methyl)-3-methoxy-lH-pyrazole

[0514] To a solution of 4-bromo-3-methoxy-lH-pyrazole (5 g, 30 mmol, CAS# 576415-02-8) and l,l-difhioro-4-(iodomethyl)cyclohexane (7.35 g, 28.2 mmol, CAS# 1147011-26-4) in DMSO (50 mL) was added CS2CO3 (27.6 g, 84.7 mmol) and the mixture was stirred at 40 °C for 3 h. Upon completion, the mixture was filtered. The crude product was purified by reversed-phase HPLC( 0.1% FA condition) to afford the title compound (3.2 g, 37% yield)) as a white solid. LC-MS (ESI) m / z 311.0[M+l ]+; ‘H'H NMR (400 MHz, DMSO-d6) 8 = 7.78 (s, 1H),Page 183 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO 3.85 (d, 7= 7.2 Hz, 2H), 3.81 (s, 3H), 2.03 - 1.91 (m, 3H), 1.81 - 1.68 (m, 2H), 1.57 (brd, J = 13.2 Hz, 2H), 1.22 - 1.13 (m, 2H).Step 2 - 4-Bromo-l-((4,4-difluorocyclohexyl)methyl)-lH-pyrazol-3-ol

[0515] To a solution of 4-bromo-l-[(4,4-difluorocyclohexyl)methyl]-3-methoxy-pyrazole (750 mg, 2.43 mmol) in AcOH (30 mL) was added HBr (37.2 g, 184 mmol, 92.0 mL, 40% solution) and the mixture was stirred at 90 °C for 4 h under N2. Upon completion, the mixture was concentrated under reduced pressure to give a residue. The crude product was purified by reversed-phase HPLC( 0.1% FA condition) to give the title compound (250 mg, 35% yield) as a white solid. LC-MS (ESI) m / z 296.0 [M+l]+.Step 3 - Tert-butyl 4-(((4-bromo-l-((4,4-difluorocyclohexyl)methyl)-lH-pyrazoT3-yl)oxy )melhyl)piperidine-l -carboxy late

[0516] To a solution of 4-bromo-l-[(4,4-difluorocyclohexyl)methyl]pyrazol-3-ol (200 mg, 508 pmol) and tert-butyl 4-(bromomethyl)piperidine-l -carboxylate (141 mg, 508 pmol, CAS# 158407-84-6) in NMP (2 mL) was added K2CO3 (210 mg, 1.52 mmol). The mixture was stirred at 100 °C for 2h. Upon completion, the reaction mixture was poured into II2O (4 mL) and extracted with EtOAc (5mL x3). The combined organic layers were washed with brine (10 mL x 2), dried over Na2SC>4 filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiCL, Petroleum etherEthyl acetate=3:l to Petroleum etherEthyl acetate=O:l). The residue was then re -purified by column chromatography (SiCL, Petroleum etherEthyl acetate=5:l to Petroleum etherEthyl acetate=O:l) to afford the title compound (80 mg, 32% yield) as a white solid. LC-MS (ESI) m / z 394.0[M+l]+Step 4 - Tert-butyl 4-(((l-((4,4-difluorocyclohexyl)methyl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazol-3-yl)oxy)methyl)piperidine-l-carboxylate

[0517] To a solution of tert-butyl 4-[[4-bromo-l-[(4,4-difluorocyclohexyl)methyl]pyrazol-3-yl]oxymethyl]piperidine-l -carboxylate (70 mg, 142 pmol) and 4,4,5,5-tetramethyL2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (108 mg, 426 mol) in dioxane (0.5 mL) was added K2CO3 (58.9 mg, 426 pmol) and Pd(dppf)C12. CH2C12 (11.6 mg, 14.2 pmol). The mixture was then stirred at 100 °C for Ih under N2. Upon completion, the mixture was filtered and concentrated under reduced pressure to give a residue. The crude product was purified by reversed-phase HPLC( 0.1% FA condition) to afford the title compound (40 mg, 52% yield) as a white solid. LC-MS (ESI) m / z 540.2 [M+l]+.Page 184 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO 4-Hydroxy-l-methyl-3-((2-(trimethylsilyl)ethoxy)methyl)-lH-benzo[d]imidazol- 2(3H)-one (Intermediate Y)Step 1 - l-(Benzyloxy)-3-fluoro-2-nitrobenzene

[0518] To a solution of 3-fluoro-2-nitro-phenol (165 g, 1.05 mol, CAS# 385-01-3) and K2CO3 (290 g, 2.10 mol) in DMF (1600 mL) was added BnBr (269 g, 1.58 mol, 187 mL) at 0 °C. Then the mixture was stirred at 25 °C for 10 h. Upon completion, the reaction mixture was poured into ice water (1.6 L) and extracted with EtOAc (1 L x 4). The combined organic layers were washed with brine (1 L x 8), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate=l / 0 to 10 / 1) to afford the title compound (240 g, 92% yield) as a yellow oil. 'll NMR (400 MHz, DMSO-d6) 5 = 7.65 - 7.58 (m, 1H), 7.44 - 7.32 (m, 5H), 7.29 (d, J = 8.8 Hz, 1H), 7.13 (t, J = 9.2 Hz, 1H), 5.33 (s, 2H).Step 2 - 3-(Benzyloxy)-N-methyl-2-nitroaniline

[0519] To a solution of l-benzyloxy-3-fluoro-2-nitro-benzene (30.0 g, 121 mmol) and methanamine hydrochloride (40.9 g, 606 mmol) in NMP (300 mL) was added K2CO3 (167 g, 1.21 mol). Then the mixture was stirred at 60 °C for 10 h. Upon completion, the reaction mixture was poured into ice water (300 mL) and extracted with EtOAc (500 mL x 3). The combined organic layers were washed with brine (500 mL x 3), dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound (30.0 g) as a yellow oil. ’ll NMR (400 MHz, DMSO-d6) 5 = 7.41 - 7.36 (m. 4H), 7.34 - 7.24 (m, 2H), 6.49 (d, J = 8.4 Hz. 1H), 6.40 (d, J = 8.8 Hz, 1H), 6.19 (br d, J = 4.8 Hz, 1H), 5.17 (s, 2H), 2.74 (d, J = 4.8 Hz, 3H).Page 185 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO Step 3 - 3-(benzyloxy)-N1-methylbenzene-1,2-diamine

[0520] To a solution of 3-(benzyloxy)-N-methyl-2-nitroaniline (30.0 g, 116 mmol) in EtOH (1000 mL) and H2O (500 mL) was added Fe (32.4 g, 580 mmol) and NH4CI (62.1 g, 1 • 16 mol). The mixture was then stirred at 80 °C for 0.5 h. Upon completion, the reaction mixture was filtered and concentrated under reduced pressure to give a residue and extracted with EtOAc (200 mL x 3). The combined organic layers were washed with brine (200 mL x 3), dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound (25.0 g) as a yellow solid.1H NMR (400 MHz, DMSO-d6) δ = 7.46 (d, J = 7.2 Hz, 2H), 7.41 -7.35 (m, 2H). 7.34 - 7.28 (m, 1H), 6.54 - 6.47 (m, 1H), 6.37 (dd, J = 1.2, 8.4 Hz, 1H), 6.15 (dd, J = 0.8, 8.0 Hz, 1H), 5.05 (s, 2H), 4.65 (br d, J = 2.8 Hz, 1H), 4.09 - 3.94 (m, 2H), 2.70 (br d, J = 3.2 Hz, 3H)Step 4 - 4-(benzyloxy)-l-nwthyl-l,3-dihydro-2H-benzo[d]imidazol-2-one

[0521] To a solution of 3-benzyloxy-N1-methyl-benzene-1,2-diamine (25.0 g, 109 mmol) in DMF (300 mL) was added GDI (26.6 g, 164 mmol) and DIEA (42.4 g, 329 mmol, 57.2 mL). The mixture was then stirred at 100 °C for 12 h. Upon completion, the reaction mixture was poured into ice water (300 mL) and extracted with EtOAc (500 mL x 3). The combined organic layers were washed with brine (500 mL x 3), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (TSCO®; 120 g SepaFlash® Silica Flash Column, Eluent of 0-40% Ethyl acetate / Petroleum ether gradient @ 150 mL / min) to afford the title compound (7.20 g, 26% yield) as a yellow solid. 'll NMR (400 MHz, DMSO-d6) 5 = 11.03 (s, 1H), 7.52 (d, J = 7.2 Hz, 2H), 7.41 - 7.35 (m, 2H), 7.33 - 7.28 (m, 1H), 6.96 - 6.89 (m, 1H), 6.75 (dd, J = 8.0. 17.4 Hz, 2H), 5.21 (s, 2H), 3.25 (s, 3H).Step 5 - 4-(benzyloxy)-l-methyl-3-((2-(trimethylsilyl)ethoxy)methyl)-l,3-dihydro-2H-benzo[ d ]imidazol-2-one

[0522] To a solution of 4-(benzyloxy)-l -methyl- l,3-dihydro-2H-benzo[d]imidazol-2-one (7.00 g, 27.5 mmol) in DMF (70 mL) was added NaH (1.65 g, 41.2 mmol, 60% dispersion in mineral oil) at 0 °C. After stirring for 1 hr, SEM-C1 (5.51 g, 33.0 mmol, 5.85 mL) was added and the mixture was stirred at 25 °C for 12 h. Upon completion, the reaction mixture was quenched with ice water (70 mL) and extracted with EtOAc (70 mL x 3). The combined organic layers were washed with brine (70 mL x 3), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue The residue was purified by flash silica gel chromatography (ISCO 80 g SepaFlash Silica Flash Column, Eluent of 0-10% Ethyl Page 186 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO acetate / Petroleum ether gradient @ 100 mL / min) to afford the title compound (7.40 g, 70% yield) as a yellow oil.1H NMR (400 MHz, DMSO-d6) 5 = 7.53 (d, J = 7.2 Hz, 2H), 7.41 - 7.30 (m, 3H), 7.07 - 7.01 (m, 1H), 6.87 (d, J = 8.0 Hz, 1H), 6.82 (d, J = 7.6 Hz, 1H), 5.35 (s, 2H), 5.20 (s, 2H), 3.48 (t, J = 8.0 Hz, 2H), 3.31 (s, 3H), 0.77 (t, J = 8.0 Hz, 2H), -0.10 - -0.14 (m, 9H).Step 6 - 4-hydroxy-l-methyl-3-((2-(trimethylsilyl)ethoxy)methyl)-l,3-dihydro-2H-benzo[ d ]imidazol-2-one

[0523] To a solution of Pd / C (2.00 g, 1.88 mmol, 10 wt%) in MeOH (70 mL) was added 4-(benzyloxy)- 1 -methyl-3-((2-(trimethylsilyl)ethoxy)methyl)- 1,3-dihydro-2H-benzo[d]imidazol-2-one (7.40 g, 19.2 mmol), then the mixture was stirred at 25 °C for 10 h under H2 (15 psi). On completion, the reaction mixture was filtered and concentrated under reduced pressure to give the title compound (5.50 g, 95% yield) as a gray solid, 'll NMR (400 MHz, DMSO-d6) 5 = 10.19 - 9.63 (m. 1H), 6.91 - 6.85 (m, 1H), 6.62 (d, J = 8.0 Hz, 1H), 6.56 (d, J = 8.4 Hz, 1H), 5.35 (s, 2H), 3.59 - 3.54 (m, 2H), 3.27 (s, 3H), 0.85 - 0.78 (m, 2H), -0.08 (s, 8H).l-((6,6-Difluorospiro[3.3]heptan-2-yl)methyl)-4-(tributylstannyl)-lH-imidazole (Intermediate Z)Step 1 - (6,6-Difluorospiro[3.3]heptan-2-yl)methanolPage 187 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0524] To a solution of 6,6-difluorospiro[3.3]heptane-2-carboxylic acid (1 g, 6 mmol, CAS# 1419101-45-3) in THF (10 mL), was added LiAlH4 (2.5 M, 3.63 mL) at 0 °C, then the mixture was stirred at 0 °C for 2 h. Upon completion, Na2SO4.10H2O (5 g) was added to the mixture slowly. The mixture was then filtered and the filtrate was concentrated to afford the title compound (900 mg, 98% yield).1H NMR (400 MHz, CDCl3) 5 = 3.59 (d, J = 6.4 Hz, 2H), 2.60 (dt, J= 2.0, 12.4 Hz, 2H), 2.53 - 2.40 (m, 3H), 2.23 - 2.15 (m, 2H), 1.97 - 1.89 (m, 2H).Step 2 - (6,6-Difluorospiro[3.3]heptan-2-yl)methyl 4-methylbenzenesulfonate

[0525] To a solution of (6,6-difluorospiro[3.3]heptan-2-yl)methanol (900 mg, 5.55 mmol) in DCM (10 mL), was added TEA (1.12 g, 11.1 mmol, 1.54 mL), DMAP (67.8 mg, 554 pmol), and TosCl (1.16 g, 6.10 mmol) at 0 °C. Then the mixture was stirred at 25 °C for 2 h. Upon completion, the reaction mixture was poured into ice water (5 mL) and extracted with DCM (5 mL x 3). The combined organic layers were washed with brine (5 mL x 3), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO; 12 g SepaFlash Silica Flash Column, Eluent of 0-10% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford the title compound (1.1 g, 63% yield). 'll NMR (400 MHz, CDCL) 6 = 7.79 (d, J = 8.4 Hz, 2H), 7.36 (d, J = 8.0 Hz, 2H), 3.97 (d, J= 6.4 Hz, 2H), 2.60 - 2.51 (m, 3H), 2.49 - 2.37 (m, 5H), 2.21 - 2.12 (m, 2H), 1.93 - 1.87 (m, 2H).Step 3 - l-((6,6-Difluorospiro[3.3]heptan-2-yl)methyl)-4,5-diiodo-lH-imidazole

[0526] To a solution of (2,2-difluorospiro[3.3]heptan-6-yl)methyl 4-methylbenzenesulfonate (1.1 g, 3.5 mmol), 4,5 -diiodo- IH-imidazole (1.11 g, 3.48 mmol, CAS# 15813-09-9) in DMF (10 mL) was added K2CO3 (961.1 mg, 6.95 mmol). Then the mixture was stirred at 100 °C for 1 h. Upon completion, the reaction mixture was poured into ice water (10 mL) and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (10 mL x 3), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO; 20 g SepaFlash Silica Flash Column, Eluent of 0-15% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) to afford the title compound (1.3 g, 81% yield). ’ll NMR (400 MHz, DMSO-d6) 5 = 7.90 (s, 1H), 4.00 (d, J = 7.6 Hz, 2H), 2.65 - 2.54 (m, 5H), 2.15 - 2.06 (m, 2H), 1.97 - 1.89 (m, 2H).Step 4 - l-((6,6-Difluorospiro[3.3]heptan-2-yl)methyl)-4-iodo-lH-imidazole

[0527] To a solution of l-((6,6-difluorospiro[3.3]heptan-2-yl)methyl)-4,5-diiodo-lH-imidazole (1.3 g, 2.80 mmol) in THF (20 mL), was added EtMgBr (3 M, 1.21 mL) at -50 °C,Page 188 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO then the mixture was stirred at -50 °C for 0.5 h under N2. Upon completion, the reaction mixture was poured into iced NH4CI (sat. aq. 10 mL) and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (10 mL x 3), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO; 12g SepaFlash Silica Flash Column, Eluent of 0-25% Ethyl acetate / Petroleum ether gradient @ 100 mL / min) to afford the title compound (460 mg, 49% yield).1H NMR (400 MHz, DMSO-de) 8 = 7.59 (s, 1H), 7.34 (s, 1H), 3.95 (d, 7 = 7.6 Hz, 2H), 2.65 - 2.52 (m, 5H), 2.13 - 2.07 (m, 2H), 1.91 - 1.85 (m, 2H).Step 5 - l-((6,6-Difluorospiro[3.3]heptan-2-yl)methyl)-4-(tributylstannyl)-lH-imidazole

[0528] To a solution of l-((6,6-difluorospiro[3.3]heptan-2-yl)methyl)-4-iodo-lH-imidazole (460 mg, 1.36 mmol) in THF (5 mL) was added i-PrMgCl (2 M, 1.36 mL), and the mixture was stirred at 0 °C for 30 min. Then tributyl(chloro)stannane (1.31 g, 4.01 mmol, 1.08 mL) was added at 0 °C, and the mixture was stirred at 25 °C for 1 h under N2. Upon completion, the reaction mixture was poured into ice NH4CI ( sat. aq. 20 mL) and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (20 mL x 3), dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound (680 mg, 100% yield). LC-MS (ESI+) m / z 503.2 (M+H)+.4-Cyclobutyl-6-((l-methyI-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)oxy)picolinic acid (Intermediate AA)Page 189 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOStep 1 - l-(2,6-dichloropyridin-4-yl)cyclobutan-l-ol

[0529] The title compound was synthesized via flow chemistry. Solution 1: 2,6-dichloro-4-iodopyridine (225 g, 822 mmol) in THF (2 L); Solution 2: i-PrMgCl (2 M, 451.83 mL); Solution 3: cyclobutanone (57.58 g, 821.5 mmol, 61.39 mL)in THF (1.0 L). Solution 1 was pumped by Pump 1 (SI, Pl, 12.85 mL / min) to flow reactor 1 (FLR1, SS, Static mixer, 1.5 mL, 0 °C). Solution 2 was pumped by Pump 2 (S2, P2, 2.398 mL / min) to flow reactor 1 (FLR1, SS, Static mixer, 1.5 mL, 0 °C). Solution 3 was pumped by Pump 3 (S3, P3, 6.244 mL / min) to flow reactor 2 (FLR1, PFA, Coils reactor, 3.175(1 / 8”) mm, 21.372 mL, 0 °C). The residence time of flow reactor 1 was 1.5 min; the residence time of flow reactor 2 was 1.561 min. Pump 1 and Pump 2 was started at the same time. The mixture was quenched by slowly collecting the mixture into a bottle with 2 M NH4CI (aq., 2000 mL) at 0 °C. The mixture was extracted with EtOAc (200 mL x 3), then the combined organic layer was concentrated under reduced pressure to remove solvent. The residue was purified by column chromatography (SiCL, Petroleum ether / Ethyl acetate = 1 / 0 to 85 / 15) to give the title compound (100 g, 56% yield). LC-MS (ESI+) m / z 218.0 / 220.2 (M+H)+.Step 2 - 2,6-Dichloro-4-(cyclobut-l -en-1 -yl)pyridinePage 190 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0530] To a solution of l-(2,6-dichloropyridin-4-yl)cyclobutan-l-ol (100 g, 400 mmol) in toluene (1000 mL) was added methoxycarbonyl-(triethylammonio)sulfonyl-azanide (139.32 g, 584.65 mmol), then the mixture was stirred at 80 °C for 12 h. Upon completion, the mixture was concentrated under reduced pressure to remove the solvent. The residue was washed with H2O (200 mL), filtered and the solid was collected. Then the solid was washed with MeOH (100 mL), filtered and the solid was collected to give the title compound (30 g, 39% yield). LC-MS (ESI+) m / z 200.2 (M+H)+.Step 3 - 2,6-Dichloro-4-cyclobutylpyridine

[0531] The title compound was synthesized via flow chemistry. Solution 1: 2,6-dichloro-4-(cyclobut-l-en-l-yl)pyridine (30 g, 150 mmol) in THF (600 mL). The fixed bed (named FLR1, volume 4 mL) was completely packed with granular catalyst Ru-SiCF (10.59 g, 104.8 mmol, 1.50 eq). The H2 back pressure regulator was adjusted to 1.0 MPa, and the flow rate of H2 was 30 mL / min. Then the solution SI was pumped by Pump 1 (SI, Pl, 0.3mL / min) to fixed bed (FLR1, SS, fixed bed, 6.350(l / 4”)mm, 5mL, 50 °C). Then the reaction mixture was collected from the reactor output. The mixture was filtered and the filtrate was concentrated under reduced pressure to remove solvent and give the title compound (26 g, 86% yield). LC-MS (ESI+) m / z 202.1 (M+H)+.Step 4 - 4-((6-Chloro-4-cyclobutylpyridin-2-yl)oxy)-l -methyl-1,3-dihydro-2H-benzo[ d ]imidazol-2-one

[0532] To a solution of 2,6-dichloro-4-cyclobutylpyridine (26 g, 120 mmol) in DMSO (130 mL) was added 4-hydroxy-l -methyl- l,3-dihydro-2H-benzo[d]imidazol-2-one (20.91 g, 115.8 mmol) and CsF (35.18 g, 231.6 mmol), then the mixture was stirred at 110 °C for 12 h. Upon completion, the mixture was extracted with EtOAc (50 mL x 3), and concentrated under reduced pressure to give a residue. The residue was triturated with EtOAc at 25 °C for 30 min and filtered to give the title compound (20 g, 52% yield). LC-MS (ESI+) m / z 330.1 (M+H)+.Step 5 - 4-Cyclobutyl-6-((l-methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl )oxy)picolinonitrile

[0533] To a solution of 4-((6-chloro-4-cyclobutylpyridin-2-yl)oxy)-l -methyl- l,3-dihydro-2H-benzo[d]imidazol-2-one (10 g, 30 mmol) in DMF (100 mL) was added Zn(CN)2 (7.27 g, 61.9 mmol, 3.93 mL), DPPF (1.68 g, 3.03 mmol) and Pd2(dba)3 (2.78 g, 3.03 mmol) under N2 atmosphere. Then the mixture was stirred at 120 °C for 4 h under N2 atmosphere. Upon completion, the mixture was added to H2O (40 ml) and then extracted with EtOAc (40 ml x 3).Page 191 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO The water layer was quenched by adding NaClO (aq., 20 mL). The organic lawyer was concentrated under reduced pressure to give a residue. The crude product was triturated with EtOAc at 25 °C for 30 min and filtered to give the title compound (8.1 g, 83% yield). LC-MS (ESI+) m / z 321.1 (M+H)+.Step 6 - 4-Cyclobutyl-6-(( 1 -methyl-2-oxo-2,3-dihydro- lH-benzo[d]imidazol-4-yl)oxy)picolinic acid

[0534] To a 500 mL three-neck round bottom flask, equipped with a refluxing condenser and a magnetic stir bar, was charged with EtOH (260 mL), followed by the addition of 4-cyclobutyl-6-((l-methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)oxy)picolinonitrile (26 g, 81 mmol) and NaOH (2 M, 162.33 mL) in one batch at 25 °C. Then the reaction mixture was allowed to stir vigorously at 80 °C for 12 hrs. Upon completion, the mixture was adjusted pH to 6~7 by adding 2 M HCl. Then the mixture was filtered and the solid was collected, and the filtrate was concentrated under reduced pressure to give a residue. The solid products were combined and triturated with MeOH at 25 °C for 30 min three times and filtered to give the title compound (22 g, 65 mmol). LC-MS (ESI+) m / z 340.1 (M+H)+. 1HNMR (400MHz, DMSO-d6): 5 11.25 - 10.90 (m, 1H), 7.74 (br s, 1H), 7.40 - 7.20 (m, 1H), 7.13 - 6.99 (m, 2H), 6.83 (br s, 1H). 6.63 (br s, 1H), 3.32 (br s, 3H), 2.23 (br s, 2H), 2.04 - 1.91 (m, 4H), 1.77 (br s, 1H).4,6-Dichloro-2-iodopyrimidine (Intermediate AB)

[0535] To a solution of 4,6-dichloropyrimidin-2-aminc (10.0 g, 60.9 mmol, CAS# 56-05-3) in MeCN (40 mL) was added CH2I2 (17.9 g, 67.0 mmol, 5.41 mL) and isopentyl nitrite (35.7 g, 304 mmol, 41.0 mL). The mixture was then stirred at 80 °C for 4 h. The reaction mixture was poured into H2O (100 mL) and extracted with EtOAc (100 mL x3). The combined organic layers were washed with brine (100 mL x 2), dried over Na2SO4 filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether: Ethyl acetate=50:l to Petroleum ether: Ethyl acetate=10:l) to afford the title compound (6.80 g, 41% yield). LC-MS (ESI+) m / z 274.9[M+H]+.4-Hydroxy-l,3-dihydrobenzimidazol-2-one (Intermediate AC)Page 192 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOStep 1 - 4-Methoxy-l,3-dihydro-2H-benzo[d]imidazol-2-one

[0536] A mixture of 3-methoxybenzene-l,2-diamine (1.00 g, 7.24 mmol, CAS# 37466-89-0) and GDI (1.41 g, 8.69 mmol) in THF ( 10 mL) was degassed and purged with N23 times. Then the mixture was stirred at 40 °C for 12 h under N2 atmosphere. The reaction mixture was quenched with water (20 mL) at rt, and extracted with EtOAc (40 mL x 2). The combined organic layers were washed with brine (40 mL x 2), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (S1O2. Petroleum ether / Ethyl acetate=l / O to 0 / 1) and triturated with DCM (10 mL) at 30 °C for 20 min to afford the title compound (624 mg, 53% yield).JH NMR (400 MHz, DMSO-de) 5 = 10.71 - 10.48 (m, 2H), 6.91 - 6.83 (m, 1H), 6.62 (d, J= 8.4 Hz, 1H), 6.57 (d, J = 8.0 Hz, 1H), 3.82 (s, 3H).Step 2 - 4-Hydroxy-l,3-dihydro-2H-benzo[d]imidazoT2-one

[0537] To a solution of 4-methoxy-l,3-dihydro-2H-benzo[d]imidazol-2-one (600 mg, 3.65 mmol) in DCM (8 mL) was added BBrs (2.75 g, 11.0 mmol, 1.06 mL) at -78 °C under N2. The mixture was then stirred at 25 °C for 1 h under N2. The reaction mixture was quenched with NaHCCF (aq., 20 mL) at 0 °C, and extracted with EtOAc (30 mL x 2). The combined organic layers were washed with brine (30 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to afford the title compound (320 mg, 58% yield). LC-MS (ESI+) m / z, 151.0 (M+H)+.4-((4,4-DifluorocyclohexyI)oxy)-lH-pyrazole (Intermediate AD)Step 1 - Tert-butyl 4-((4,4-difluorocyclohexyl)oxy)-lH-pyrazole-l-carboxylate

[0538] A mixture of 4,4-difluorocyclohexanol (591 mg, 4.34 mmol), tert-butyl 4-hydroxypyrazole-1 -carboxylate (800 mg, 4.34 mmol) and PPhg (1.25 g, 4.78 mmol) in THF (8Page 193 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO mL) was added DIAD (966 mg, 4.78 mmol, 926. L) at 0 °C, and then the mixture was stirred at 60 °C for 12 hr under N2 atmosphere. The reaction mixture was poured into water (20 mL), and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL x 3), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO; 40 g SepaFlash Silica Flash Column, Eluent of 10% Ethyl acetate / Petroleum ether gradient 100 mL / min) to afford the compound (750 mg, 57% yield). LC-MS (ESI+) m / z 247.1 (M-55)+.Step 2 - 4-((4,4-Dijluorocyclohexyl)oxy)-lH-pyrazole

[0539] To a solution of tert-butyl 4-((4,4-difluorocyclohexyl)oxy)-lH-pyrazole-l -carboxylate (750 mg, 2.21 mmol) in DCM (2 mL) was added HCl / Dioxane (2 M, 2 mL). The mixture was then stirred at 25 °C for 8 hr. The reaction mixture was concentrated under reduced pressure to give the title compound (410 mg, HCl). LC-MS (ESI+) mJz 203.1 (M+II)+.Tert-butyl 4-(2-(4-((6-bromo-4-methylpyridin-2-yl)oxy)-2-oxo-3-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-lH-benzo[d]imidazol-l-yl)ethyl)piperidine-1-carboxylate (Intermediate AE)

[0540] To a solution of tert-butyl 4-(2-(4-((6-bromo-4-methylpyridin-2-yl)oxy)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl)ethyl)piperidine-l-carboxylate (3.0 g, 5.65 mmol, Intermediate F) in DMF (30 mL) was added NaH (339 mg, 8.47 mmol, 60% dispersion in mineral oil) at 0 °C for 0.5 hr. Then SEM-C1 (1.41 g, 8.47 mmol, 1.5 mL) was added and the mixture was stirred at 25 °C for 12 hr. The reaction mixture was quenched by addition sat NH4CI (5 mL) and extracted with EtOAc (15 mL x 3). The combined organic layers were washed with brine (8 mL), dried over Na2SO4, and evaporated. The residue was purified by flash silica gel chromatography (ISCO; 80 g SepaFlash Silica Flash Column, Eluent of 50% Ethyl acetate / Petroleum ether gradient 100 mL / min) to afford the title compound (3.5 g, 94% yield). LC-MS (ESI+) m / z 684.2 (M+Na)+.Page 194 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO (S)-3-(3,4-difluorophenoxy)pyrrolidine (Intermediate AF)Step 1 - Tert-butyl (S)-3-(3,4-difluorophenoxy)pyrrolidine-l-carboxylate

[0541] To a solution of tert-butyl (R)-3-hydroxypyrrolidine-l -carboxylate (2.88 g, 15.3 mmol, CAS# 109431-87-0) and 3,4-difluorophenol (2.00 g, 15.3 mmol, CAS# 2713-33-9) in THF (20 mL) was added dropwise DIAD (3.42 g, 16.9 mmol, 3.28 mL) and PPI13 (4.44 g, 16.9 mmol) in THF (4 mL) at 0 °C under N2. The mixture was then stirred at 0-60 °C for 12 h under N2. The reaction mixture was poured into water (20 mL), and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (10 mL x 3), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (Si O2, Petroleum ether / Ethyl acetate= 10 / 1-5 / 1) to give the title compound (3.2 g, 62% yield). LC-MS (ESI+) m / z 300.13 (M+H)+.Step 2 - (S)-3-(3,4-difluorophenoxy)pyrrolidine

[0542] To a solution of teit-butyl (S)-3-(3,4-difluorophenoxy)pyrrolidine-l-carboxylate (400 mg, 1.34 mmol) in DCM (4 mL) was added HCl / dioxane (2 M, 2 mL) and the mixture was stirred at 25 °C for 12 h. The reaction mixture was concentrated under reduced pressure to give the title compound (120 mg). LC-MS (ESI+) m / z 200.08 (M+H)+.8-((6-Bromo-4-methylpyridin-2-yI)oxy)-3,4-dihydroquinolin-2(lH)-one (Intermediate AG)

[0543] To a solution of 8-hydroxy-3,4-dihydroquinolin-2(l )-one (300 mg, 1.84 mmol, CAS# 19968-71-3) in DMF (3 mL) was added K2CO3 (762 mg. 5.52 mmol) and 2-bromo-6-fluoro-4-methylpyridine (349 mg, 1.84 mmol, CAS# 180608-37-1). The mixture was then stirred at 80 °C for 12 h. The mixture was quenched with H2O (40 mL) at 0 °C, and extracted with EA (40 mL) x 2. The combined organic layers were washed with brine (40 mL x 2), dried over Page 195 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO; 20 g SepaFlash Silica Flash Column, Eluent of 0-50% Ethyl acetate / Petroleum ether gradient @ 80 mL / min) and concentrated under reduced pressure to give the title compound (300 mg, 47% yield).rH NMR (400 MHz, DMSO-d6) 5 = 9.79 (s, 1H), 7.23 (s, 1H), 7.11 - 7.05 (m, 1H), 7.00 - 6.94 (m, 2H), 6.86 (s, 1H), 2.94 (t, J = 7.6 Hz, 2H), 2.49 - 2.45 (m, 2H), 2.31 (s, 3H).Example 3. Method 1: Synthesis of l-(2-(l-acetylpiperidin-4-yl)ethyl)-4-((6-(l-((4,4-difluorocyclohexyl)methyI)-lH-imidazol-4-yI)-4-methyIpyridin-2-yl)oxy)-l,3-dihydro-2H-benzo[d]imidazol-2-one (1-1)Step 1 - Tert-butyl 4-(2-(4-((6-(l-((4,4-difluorocyclohexyl)methyl)-lH-imidazol-4-yl)-4-methylpyridin-2-yl)oxy)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl)ethyl)piperidine-l-carboxylate

[0544] A mixture of tributyl-[l-[(4,4-difluorocyclohexyl)methyl]imidazol-4-yl]stannane (920 mg, 1.88 mmol, Intermediate D), tert-butyl 4-[2-[4-[(6-bromo-4-methyl-2-pyridyl)oxy]-2-oxo-3H-benzimidazol-l-yl]ethyl]piperidine-l -carboxylate (200 mg, 376.34 pmol, Intermediate F), Pd(t-Bu3Ph (76.9 mg, 150 pmol), and Cui (28.6 mg, 150 pmol) in DMF (5Page 196 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO mL) was degassed and purged with N2 three times. Then the mixture was stirred at 100 °C for 3 hr under N2 atmosphere. Upon completion, the reaction mixture was quenched with aq. KF (20 mL), diluted with water (50 mL), and extracted with ethyl acetate (3x50 mL). The extracts were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give the crude residue. The crude product was purified by reversed-phase HPLC( 0.1% FA condition) to give the title compound (100 mg, 39% yield) as a white solid. LC-MS (ESI+) m / z 651.4 (M+H)+.Step 2 - 4-((6-(l-((4,4-Difluorocyclohexyl)melhyl)-lH-imidazol-4-yl)-4-methylpyridin-2-yl)oxy)-l-(2-(piperidin-4-yl)ethyl)-l,3-dihydro-2H-benzo[d]imidazol-2-one

[0545] To a solution of tert-butyl 4-[2-[4-[[6-[l-[(4,4-difluorocyclohexyl)methyl]imidazol-4-yl]-4-methyl-2-pyridyl]oxy]-2-oxo-3H-benzimidazol-l-yl]ethyl]piperidine-l-carboxylate (100 mg, 153 pmol) in DCM (1 mL) was added HCl / EtOAc (2 M, 1 mL) and the mixture was stirred at 25 °C for 2 hrs. Upon completion, the reaction mixture was concentrated in vacuo to give the title compound (80 mg) as a white solid. LC-MS (ESI+) m / z 551.3 (M+H)+.Step 3 - l-(2-(l-acetylpiperidin-4-yl)ethyl)-4-( ( 6-( l-(( 4,4-difluorocyclohexyl)methyl)-lH-imidazol-4-yi)-4-methylpyridin-2-yl)oxy)-l,3-dihydro-2H-benzo[d]imidazol-2-one

[0546] To a solution of 7-[[6-[l-[(4,4-difluorocyclohexyl)methyl]imidazol-4-yl]-4-methyl-2-pyridyl]oxy]-3-[2-(4-piperidyl)ethyl]-lH-benzimidazol-2-one (50 mg, 90.8 pmol) in THF (2 mL) was added AC2O (18.5 mg, 182 pmol) and TEA (18.4 mg, 182 μmol). Then the mixture was stirred at 25 °C for 2 hrs. Upon completion, the reaction mixture was filtered and concentrated in vacuo to give the crude residue. The crude product was purified by reversed-phase HPLC(0.1% FA condition) to give the title compound (20.3 mg, 36% yield) as a white solid. LC-MS (ESI+) m / z 593.2 (M+H)+; 'll NMR (400 MHz, DMSO-d6) 5 = 11.07 (br d, J = 1.2 Hz, III), 7.72 - 7.65 (m, III), 7.50 - 7.43 (m, III), 7.35 - 7.27 (m, HI), 7.07 - 6.98 (m, 2H), 6.84 - 6.74 (m, 1H), 6.61 - 6.50 (m, 1H), 4.38 - 4.32 (m. 2H), 3.93 - 3.83 (m, 6H), 3.01 -2.93 (m, 2H), 2.38 - 2.29 (m, 3H), 1.98 (br s, 5H), 1.84 - 1.74 (m, 4H), 1.63 - 1.52 (m, 4H), 1.26 - 1.12 (m, 3H), 1.06 - 0.94 (m, 1H).Table 3. Compounds synthesized via Method 1, the Stille coupling of the corresponding halides and tin reagents in Step 1, followed by deprotection in Step 2 and acylation in Step 3.Page 197 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 198 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOstandard deprotection conditions at 25 °C for 1-2 h. Step 3 acylation was run at 25 °C for 2- 12 hrs with THE or EtOAc as the solvent.bThe product of Step 1 was separated by SFC (column: DAICEL CHIRALPAK IK(250mm*30mm,10um);mobile phase: [CO2- MeOH / ACN]; B%:55%, isocratic elution mode) and SFC (column: DAICEL CHIRALPAKIK (250mm*50mm,10um); mobilephase:[Hexane-EtOH(0.1%IPAm)]; B%:40%, isocratic elution mode) to give the first peak as tert-butyl 4-(2-(4-((6-(l-((lS,2S,4R)-bicyclo[2.2.1]heptan-2- ylmethyl)-lH-imidazol-4-yl)-4-methylpyridin-2-yl)oxy)-2-oxo-2,3-dihydro-lH- benzo[d]imidazol-l-yl)ethyl)piperidine-l -carboxylate or alternatively 4-(2-(4-((6-(l-((lS,4R)- bicyclo[2.2.1]heptan-2-ylmethyl)-lH-imidazol-4-yl)-4-methylpyridin-2-yl)oxy)-2-oxo-2,3- Page 199 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO dihydro-lH-benzo[d]imidazol-l-yl)ethyl)piperidine-l-carboxylate, ISO-1 (RT = 2.123 min, Analytical Method: Column: Chiralpak IK-3 50x4.6mm I. D., 3um Mobile phase: Phase A for CO2, and Phase B for MeOH+ACN(0.05%DEA); Isocratic elution: B in A for 50%; Flow rate: 3mL / min; Detector: PDA; Column Temp: 35 °C; Back Pressure: 100 Bar), and the second eluting peak as tert-butyl 4-(2-(4-((6-(l-((lS,2R,4R)-bicyclo[2.2.1]heptan-2-ylmethyl)-lH-imidazol-4-yl)-4-methylpyridin-2-yl)oxy)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl)ethyl)piperidine-l -carboxylate or alternatively 4-(2-(4-((6-(l-((lS,4R)-bicyclo[2.2.1]heptan-2-ylmethyl)-lH-imidazol-4-yl)-4-methylpyridin-2-yl)oxy)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl)ethyl)piperidine-l -carboxylate, ISO-2 (RT = 2.882 min, Analytical Method: Column: Chiralpak IK-3 50 x 4.6mm I. D, 3um; Mobile phase: Phase A for Hexane(0.05%IPAm), and Phase B for EtOH+ACN(0.05%IPAm); Isocratic elution: B in A 25%; Flow rate: ImL / min; Detector: PDA; Column Temp: 35 °C; Back Pressure: 100 Bar);), and the third eluting peak as tert-butyl 4-(2-(4-((6-(l-((lR,4S)-bicyclo[2.2.1]heptan-2-ylmethyl)-lH-imidazol-4-yl)-4-methylpyridin-2-yl)oxy)-2-oxo-2,3-dihydro-lH-benzo|djimidazol-l-yl)ethyl)piperidine-l -carboxylate or alternatively tert-butyl 4-(2-(4-((6-(l-((lR,4S)-bicyclo[2.2.1]heptan-2-ylmethyl)-lH-imidazol-4-yl)-4-methylpyridin-2-yl)oxy)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl)ethyl)piperidine-l-carboxylate, ISO-3 (RT = 1.481, 1.585 min, Analytical Method: Column: Chiralpak AD-3 50x4.6mm I. D., 3um Mobile phase: Phase A for CO2, and Phase B for IPA+ACN(0.05%DEA); Isocratic elution: B in A for 50% Flow rate: 3mL / min; Detector: PDA; Column Temp: 35° C; Back Pressure: 100 Bar).). These isomers were then carried forward into Steps 2 & 3.cThe product after Step 3 acylation, was further separated by SFC (condition: column: DAICEL CHIRALCEL OD(250mm*30mm,10um);mobile phase: [CO2-EtOH]; B%:45%, isocratic elution mode) to give desired (S)- 1 -(2-( 1 -acetylpiperidin-4-yl)ethyl)-4-((6-( 1 -( 1 -(4,4-difluorocyclohexyl)ethyl)- 1 H-imidazol-4-yl)-4-methy lpyridin-2-yl)oxy)- 1 H-benzo[d]imidazol-2(3H)-one and (R)-l-(2-(l-acetylpiperidm-4-yl)ethyl)-4-((6-(l-(l-(4,4-difluorocyclohexyl)ethyl)-lH-imidazol-4-yl)-4-methylpyridin-2-yl)oxy)-lH-benzo[d]imidazol-2(3H)-one as a white solids. The compounds were further purified by prep-HPLC (column: Phenomenex luna C18 150*25mm* 10um;mobile phase: [water(FA)-ACN];gradient:20%-50% B over 10 min) to give (S)-l-(2-(l-acetylpiperidin-4-yl)ethyl)-4-((6-(l-(l-(4,4-difhiorocyclohexyl)ethyl)-lH-imidazol-4-yl)-4-methylpyridin-2-yl)oxy)-lH-benzo[d]imidazol-2(3H)-one and (R)- 1 -(2-( 1 -acetylpiperidin-4-yl)ethyl)-4-((6-( 1 -( 1 -(4,4-difluorocyclohexyl)ethyl)- 1 H-imidazol-4-yl)-4-methy lpyridin-2-yl)oxy)- 1 H-benzo[d]imidazol-2(3H)-one as white solids.dSteps 2 and 3 were not required for the synthesis.Page 200 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO Table 4. Compounds synthesized via Method 1, the Stille coupling of halides and tin reagents in Step 1, followed by deprotection in Step 2 and acylation in Step 3.“Step 1 was run under standard Stille conditions at 100 °C for 1-3 hr. Step 2 was run under standard deprotection conditions at 25 °C for 1-2 h. Step 3 acylation was run at 25 °C for 2-12 hrs with THF or EtOAc as the solvent.bSteps 2 and 3 were not required for the synthesis.Example 4. Method 2: l-(2-(l-acetylpiperidin-4-yl)ethyl)-4-((6-(l-((4,4-difhiorocyclohexyl)methyl)-lH-pyrazol-4-yl)-4-methylpyridin-2-yl)oxy)-l,3-dihydro-2H-benzo[d]imidazol-2-one (Compound I- 10)Page 201 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOStep 1 - tert-butyl4-(2-(4-((6-(l-((4,4-difluorocyclohexyl)methyl)-lH-pyrazol-4-yl)-4-methylpyridin-2-yl)oxy)-2-oxo-2,3-dihydro-lH-benzoldjimidazol-l-yl)ethyl)piperidine-l-carboxylate

[0547] To a solution of teit-butyl 4-(2-(4-((6-bromo-4-methylpyridin-2-yl)oxy)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl)ethyl)piperidine-l -carboxylate (52 mg, 97.9 pmol, Intermediate F), l-((4,4-difluorocyclohexyl)methyl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (38.3 mg, 117 pmol, Intermediate G) and K2CO3 (27.1 mg, 196 pmol) in dioxane (0.6 mL) and H2O (0.3 mb) was added Pd(dppf)C12*CH2CJ2 (16.0 mg, 19.6 pmol) and PCy3 (5.49 mg, 19.6 pmol, 6.34 pL). Then the mixture was stirred at 80 °C for 1 h under N2. Upon completion, the reaction mixture was quenched with water (2 mL) at 25 °C, extracted with EtOAc (4 mL x 3). The combined organic layers were washed with brine (4 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (S1O2, Petroleum ether / Ethyl acetate=l / OPage 202 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO to 0 / 1) to afford the title compound (55 mg, 81% yield) as a brown oil. LC-MS (ESI+) m / z 651.4 (M+1H)+.Step 2 - 4-( ( 6-( l-((4,4-Difluorocyclohexyl)methyl)-lH-pyrazol-4-yl)-4-methylpyridm-2-yl)oxy)-l-(2-(piperidin-4-yl)ethyl)-l,3-dihydro-2H-benzo[d]imidazol-2-one

[0548] To a solution of tert-butyl 4-(2-(4-((6-(l-((4,4-difluorocyclohexyl)methyl)-lH-pyrazol-4-yl)-4-methylpyridin-2-yl)oxy)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl)ethyl)piperidine- 1 -carboxylate (55 mg, 84.5 pmol) in DCM (1 mL) was added HCl / dioxane (2 M, 1 mL) and the mixture was stirred at 25 °C for h. Upon completion, the reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*25mm* lOum; mobile phase: [water (FA)-ACN]; gradient: 18%-48% B over 10 min) to afford the title compound (31.4 mg, 62% yield, FA) as a white solid. LC-MS (ESI+) m / z 551,2(M+1 II)+; ’ll NMR (400 MHz, DMSO-d6) 5 = 11.59 -10.43 (m, 1H), 8.43 (s, 1H), 8.07 (s, 1H), 7.74 (s, 1H), 7.24 (s, 1H), 7.06 - 6.99 (m, 2H), 6.82 - 6.76 (m, 1H), 6.53 (s, 1H), 4.02 (br d, J = 7.2 Hz, 2H), 3.85 (br t, J = 7.2 Hz, 2H), 3.10 (br d, J = 12.0 Hz, 2H), 2.64 (br t, J = 11.2 Hz, 2H), 2.30 (s, 3H), 1.96 (br d, J = 6.4 Hz, 3H), 1.86 -1.52 (m, 9H), 1.44 (br d, J = 10.8 Hz, 1H), 1.28 - 1.14 (m, 4H).Step 3 - l-(2-(l -acetylpiperidin-4-yl)ethyl)-4-( ( 6-(l-( ( 4,4-difltiorocyclohexyl)methyl)-1 H-pyrazol-4-yl)-4-methylpyridin-2-yl)oxy)-l,3-dihydro-2H-benzo[d]imidazol-2-one

[0549] To a solution of 4-((6-(l-((4,4-difluorocyclohexyl)methyl)-lH-pyrazoL4-yl)-4-methylpyridin-2-yl)oxy)-l-(2-(piperidin-4-yl)ethyl)-l,3-dihydro-2H-benzo[d]imidazol-2-one (100 mg, 182 pmol) in EtOAc (1 mL) was added acetyl acetate (55.6 mg, 545 pmol, 51.2 pL) and TEA (18.4 mg, 182 pmol, 25.3 pL). The mixture was then stirred at 25 °C for 12 h. Upon completion, the reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*25mm* lOum; mobile phase: [water(FA)-ACN];gradient:43%-63% B over 10 min) to afford the title compound (32.5 mg, 28% yield, FA) as a white solid. LC-MS (ESI+) m / z 593.3 (M+H)+; 'll NMR (400 MHz, DMSO-d6) 5 = 11.14 - 10.95 (m, 2H), 8.26 (s, 1H), 8.00 (s, 1H), 7.77 (s, 1H), 7.02 - 6.96 (m, 2H), 6.94 (dd, J= 4.0, 6.0 Hz, 2H), 6.92 - 6.90 (m, 1H), 6.74 (dd, J = 1.2, 8.0 Hz, 1H), 6.17 (d, J = 2.0 Hz, 1H), 5.36 (dd, J = 5.6, 12.4 Hz, 1H), 3.99 (d, J = 7.2 Hz, 2H), 3.67 (t,. / = 6.8 Hz, 2H), 3.58 (s, 3H), 3.55 - 3.50 (m, 6H), 3.48 (s, 3H), 3.32 (br s, 13H), 3.15 (br t, J = 6.8 Hz, 2H), 2.93 - 2.83 (m, 1 H), 2.72 - 2.58 (m, 2H), 2.54 - 2.52 (m, 2H), 2.04 - 1.91 (m, 4H), 1.83 - 1.66 (m, 2H), 1.56 (br d, J = 13.2 Hz, 2H), 1.26 - 1.12 (m, 2H).Page 203 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO Table 5. Compounds synthesized via Method 2, the Suzuki coupling of the corresponding halides and boronic esters in Step 1, followed by deprotection in Step 2 and acylation in Step 3.“Step 1 was run under standard Suzuki conditions at 80 °C for 1-3 hr. Step 2 was run under standard deprotection conditions at 25 °C for 1-2 h. Step 3 acylation was run at 25 °C for 2-12 hrs with THF or EtOAc as the solvent.bStep 3 was not required for the synthesis.Table 6. Compounds synthesized via Method 2, the Suzuki coupling of halides and boronic esters in Step 1, followed by deprotection in Step 2 and acylation in Step 3.Page 204 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOaStep 1 was run under standard Suzuki conditions at 80 °C for 1-3 hr. Step 2 was run under standard deprotection conditions at 25 °C for 1-2 h. Step 3 acylation was run at 25 °C for 2-12 hrs with THF or EtOAc as the solvent.bStep 3 was not required for the synthesis.cThe final product was separated by SFC (column: (s,s) WHELK-01 (250mm*30mm,10um);mobile Page 205 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO phase: [CO2-ACN / i-PrOH(0.1% NH3H2O)]; B%:65%, isocratic elution mode) to give the first eluting peak as (S)-l-(2-(l-acetylpiperidin-4-yl)ethyl)-4-((6-(l-(l-(3,4-difluorophenyl)ethyl)-lH-pyrazol-4-yl)-4-methylpyridin-2-yl)oxy)-lH-benzo[d]imidazol-2(3H)-one or alternatively l-(2-(l-acetylpiperidin-4-yl)ethyl)-4-((6-(l-(l-(3,4-difluorophenyl)ethyl)-lH-pyrazol-4-yl)-4-methylpyridin-2-yl)oxy)-lH-benzo[d]imidazol-2(3H)-one, ISO-1 (RT = 1.174min) and the second eluting peak as (R)-l-(2-(l-acetylpiperidin-4-yl)ethyl)-4-((6-(l-(l-(3,4-difluorophenyl)ethyl)-lH-pyrazol-4-yl)-4-methylpyridin-2-yl)oxy)-lH-benzo[d]imidazol-2(3H)-one or alternatively l-(2-(l-acetylpiperidin-4-yl)ethyl)-4-((6-(l-(l-(3,4-difluorophenyl)ethyl)-lH-pyrazol-4-yl)-4-methylpyridin-2-yl)oxy)-lH-benzo[d]imidazol-2(3H)-one, ISO-2 (RT = 1.695 min). Analytical Method: Column:(S, S)Whelk-Ol 50x4.6mm I. D., 3.5um Mobile phase: Phase A for CO2, and Phase B for IPA+ACN(0.05%DEA); Isocratic elution: B in A for 50%; Flow rate: 3mL / min; Detector: PDA; Column Temp: 35 °C; Back Pressure: 100 Bar.dOnly Step 1 required for synthesis, where a boronic ester and an activated halogen were coupled to give the title compound.eAfter Step 1, in Step 2 the compound was treated with TMSC1, Nal in ACN at 80 °C for 12 hr. No Step 3 was required.Example 5. Method 3: l-(2-(l-acetylpiperidin-4-yl)ethyl)-4-((6-(4-((4,4-difluorocyclohexyl)oxy)-lH-pyrazol-l-yl)-4-methylpyridin-2-yl)oxy)-l,3-dihydro-2H-benzo[d]imidazol-2-one (Compound 1-207)Page 206 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOStep 1 - Tert-butyl '4-(2-(4-((6-(4-((4,4-difluorocyclohexyl)oxy)-lH-pyrazol-l-yl)-4-methylpyridin-2-yl)oxy)-2-oxo-3-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-lH-benzo[ d ]imidazol-l -yl)elhyl )piperidine-l-carboxylale

[0550] A mixture of 4-((4,4-difluorocyclohexyl)oxy)-lH-pyrazole (81.59 mg, 341.9 pmol, HO, Intermediate AD), tert-butyl 4-[2-[4-[(6-bromo-4-methyl-2-pyridyl)oxy]-2-oxo-3-(2-trimethylsilylethoxymethyl)benzimidazol-l-yl]ethyl]piperidine-l -carboxylate (178 mg, 269 pmol, Intermediate AE), Cui (5.12 mg, 26.9 pmol), K3PO4 (114 mg, 538 pmol) and pyridine-2-carboxylic acid (33.1 mg, 269 pmol) in DMSO (2 mL) was degassed and purged with N23 times. Then the mixture was stirred at 100 °C for 12 hr under N2 atmosphere. The reaction mixture was quenched with water (10 mL) at 25 °C, and extracted with EtOAc (20 mL x 3).Page 207 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO The combined organic layers were washed with brine (20 mL x 3), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO; 40 g SepaFlash Silica Flash Column, Eluent of 30% Ethyl acetate / Petroleum ether gradient 100 mL / min) to afford the title compound (190 mg, 90% yield). LC-MS (ESI+) m / z 805.4 (M+Na)+.Step 2 - 4-((6-(4-((4,4-Difluorocyclohexyl)oxy)-lH-pyrazol-l-yl)-4-methylpyridin-2-yl)oxy)-l-(2- piperidm-4-yl)ethyl)-l,3-dihydro-2H-benzo[d]imidazol-2-one

[0551] To a solution of tert-butyl 4-(2-(4-((6-(4-((4,4-difluorocyclohexyl)oxy)-lH-pyrazol-l-yl)-4-methylpyridin-2-yl)oxy)-2-oxo-3-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-lH-benzo[d]imidazol-l-yl)ethyl)piperidine-l -carboxylate (190 mg, 243 pmol) in CH2CI2 (1 mL) was added HCl / dioxane (2 M, 2 mL) and the mixture was stirred at 25 °C for 12 hr. Then, NH3 II2O (1 mL) and dioxane (1 mL) was added to the mixture, and the mixture was stirred at 60 °C for 48 hr. The reaction mixture was concentrated under reduced pressure to give the title compound. LC-MS (ESI+) m / z. 553.2 (M+H)+.Step 3 - l-(2-(l-Acetylpiperidin-4-yl)ethyl)-4-((6-(4-((4,4-difluorocyclohexyl)oxy)-lH-pyrazol-l-yl )-4-methylpyridin-2 -yl )oxy )- 1,3-dihydro-2H-benzo[ d ]imidazol-2-one

[0552] To a solution of 4-((6-(4-((4,4-difluorocyclohexyl)oxy)-lH-pyrazol-l-yl)-4-methylpyridin-2-yl)oxy)- 1 -(2-(piperidin-4-yl)ethyl)- 1,3-dihydro-2H-benzo[d]imidazol-2-one (130 mg, 235 pmol) in EtOAc (1 mL) was added TEA (23.8 mg, 235 pmol, 32.7 pL) and AC2O (48.0 mg, 470 pmol, 44.2 pL) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was concentrated under reduced pressure to give the crude product. The residue was purified by prep-HPLC (TFA condition) to give title compound (15 mg, 10% yield). LC-MS (ESI+) m / z 595.3 (M+H)+; 'll NMR (400 MHz, DMSO-d6) 5 = 8.44 (br s, 1H), 7.74 (s, 1H), 7.67 (s, 1H), 7.40 (s, III), 7.06 (d,. / = 4.4 Hz, 211), 6.87 - 6.82 (m, III), 6.62 (s. Ill), 4.36 - 4.30 (m, III), 4.28 - 4.21 (m, 1H), 3.86 (t, J = 7.2 Hz, 2H), 3.78 (d, J = 13.6 Hz, 1H), 2.98 - 2.92 (m, 1H), 2.67 (d, J = 1.6 Hz, 1H), 2.54 (s, 3H), 2.48 - 2.42 (m, 2H), 1.97 (s, 3H), 1.92 - 1.83 (m, 4H), 1.82 - 1.75 (m, 4H), 1.64 - 1.58 (m, 2H), 1.54 - 1.47 (m, 1H), 1.12 (d, J = 11.6 Hz, 1H), 1.04 -0.96 (m, 1H).Table 7. Compounds synthesized via Method 3, the coupling of the corresponding amines and halides in Step 1, followed by deprotection in Step 2 and acylation in Step 3.Page 208 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOaStep 1 was run under standard coupling conditions at 100 °C for 1-12 hr. Step 2 was run under standard deprotection conditions at 25 °C for 1-48 h. Step 3 acylation was run at 25 °C for 2-12 hrs with THF or EtOAc as the solvent. Purification was achieved by standard conditions including by prep-HPLC andprep-TLC.hIn Step 1, RuPhos, Pd(dppf)C12-CH2C12 and CS2CO3 in dioxane was used for the coupling at 100 °C for 1 h. In Step 2, the mixture was concentrated after the HC1 reaction, then NH3-H2O was added with dioxane and the reaction was run at rt for 0.5 hr.Table 8. Compounds synthesized via Method 3, the coupling of amines and halides in Step 1, followed by deprotection in Step 2 and acylation in Step 3.Page 209 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOaStep 1 was run under standard coupling conditions at 100 °C for 1- 12 hr. Step 2 was run under standard deprotection conditions at 25 °C for 1-12 h. Step 3 acylation was run at 25 °C for 2-12 hrs with THF or EtOAc as the solvent. Purification was achieved by standard conditions including by prep-HPLC and prep-TLC.bOnly Step 1 required for synthesis, where the amine and activated chloride coupling was achieved with TEA in DMF at 60 °C for 3 h.cOnly Step 1 and Step 2 (without NH3) was performed to make the title compound. In Step 1, RuPhos, RuPhos PD G2, and LiHMDS in dioxane was used for the coupling at 0-100 °C for 2 hrs.dOnly Step 1 required for synthesis, where the amine and activated chloride coupling was achieved with TEA in DMF at 80 °C for 12 h. This step was then followed by hydrolysis of the methoxy to the phenol with BBn in DCM at 25 °C for 2 h.Example 6. Synthesis of Additional Exemplary Compounds

[0553] The following compounds were synthesized via further methodology.A. (S)-4-((2-(3-(3,4-difluorophenoxy)pyrrolidin-l-yl)-6-methylpyrimidin-4-yl)oxy)-l-(2-methoxyethyI)-l,3-dihydro-2H-benzo[d]imidazol-2-one (Compound 1-287)

[0554] To a solution of 7-(2-chloro-6-niethyl-pyrimidin-4-yl)oxy-3-(2-methoxyelhyl)-lH-benzimidazol-2-one (100 mg, 298 pmol, Intermediate B), (3S)-3-(3,4-difluorophenoxy)pyrrolidine (71.4 mg, 358 pmol, Intermediate C) in DMF (1 mH) was added TEA (90.6 mg, 896 pmol, 124 pL). The mixture was then stirred at 60 °C for 1 h. Upon completion, the mixture was filtered. The filtrate was purified by perp-HPLC (column: Phenomenex luna C18 150*25mm* 10um;mobile phase: [water(FA)-ACN];gradient:27%-57% B over 10 min) to afford the title compound (65.8 mg, 44% yield) as a white solid. LC-MS (ESI+) m / z 498.1 [M+H]+; 'll NMR (400 MHz, DMSO-d6) 5 = 11.03 (br s, 1H), 7.39 - 7.23 (m, 1H), 7.12 - 6.95 (m, 3H), 6.84 - 6.68 (m, 2H), 5.98 (s, 1H), 5.05 (br s, 1H), 3.95 (br t, 7 = 5.6 Hz, 2H), 3.57 (br s, 4H), 3.51 - 3.34 (m, 2H), 3.22 (s, 3H), 2.22 (s, 3H), 2.19 - 2.04 (m, 2H).Page 210 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO B.4-((2-(l-(3,4-Difluorobenzyl)-lH-pyrazol-4-yl)-6-methylpyrimidin-4-yl)oxy)-l- (2-methoxyethyl)-l,3-dihydro-2H-benzo[d]imidazol-2-one (Compound 1-13)

[0555] To a solution of 7-(2-chloro-6-methyl-pyrimidin-4-yl)oxy-3-(2-methoxyethyl)-lH-benzimidazol-2-one (100 mg, 298 pmol, Intermediate B) and l-[(3,4-difluorophenyl)methyl]-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazole (143 mg, 448 pmol, Intermediate E) in dioxane (1 mL) and H2O (0.3 mL) was added Pd(dppf)C12. CH2C12 (73.1 mg, 89.6 pmol), PCy₃ (50.2 mg, 179 pmol, 58.1 pL), and K3PO4 (190 mg, 896 pmol). Then the mixture was stirred at 80 °C for 1 h under N2. Upon completion, the reaction mixture was poured into ice water (5 mL) and extracted with EtOAc (5 mL x 3), the combined organic layers were washed with brine (5 mL x 3), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The crude product was purified by reversed-phase HPLC (0.1% PA condition) to afford the title compound (22.2 mg, 15% yield) as a yellow solid. LC-MS (ESI+) m / z 493.17 (M+H)+; ’ll NMR (400 MHz, DMSO-d6) 5 = 11.07 (s, 1H), 8.33 (s, 1H), 7.79 (s, 1H), 7.45 - 7.31 (m, 2H), 7.14 - 7.03 (m, 3H), 6.86 (d, J = 8.0 Hz, 1H), 6.60 (s, 1H), 5.35 (s, 2H), 3.98 (t, J= 5.2 Hz, 2H), 3.61 (t, J= 5.2 Hz, 2H), 3.25 (s, 3H), 2.41 (s, 3H).C. Synthesis of 4-((6-(l-((4,4-difluorocydohexyl)methyl)-lH-l,2,3-triazol-4-yl)-4-methylpyridin-2-yl)oxy)-l-(2-(piperidin-4-yl)ethyl)-lH-benzo[d]imidazol-2(3H)-one (Compound 1-14)Page 211 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOStep 1 - Tert-butyl 4-(2-(4-((4-inethyl-6-((triinethylsilyl)ethynyl)pyridin-2-yl)oxy)-2-oxo-2, 3-dihydro-lH-benzo[d]imidazol-l-yl)ethyi)piperidme-l -carboxylate

[0556] To a solution of tert-butyl 4-(2-(4-((6-bromo-4-methylpyridin-2-yl)oxy)-2-oxo-2,3-dihydro-lH-benzo [d]imidazol-l-yl)ethyl)piperidine-l -carboxylate (500 mg, 940 pmol, Intermediate F) and ethynyltrimethylsilane (646 mg, 6.59 mmol, CAS# 1066-54-2) in DMF (5 mL) was added Cui (26.8 mg, 141 pmol), Pd(PPh3)4 (163 mg, 141 pmol) and TEA (476 mg, 4.70 mmol). Then the mixture was stirred at 100 °C for 1 h under N2 atmosphere. Upon completion, the reaction mixture was quenched with H2O (20 mL) at 20 °C, and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (20 mL x 2), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO; 20 g SepaFlash Silica Flash Column, Eluent of 0-100% Ethyl acetate / Petroleum ether gradient @ 50 mL / min) to give the title compound (400 mg) as yellow solid. LC-MS (ESI ) m / z 549.3 (M+H)+.Page 212 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO Step 2 - Tert-butyl 4-(2-(4-((6-(l-((4,4-difluorocyclohexyl)methyT)-lH-l,2,3-triazol-4-yl)-4-methylpyridin-2-yl)oxy)-2-oxo-2,3-dihydro-lH-benz.oldjimidaz.ol-l-yl)ethyl)piperidine-1 -carboxylate

[0557] To a solution of tert-butyl 4-(2-(4-((4-methyl-6-((trimethylsilyl)ethynyl)pyridin-2-yl)oxy)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl)ethyl)piperidine-l -carboxylate (100 mg, 182 pmol) and 4-(azidomethyl)- 1,1 -difluorocyclohexane (31.9 mg, 182 pmol, Intermediate I) in DMF (2 ml.) was added Cui (3.47 mg, 18.2 pmol), and the mixture was stirred at 25 °C for 12 h. Upon completion, the reaction mixture was quenched with H2O (2 mL) at 20 °C, and extracted with EtOAc (2 mL x 3). The combined organic layers were washed with brine (2 mL x 2), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (0.1 % FA condition) to give the title compound (40 mg, 34% yield) as brown solid. LC-MS (ESI-) m z 652.4 (M+H)+.Step 3 - 4-((6-(l-((4,4-difluorocyclohexyl)methyl)-lH-l,2,3-triazol-4-yl)-4-methylpyridin-2-yl)oxy)-l-(2-(piperidin-4-yl)ethyl)-lH-benzo[d]imidazol-2(3H)-one

[0558] To a solution of tert-butyl 4-(2-(4-((6-(l-((4,4-difluorocyclohexyl)methyl)-lH-l,2,3-triazol-4-yl)-4-methylpyridin-2-yl)oxy)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl)ethyl)piperidine-l -carboxylate (40 mg, 61.3 pmol) in DCM (1 mL) was added HCl / di oxane (2 M, 1.33 mL), then the mixture was stirred at 25 °C for 1 h. Upon completion, concentrated in vacuo to give the title compound (30 mg, 89% yield) as yellow solid. LC-MS (ESI ) m / z 552.3 (M+H)+.Step 4 - l-(2-(l-acetylpiperidin-4-yl)ethyl)-4-( ( 6-( l-(( 4,4-difluorocycloliexyl)methyl)-1 H-l,2,3-triazol-4-yl)-4-methylpyridin-2-yl)oxy)-l,3-dihydro-2H-benzo[d]imidazol-2-one

[0559] To a solution of 4-((6-(l-((4,4-difluorocyclohexyl)methyl)-lH-l,2,3-triazol-4-yl)-4-methylpyridin-2-yl)oxy)-l-(2-(piperidin-4-yl)ethyl)-HI-benzo[d]imidazol-2(3II)-one (30 mg, 54.3 pmol) in EtOAc (1 mL) was added TEA (5.5 mg, 54.3 pmol) and AC2O (11.1 mg, 108 pmol), then the mixture was stirred at 25 °C for 0.5 h. Upon completion, the mixture was filtered and concentrated in vacuo. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*25mm* 10um;mobile phase: [water(FA)-ACN]; gradient:39%-69% B over 8 min) to give the title compound (21.1 mg, 61% yield, FA) as white solid. LC-MS (ESI-) m / z 594.3 (M+H)+; ’ll NMR (400 MHz, DMSO-d6) 5 = 11.08 (br s, 1H), 8.18 (s, 1H), 7.64 (s, 1H), 7.08 - 6.98 (m, 2H), 6.80 (dd, 7= 2.4, 6.4 Hz, 1H), 6.69 (s, 1H), 4.33 (br d, 7 = 7.2 Hz, 3H), 3.85 (br t, 7 = 7.2 Hz, 2H), 3.78 (br d, 7= 13.6 Hz, 1H), 2.96 (brt, 7= 11.6 Hz,Page 213 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO 1H), 2.47 (br s, 1H), 2.37 (s, 3H), 1.97 (s, 6H), 1.85 - 1.67 (m, 4H), 1.65 - 1.47 (m, 5H), 1.27 -1.07 (m, 3H), 0.99 (dq, J= 3.6, 12.0 Hz, 1H).D. Syntheses of (S)-4-((6-(l-(l-(4,4-difluorocyclohexyl)ethyl)-lH-l,2,3-triazol-4-yl)-4-methylpyridin-2-yl)oxy)-l-methyl-lH-benzo[d]imidazol-2(3H)-one (Compound I-27) and (R)-4-((6-(l-(l-(4,4-difluorocyclohexyl)ethyl)-lH-l,2,3-triazol-4-yl)-4-methylpyridin-2-yI)oxy)-l-methyl-lH-benzo[d]imidazol-2(3H)-one (Compound 1-18)Step 1 - 1 -Methyl-4-( ( 4-methyl-6-( ( trimethylsilyl )ethyny I )pyridin-2 -yl )oxy)-3-( ( 2 - ( trimethylsilyl)ethoxy)inethyl )-lH-benzo[ d ]irnidazol-2(3H)-one

[0560] To a solution of 4-[(6-bromo-4-methyl-2-pyridyl)oxy]-l-methyl-3-(2-trimethylsilylethoxymethyl)benzimidazol-2-one (1.00 g, 2.15 mmol, Intermediate L) and ethynyl(trimethyl)silane (1.06 g, 10.77 mmol, 1.50 mL) in DMF (10 mL) was added Pd(PPh3)2C12 (152 mg, 215 (imol), TEA (655 mg, 6.46 mmol, 890 pL) and Cui (410 mg, 2.15 mmol). The mixture was then stirred at 80 °C for 12 h. Upon completion, the reaction Page 214 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO mixture was poured into ice water (50 mL) and extracted with EtOAc (100 mL x 3), and the combined organic layers were washed with brine (100 mL x 3), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (PE / EtOAc =50 / 1 to 1 / 1) to afford the title compound (760 mg, 73% yield) as a yellow oil. LC-MS (ESI+) m / z 482.2(M+H)+.Step 2 - 4-((6-(l- l-(4,4-difluorocyclohexyl)ethyl)-lH-l,2,3-triazol-4-yl)-4-methylpyridin-2-yl)oxy)-l-methyl-3- (2-(trimethylsilyi)ethoxy)methyl)-lH-benzo[d]imidazol-2(3H)-one

[0561] To a solution of l-methyl-4-[[4-methyl-6-(2-trimethylsilylethynyl)-2-pyridyl]oxy]-3-(2-trimethylsilylethoxymethyl)benzimidazol-2-one (400 mg, 830 pmol) and 4-(l-azidoethyl)-1,1 -difluorocyclohexane (315 mg, 1.66 mmol, Intermediate K) in THF (5 mL) and H2O (1 mL) were added CuSO₄·5H₂O (415 mg, 1.66 mmol), TBAF (1 M, 830 pL) and sodium (2R)-2-[(lS)-l,2-dihydroxyethyl]-4-hydroxy-5-oxo-2H-furan-3-olate (165 mg, 830 pmol, CAS# 134-03-2). The mixture was stirred at 60 °C for 12 h. Upon completion, the reaction mixture was poured into ice water (50 mL) and extracted with EtOAc (50 mL x 3), and the combined organic layers were washed with brine (50 mL x 3), dried over sodium sulfate, filtered and concentrated under reduced pressure to give residue. The residue was purified by column chromatography (PE / EtOAc =30 / 1 to 1 / 1) to afford the title compound (120 mg, 24% yield) as a yellow oil. LC-MS (ESI+) m / z 599.3(M+H)+.Step 3 - 4-((6-(l-(l-(4,4-DiJluorocyclohexyl)ethyl)-lH-l,2,3-lriazol-4-yl)-4-methylpyridin-2-yl)oxy)-l-methyl-lH-benzo[d]imidaz.ol-2(3H)-one

[0562] To a solution of 4-[[6-[l-[l-(4,4-difluorocyclohexyl)ethyl]triazol-4-yl]-4-methyl-2-pyridyl]oxy]-l-methyl-3-(2-trimethylsilylethoxymethyl)benzimidazol-2-one (50 mg, 83.5 pmol) in DCM (2 mL) was added TFA (1.54 g, 13.5 mmol, 1 mL) and the mixture was stirred at 20 °C for 1 h. Then the reaction mixture was concentrated in vacuo to give residue. Next, to the residue was added NH₃ / MeOH (7 M, 2 mL) and the mixture was stirred at 20 °C for 1 h. Upon completion, the reaction mixture was concentrated in vacuo to give residue. The residue was purified by prep-TLC (PE / EtOAc = 1 / 1) to afford the title compound (30 mg, 54% yield) as a yellow solid. LC-MS (ESI+) m / z 469.2(M+H)+.Step 4 - (R)-4-((6-(l-(l-(4,4-difluorocyclohexyl)ethyl)-lH-l,2,3-triazol-4-yl)-4-methylpyridin-2-yl)oxy)-l-methyl-l H-benz,o[d ]imidazol-2( 3H)-one and ( S )-4-( (6-(l-(l-(4,4-Page 215 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO difluorocyclohexyl)ethyl)-lH-l,2,3-triazol-4-yl)-4-methylpyridin-2-yl)oxy)-l-methyl-lH-benzo[d]imidazol-2(3H)-one

[0563] 4-((6-(l-(l-(4,4-Difluorocyclohexyl)ethyl)-lH-l,2,3-triazol-4-yl)-4-methylpyridin-2-yl)oxy)-l-methyl-lH-benzo[d]imidazol-2(3H)-one (400 mg, 854 pmol) was separated by SFC to afford the first eluting peak as (S)-4-((6-(l-(l-(4,4-difluorocyclohexyl)ethyl)-lH-l,2,3-triazol-4-yl)-4-methylpyridin-2-yl)oxy)-l-methyl-lH-benzo[d]imidazol-2(3H)-one (113 mg, 28% yield) as an off-white solid (LC-MS (ESI+) m / z 469.5 (M+H)+; ’ll NMR (400 MHz, DMSO-rfc) 5 = 11.08 (s, 1H), 8.28 (s, 1H), 7.64 (s, 1H), 7.14-6.96 (m, 2H), 6.80 (d, 7 = 8.0 Hz, 1H), 6.64 (s, 1H), 4.63 (t, 7 = 7.2 Hz, 1H), 2.55-2.51 (m, 3H), 2.37 (s. 3H), 2.08-1.85 (m, 4H), 1.83-1.62 (m, 2H), 1.53 (d, 7 = 6.8 Hz, 3H), 1.31-1.18 (m, 2H), 1.17-1.04 (m, 1H)) and the second eluting peak as (R)-4-((6-(l-(l-(4,4-difluorocyclohexyl)ethyl)-lH-l,2,3-triazol-4-yl)-4-methylpyridin-2-yl)oxy)-l-methyl-lH-benzo[d]imidazol-2(3H)-one (122 mg, 30% yield) as a yellow solid (LC-MS (ES ) m / z 469.5 (M+H)+; 'll NMR (400 MHz, DMSO-cfe) 5 = 11.09 (s, 1H), 8.28 (s, 1H), 7.64 (s, 1H), 7.13-6.95 (m, 2H), 6.80 (d, 7= 8.0 Hz, 1H), 6.64 (s, 1H), 4.63 (t, 7 = 7.2 Hz, 1H), 2.55-2.52 (m, 3H), 2.37 (s, 3H), 2.08-1.95 (m, 2H). 1.94-1.64 (m, 4H), 1.53 (d, 7= 6.8 Hz, 3H), 1.29-1.20 (m, 2H), 1.07-1.18 (m, 1H)).E. Syntheses of (S)-4-((6-(l-(l-(4,4-difluorocyclohexyl)ethyl)-lH-imidazol-4-yl)-4-methylpyridin-2-yl)oxy)-l-methyl-lH-benzo[d]imidazol-2(3H)-one (Compound 1-15) and (R)-4-((6-(l-(l-(4,4-difluorocyclohexyl)ethyl)-lH-imidazol-4-yl)-4-methylpyridin-2-yl)oxy)-l-methyl-lH-benzo[d]imidazol-2(3H)-one (Compound 1-16)Page 216 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOStep 1 - 4-((6-(l-(l-(4,4-difluorocyclohexyl)ethyl)-lH-imidazol-4-yl)-4-methylpyridin-2-yl)oxy)-l-methyl-3-((2-(trimethylsilyl)ethoxy)methyl)-lH-benzo[d]imidazol-2(3H)-one

[0564] A mixture of 4-[(6-bromo-4-methyl-2-pyridyl)oxy]-l-methyl-3-(2-trimethylsilylethoxymethyl)benzimidazol-2-one (350 mg, 754 pmol, Intermediate L), tributyl-[l-[l-(4,4-difluorocyclohexyl)ethyl]imidazol-4-yl]stannane (1.14 g, 2.26 mmol, Intermediate P) and Pd(t-Bu3P)2(154 mg, 301 pmol) in DMF (3 mL) was degassed and purged with N2three times. Then the mixture was stirred at 100 °C for 3 h under N2atmosphere. Upon completion, the reaction mixture was quenched with H2O (50 mL), and then diluted with EA (50 mL). The aqueous phase was extracted with EA (50 mL x 3). The combined organic phase was washed with brine (150 mL), dried with anhydrous sodium sulfate, filtered and concentrated in vacuum to give residue. The residue was purified by flash silica gel chromatography (12 g SepaFlash Silica Flash Column, Ethyl acetate / Petroleum ether: 0-40%) to afford the title compound (430 mg, 81% yield) as a yellow gum. LC-MS (ESI+) m / z 598.4 (M+H)+.Step 2 - 4-((6-(l-(l-(4,4-Difluorocyclohexyl)ethyl)-lH-imidazol-4-yl)-4-methylpyridin-2-yl)oxy)-3-(hydroxymethyl)-l-methyl-lH-benzo[d]imidazol-2(3H)-one

[0565] To a solution of 4-[[6-[l-[l-(4,4-difluorocyclohexyl)ethyl]imidazol-4-yl]-4-methyl-2-pyridyl]oxy]-l-methyl-3-(2-trimethylsilylethoxymethyl)benzimidazol-2-one (430 mg, 719 pmol) in DCM (5 mL) was added TFA (3.47 g, 30.5 mmol, 2.26 mL) and the reaction was Page 217 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO stirred at 20 °C for 1 h. Upon completion, iced water (5 mL) was added and the mixture was neutralized to pH =7 with aq. NaHCO₃. then the aqueous phase was extracted with DCM (20 mL x 3). The combined organic phase was washed with brine (50 mL), dried with anhydrous sodium sulfate, filtered and concentrated in vacuo to afford the title compound (350 mg, 98% yield) as a yellow gum.Step 3 - 4-((6-(l-(l-(4,4-Difluorocyclohexyl)ethyl)-JH-imidazol-4-yl)-4-methylpyridin-2-yl)oxy)-l -methyl- 1 H-benzo[dJimidazol-2(3H)-one

[0566] A solution of 4-[[6-[l-[l-(4,4-difhiorocyclohexyl)ethyl]imidazol-4-yl]-4-methyl-2-pyridyl]oxy]-3-(hydroxymethyl)-l-methyl-benzimidazol-2-one (350 mg, 703 pmol) in NH₃ / MeOH (4 mL) was stirred at 20 °C for 0.5 h. Upon completion, the reaction mixture was concentrated under reduced pressure to remove solvent to give a residue. The residue was purified by prep-HPLC (column: CD06-Waters Xbidge C18 150 * 40 * 10 um; mobile phase:[water (NH4HCO3)-ACN]; gradient: 32%-62% B over 10 min) to afford the title compound (200 mg, 59% yield) as a white solid. LC-MS (ESI+) m / z 468.1 (M+H)+.Step 4 - (S)-4-((6-(l-(l-(4,4-difluorocyclohexyl)ethyl)-lH-imidazol-4-yl)-4-methylpyridin-2-yl)oxy)-l-methyl-lH-benzo[d]imidazol-2(3H)-one and (R)-4-((6-(l-(l-(4,4-difluorocyclohexyl)ethyl)-lH-imidaz.ol-4-yl)-4-methylpyridin-2-yl)oxy)-l -methyl- 1H-benzo[ d ]imidazol-2( 3H)-one

[0567] 4-((6-(l-(l-(4,4-Difluorocyclohexyl)ethyl)-lH-imidazol-4-yl)-4-methylpyridin-2-yl)oxy)-l-methyl-lH-benzo[d]imidazol-2(3H)-one was separated by SFC (column: DAICEL CHIRALCEL OD(250 mm * 30 mm, 10 um); mobile phase: [CO2-MeOH(0.1%NH3H2O)]; B%:30%, isocratic elution mode) to afford the first eluting peak (5)-4-((6-(l-(l-(4,4-difluorocyclohexyl)ethyl)-lH-imidazol-4-yl)-4-methylpyridin-2-yl)oxy)-l-methyl-lH-benzo[d]imidazol-2(3II)-one (67.9 mg, 34% yield, RT = 1.538 min) as a white solid (LC-MS (ESI+) m / z 468.2 (M+H)+; ’ll NMR (400 MHz, DMSO-de) 5 = 11.05 (s, 1H), 7.74 (s, 1H), 7.45 (s, 1H), 7.39 (s, 1H), 7.07 - 6.94 (m, 2H), 6.76 (d, J = 8.0 Hz, 1H), 6.47 (s, 1H), 4.21 -4.05 (m, 1H), 3.31 - 3.31 (m, 3H), 2.30 (s, 3H), 2.07 - 1.90 (m, 2H), 1.87 - 1.63 (m, 4H), 1.41 (d, J = 6.8 Hz, 3H), 1.30 - 1.18 (m, 2H), 1.15 - 1.03 (m, 1H) and (R)-4-((6-(l-(l-(4,4-difluorocyclohexyl)ethyl)-lH-imidazol-4-yl)-4-niethylpyridin-2-yl)oxy)-l -methyl- 1H-benzo[d]imidazol-2(3H)-one (67.3 mg, 33% yield, RT = 1.790 min) as a white solid (LC-MS (ESI+) m / z 468.2 (M+H)+; ’ll NMR (400 MHz, DMSO-&) 5 = 11.05 (s, 1H), 7.74 (d, 7= 1.2 Hz, 1H), 7.45 (s, 1H), 7.39 (d, 7= 0.8 Hz, 1H), 7.07 - 6.95 (m, 2H), 6.76 (dd, J= 0.8, 8.0 Hz,Page 218 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO 1H), 6.47 (s, 1H), 4.21 - 4.05 (m, 1H), 3.31 - 3.30 (m, 3H). 2.30 (s, 3H), 2.06 - 1.90 (m, 2H), 1.86 - 1.67 (m, 4H), 1.41 (d, J= 6.8 Hz, 3H), 1.29 - 1.18 (m, 2H), 1.14 - 1.05 (m, 1H)).F. Synthesis of (S)-l-(2-(l-acetylpiperidin-4-yl)ethyl)-4-((6-(l-(l-(4,4-difluorocyclohexyl)ethyI)-lH-imidazol-4-yI)-4-(4-(piperidin-l-yl)butyl)pyridin-2-yl)oxy)-lH-benzo[d]imidazol-2(3H)-one (Compound 1-19)Step 1 - (S)-4-((4-(3-(l,3-dioxolan-2-yl)propyl)-6-(l-(l-(4,4-difluorocyclohexyl)ethyl)'-lH-imidazol-4-yl)pyridin-2-yl )oxy)-l -(2-(l -acetylpiperidin-4-yl )ethyl)-l H -benzo [ d ]imidazol-2 ( 3H)-one

[0568] To a solution of 4-((4-(3-(l,3-dioxolan-2-yl)propyl)-6-chloropyridin-2-yl)oxy)-l-(2-(l-acetylpiperidin-4-yl)ethyl)-lH-benzo[d]imidazol-2(3H)-one (324 mg, 613 pmol, Intermediate U), (S)-l-(l-(4,4-difluorocyclohexyl)ethyl)-4-(tributylstannyl)-lH-imidazole (370 mg, 735 prnol, Intermediate Q), palladium tritert-butylphosphane (125 mg, 245 pmol) in DMF (5 mL) was degassed and purged with N2 three times. Then the mixture was stirred at 100 °C for 1 h under N2 atmosphere. Upon completion, the reaction mixture was quenched with KF (20 mL), and then extracted with EtOAc (20 mL x 3). The combined organic layers Page 219 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO were washed with brine (20 mL x 3), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiCh, Petroleum ether / Ethyl acetate=0 / l to DCM: MeOH = 10:1) to give the title compound (400 mg, 74% yield) as a white solid. LC-MS (ESI+) m / z 707.3 (M+H)+.Step 2 - (S)-4-(2-((l-(2-(l-acetylpiperidm-4-yl)ethyl)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)oxy)-6-(l-(I-(4,4-difluorocyclohexyl)ethyl)-IH-imidazol-4-yl)pyridin-4-yl)butanal

[0569] A solution of (S)-4-((4-(3-(l,3-dioxolan-2-yl)propyl)-6-(l-(l-(4,4-difluorocyclohexyl)ethyl)-lH-imidazol-4-yl)pyridin-2-yl)oxy)-l-(2-(l-acetylpiperi din-4-yl)ethyl)-lH-benzo[d]imidazol-2(3H)-one (130 mg, 184 pmol) in HCOOH (1 mL) was degassed and purged with N2 three times, and then the mixture was stirred at 60 °C for 1 h under N2 atmosphere. Upon completion, the reaction mixture was filtered and concentrated under reduced pressure to give the title compound (122 mg) as an orange oil. LC-MS (ESI+) m / z 663.5 (M+H)+.Step 3 - (S)-l-(2-(l-acetylpiperidin-4-yl)ethyl)-4-((6-(l-(l-(4,4-difluorocyclohexyl)ethyl)-lH-imidaz.ol-4-yl)-4-(4-(piperidm-l-yl)butyl)pyridin-2-yl)oxy)-lH-benzo[d]imidazol-2(3H)-one

[0570] To a solution of (S)-4-(2-((L(2-(l-acetylpiperidin-4-yl)ethyl)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)oxy)-6-(l-(l-(4,4-difluorocyclohexyl)ethyl)-lH-imidazoL4-yl)pyridin-4-yl)butanal (110 mg, 166 pmol), piperidine (21.2 mg, 248 pmol, 24.6 pL), HOAc (19.9 mg, 331 pmol, 19.00 pL), and NaBH(OAc)3 (105 mg, 498 pmol) in DMSO (1 mL) and THF (1 mL) was degassed and purged with N2 three times. Then the mixture was stirred at 20 °C for 0.5 h under N2 atmosphere. Upon completion, the reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: CD07-Daisogel SP-100-8-ODS-PK 150*25* 10um;mobile phase: [water (NH4HCC>3)-ACN];gradient:28%-58% B over 10 min) to give the title compound (46.1 mg, 38% yield) as a pink solid. LC-MS (ESI+) m / z 732.4 (M+H)+; ’ll NMR (400 MHz, DMSO-d6) 5 = 11.20 - 10.95 (m, 1H), 7.74 (d, J = 1.2 Hz, 1H), 7.46 (d, 7 = 0.8 Hz, 1H), 7.35 (d, 7 = 1.2 Hz, 1H), 7.04 - 6.98 (m, 2H), 6.76 (dd, 7= 2.8, 6.4 Hz, 1H), 6.52 (d, 7 = 0.8 Hz, 1H), 4.34 (br d, 7= 13.2 Hz, 1H), 4.17 - 4.08 (m, 1H), 3.85 (br t, 7 = 7.2 Hz, 2H), 3.81 - 3.75 (m, 1H), 2.96 (s, 1H), 2.60 (t, 7 = 7.6 Hz, 2H), 2.47 (br d, 7= 2.0 Hz, 1H), 2.22 (br dd, 7= 8.0, 14.8 Hz, 6H), 2.03 - 1.92 (m, 5H), 1.76 (br d, 7 = 17.2 Hz, 5H), 1.72 (br s, 1H), 1.64 - 1.53 (m, 5H), 1.46 -Page 220 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO 1.42 (m, 5H), 1.40 (br d, J = 6.8 Hz, 3H), 1.37 - 1.31 (m, 2H), 1.23 (br s, 2H), 1.16 (br dd, J= 3.6, 17.4 Hz, 2H), 1.07 (br s, 1H), 1.00 - 0.85 (m, 1H).G. Synthesis of 4-((2-(l-(3,4-difluorobenzyl)-lH-pyrazol-4-yl)-6-(3-methoxypyrrolidin-l-yl)pyrimidin-4-yl)oxy)-l,3-dihydro-2H-benzo[d]imidazol-2-oneStep 1 - 4,6-Dichloro-2-(l-(3,4-difluorobenzyl)-lH-pyrazol-4-yl)pyrimidine

[0571] A mixture of 4,6-dichloro-2-iodo-pyrimidine (200 mg, 727 pmol, Intermediate AB), 1-[(3,4-difhiorophenyl)methyl]-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazole (232 mg, 727 pmol, Intermediate E), K2CO3 (301 mg, 2.18 mmol), and Pd PPha CL (51.0 mg, 72.7 pmol) in H2O (0.5 mL) and toluene (1.5 mL) was degassed and purged with N2 3 times. Then the mixture was stirred at 90 °C for 2 h under N2 atmosphere. The reaction mixture was poured into H2O (2 mL) and extracted with EtOAc (4 mL x3). The combined organic layers were washed with brine (4 mL x 2), dried over Na2SC>4 filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiCh, Petroleum ether: Ethyl acetate=50:l to Petroleum ether: Ethyl acetate=5:l) to afford the title compound (66.0 mg, 27% yield). LC-MS (ESI+) m / z 341.0[M+H]+.Step 2 - 4-((6-Chloro-2-(l-(3,4-difluorobenzyl)-lH-pyrazol-4-yl)pyrimidin-4-yl)oxy)-1, 3 -dihydro-2H-benzo[ d ]imidazol-2 -onePage 221 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO

[0572] To a solution of 4,6-dichloro-2-[l-[(3,4-difluorophenyl)methyl]pyrazol-4-yl]pyrimidine (66.0 mg, 193 pmol), 4-hydroxy-l,3-dihydrobenzimidazol-2-one (26.1 mg, 174 pmol, Intermediate AC) in EtOH (1 mL) was added TEA (58.7 mg, 580 pmol, 80.7 pL). The mixture was stirred at 60 °C for 1 h. The mixture was filtered. The filtrate was purified by prep-HPLC (column: Daisogel SP ODS RPS 150*25mm*5um;mobile phase: [water( NH4HCO3)-ACN]; gradient: 37%-67% B over 10 min) to afford the title compound (20.0 mg, 23% yield). LC-MS (ESI⁺) m / z 455.1 [M+H]+; ‘H NMR (400 MHz, DMSO-d6) 8 = 10.89 - 10.73 (m, 2H), 8.39 (s, 1H), 7.79 (s, 1H), 7.47 - 7.30 (m, 2H), 7.16 - 7.06 (m, 1H), 7.03 - 6.81 (m, 4H), 5.36 (s, 2H).Step 3 - 4-((2-(l-(3,4-Difluorobenzyl)-IH-pyrazol-4-yl)-6-(3-methoxypyrrolidin-l-yl)pyrimidin-4-yl)oxy)-l,3-dihydro-2H-benzo[d]imidazol-2-one

[0573] To a solution of 4-[6-chloro-2-[l-[(3,4-difluorophenyl)methyl]pyrazol-4-yl]pyrimidin-4-yl]oxy-l,3-dihydrobenzimidazol-2-one (60.0 mg, 131 pinol) and 3-methoxypyrrolidine (21.7 mg, 158 pmol, HC1, CAS# 136725-50-3) in DMF (1 mL) was added K2CO3 (54.7 mg, 395 pmol). The mixture was then stirred at 120 °C for 2 h. The mixture was filtered. The filtrate was purified by prep-HPLC (column: Phenomenex luna C18 150*25mm* 10um;mobile phase:[water(FA)-ACN];gradient: 33%-63% B over 10 min) to afford the title compound (10.0 mg, 14% yield). LCMS (ESI+) m / z 520.0 [M+1]+; ’ll NMR (400 MHz, DMSO-de) 6 = 10.75 (br d, J = 18.4 Hz, 2H), 8.23 (s, 1H), 7.79 (s, 1H), 7.45 - 7.27 (m, 2H), 7.08 (ddd, J = 2.0, 4.4, 6.4 Hz, 1H), 6.97 - 6.91 (m, 1H), 6.82 (d, 7 = 7.2 Hz, 1H), 6.75 (dd, J= 0.8, 8.0 Hz, 1H), 5.57 (s, 1H), 5.34 (s, 2H), 4.05 (br s, 1H), 3.89 - 3.66 (m, 1H), 3.89 - 3.35 (m, 3H), 3.25 (s, 3H), 2.04 (br d, 7= 2.4 Hz, 2H).H. Synthesis of l-Methyl-4-((4-methyl-6-(l-(3-methylpyrrolo[l,2-a]pyrazin-l-yl)-lH-pyrazol-4-yl)pyridin-2-yl)oxy)-l,3-dihydro-2H-benzo[d]imidazol-2-one (Compound 1-216)Page 222 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOStep 1 - l-Methyl-4-((4-methyl-6-(lH-pyrazol-4-yl)pyridin-2-yl)oxy)-l,3-dihydro-2H-benzo[ d ]imidazol-2-one

[0574] To a mixture of 7-[(6-bromo-4-methyl-2-pyridyl)oxy]-3-methyl-lH-benzimidazol-2-one (10.0 g, 29.9 mmol, Intermediate W) and 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-IH-pyrazole (6.39 g, 32.9 mmol, CAS# 269410-08-4) in dioxane (10.0 mL) and H2O (1.00 mL) was added K3PO4 (19.06 g, 89.78 mmol) and dichloropalladium dicyclohexyl(cyclopentyl)phosphane iron (2.94 g, 3.89 mmol, 0.13 eq, CAS# 917511-90-1) under N2. The mixture was then stirred at 80 °C for 16 hrs. The mixture was diluted with H2O (100 mL) and extracted with DCM (80 mL x 3). The combined organic layers were dried over Na2SC>4, filtered, the filtrate was concentrated. The residue was purified by silica gel chromatography (DCM / Methanol = 50 / 1-5 / 1) to give the title compound (8.00 g, 83% yield). LC-MS (ESI+) m / z 322.2 (M+H)+.Step 2 - l-Methyl-4-((4-methyl-6-(l-(3-methylpyrrolo[l,2-a]pyrazin-l-yl)-lH-pyrazol-4-yl)pyridm-2-yl)oxy)-l,3-dihydro-2H-benzo[d]imidazol-2-one

[0575] To a mixture of 3-methyl-7-[[4-methyl-6-(lH-pyrazol-4-yl)-2-pyridyl]oxy]-lH-benzimidazol-2-one (100 mg, 311 pmol) and l-chloro-3-methyl-pyrrolo[l,2-a]pyrazine (51.9 mg, 311 pmol, CAS# 1025054-90-3) in DMF (4 mL) was added CS2CO3 (304 mg, 934 pmol), Cui (59.3 mg, 311 pmol) and 2-(dimethylamino)acetic acid (64.2 mg, 622 pmol) under N2. The mixture was then stirred at 140 °C for 16 hrs under N2. The mixture was filtered. The filtrate was purified by prep-HPLC (column: Phenomenex Luna Cl 8 100*30mm*3um; mobile phase: [A: H2O (0.2% FA); B: ACN]; B%: 15%-50%, 8.00 min; flow rate: 25 ml / min) to give the title compound (55.0 mg, 39% yield). LC-MS (ESI+) m / z 452.1 (M+H).Page 223 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO Table 9. Compounds synthesized via further methodology.aCompounds were synthesized under standard conditions over multiple steps including coupling of amines and acids, coupling of halides and mesylates, deprotection and coupling of amines and carbamates.bThe LCMS data was reported at m / z (M-H)‘.Table 10. Compounds synthesized under various methodsPage 224 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 225 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 226 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 227 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOaCompounds were synthesized under standard conditions as described above or with further methodology over multiple steps.bThe product was further seperated by SFC (column: DAICEL CHIRALPAK AD (250mm*30mm,10um); mobile phase: [CO2-ACN / EtOH(0.1% NH3H2O)]: B%:60%, isocratic elution mode) to give the title compound as the second eluting peak (RT = 2.621 min). Analytical method: Column: Chiralpak AD-3 50x4.6mm I. D., 3um; Mobile phase: Phase A for CO2, and Phase B for EtOH (0.05% DEA); Isocratic elution: B in A for 40%; Flow rate: 3mL / min; Detector: PDA; Column Temp: 35 °C; Back Pressure: 100 Bar.CLC-MS (ESI+) m / z was reported as (M-THP+2H)+.Example 7. Homogenous Time-Resolved Fluorescence (HTRF) Binding Assay

[0576] HTRF binding assays were performed using 0.5 nM biotinylated IRF5 (230-477) purified from E.coli, IX Streptavidin-terbium (Cisbio 610SATLB) prepared by mixing SA-Tb in PPI detection buffer (Cisbio 61DB10RDF), 250 nM fluorescein-labeled small molecule probe (Probe 1, shown below), and test compounds in assay buffer consisting of 50 mM HEPES-Na pH 7.5, 150 mM NaCl, 0.5 mM TCEP, 0.005% Tween-20 with a final volume of 20 uL.Page 228 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOProbe 1

[0577] Compound stocks were dissolved at 10 mM in 100% DMSO and 11 -point titration with 3-fold serial dilution was performed in white, opaque 384 well microplates (OptiPlate 384- well Microplate, PerkinElmer 6007290). Reaction plates were incubated at 25°C for 60 minutes. Plates were centrifuged at low rpm for 5 mins, and the ratio of fluorescence intensities were measured at emission wavelengths for fluorescein acceptor (520 nm) and terbium donor (495 nm) on Envision Plate reader. % Inhibition was calculated from the 520 / 495 ratio generated by using positive control compound (Probe 1) for 100% inhibition and DMSO only reactions for 0% inhibition. Data was processed and dose response curves were generated using GraphPad Prism to determine the concentration required for inhibiting 50% of the HTRF signal (IC50).

[0578] The letter codes for ICso (nM) include: AA (<50 nM); BB (50 - 100 nM); CC (>100 nM - 1,000 nM); DD (> 1,000 nM - 10,000 nM); and NT (not tested).Table 11. HTRF ICsoPage 229 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 230 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 231 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOINCORPORATION BY REFERENCE

[0579] All publications and patents mentioned herein are hereby incorporated by reference in their entirety for all purposes as if each individual publication or patent was specifically and individually incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.EQUIVALENTS

[0580] While specific embodiments of the subject disclosure have been discussed, the above specification is illustrative and not restrictive. Many variations of the present disclosure will become apparent to those skilled in the art upon review of this specification. The full scope of the disclosure should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.

[0581] Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments described herein. Such equivalents are intended to be within the scope of the following claims.Page 232 of 263IPTS / 200423678.1

Claims

Attorney Docket No.: KME-305WO CLAIMSWhat is claimed:

1. A compound of F ormula Z:Formula Z,or a pharmaceutically acceptable salt thereof, wherein:U1is -O- or -S-;RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- C6alkyl);Z1is — C(O)~, Z2is O, NRZ2, or CRZ3RZ4, and represents a single bond, or alternatively Z1is N or CRZ3, Z2is N or CRZ3, and represents a double bond;each of Z3, Z4, and Z5is, independently, CRZ5or N;RZ2is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-Ce alkyl)-O- (Ci-C6alkyl), -C(O)-(Ci-C6alkyl), -(Ci-C6alkyl)-RY, and RY;RZ3is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Ci-Ce alkyl)-RY, and RY;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY; or alternativelyRZ3and RZ4are taken together with the carbon atom to which each is attached form 3- 8 membered monocyclic carbocyclylene:Page 233 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO each Rz5is, independently, selected from the group consisting of H, halo, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, and -ORza;each Rzais, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of V1, V2, V3, and V4is, independently, CRVor N;each Rvis, independently, selected from the group consisting of H, halo, -NO2, -CN, Ci-Ce alkyl, C1-C.6 haloalkyl, C2-C.6 alkenyl, C2-C.6 alkynyl, -NRvaRvb, -ORVC, -(C1-C.6 alkylene)-NRvaRvb, -(Ci-C6alkylene) ORVC, -(Ci-C6alkylene)O(CH2)i-4ORvc, -NRva- (Ci-Ce alkylene) -NRvaRvb, -O-(Ci-Ce alkylene)-NRvaRvb, -(C2-C10 alkenylene)- NRvaRvb, -(C2-C10 alkynylene)-NRvaRvb, RVY, -NRva-(Co-C6alkylene)-RVY, -(Ci-C6alkylene)-RVY, -O-(Ci-Ce alkylene)-RVY, -(C2-C10 alkenylene)-RVY, -(C2-C10 alkynylene)-RVY, and RVY;each RVYis, independently, selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RVYis unsubstituted or substituted with 1-4 instances of Rvd;each Rvais, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each Rvbis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-Ce alkyl)-O-(Ci-Ce alkyl), and -C(O)-(Ci-Ce alkyl);each Rvcis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Ci-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each Rvdis, independently, selected from the group consisting of halo, -OH, -NO2, -CN, Ci- Ce alkyl, Ci-C6haloalkyl, -NRvaRvb, -ORVC. -(Ci-C6alkylene)-NRvaRvb, -(Ci-C6alkylene)ORvc, -(Ci-C6alkylene)O(CH2)i-4ORvc, -NRva-(Ci-C6alkylene)-NRvaRvb, - (C2-C10 alkenylene) -NRvaRvb, and -(C2-C10 alkynylene)-NRvaRvb;each of W1, W2, and W3is, independently, CRWor N;each Rwis, independently, selected from the group consisting of H, halo, -NO2, -CN, Ci-Ce alkyl, Ci-C6haloalkyl, C2-C6alkenyl, C2-C6alkynyl, -NRwaRwb, -ORWC, -(Ci-C6alkylene)-NRwaRwb, -(Ci-C6alkylene) ORWC, -(Ci-C6alkylene)O(CH2)i-4ORwc, -NRwa- (Ci-C6alkylene)-NRwaRwb, -O-(Ci-C6alkylene) -NRwaRwb, -(C2-C10 alkenylene)- NRwaRwb, -(C2-C10 alkynylene)-NRwaRwb, -NRwa-(C0-C6alkylene)-RWY, -(Ci-C6alkylene) -RWY, -O-(Ci-Ce alkylene) -RWY, -(C2-C10 alkenylene)-RWY, and -(C2-C10 alkynylene)-RWY;Page 234 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO each RWYis, independently, selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each Rwais, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each Rwbis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C,6 alkyl)-O-(Ci-Ce alkyl), and -C(O)-(Ci-Ce alkyl);each Rwcis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Ci-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each of R11and R22is, independently, selected from a group consisting of H, halogen, Ci-Ce alkyl, C1-C6 haloalkyl, and 3-6 membered monocyclic carbocyclyl; or alternatively R11and R22are taken together with the carbon atom to which each is attached to formn is 0, 1, 2, 3, or 4;Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, 5-14 membered spirocyclic carbocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered bicyclic heteroaryl, 3-8 membered monocyclic heterocyclyl, 8-10 membered bicyclic heterocyclyl, and 5-14 membered spirocyclic heterocyclyl;each REis, independently, selected from the group consisting of-CN, -NO2, halo, Ci-Ce alkyl, Ci-C6haloalkyl, -C(O)Rea, -OReb, -N(Rec)2, and REY;REYis selected from the group consisting of phenyl and 5-6 membered monocyclic heteroaryl, wherein REYis unsubstituted or substituted with 1-3 instances of Red;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -Ryaor -C(O)Rya;each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;Page 235 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO each Recis, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Redis, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Ryais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl; ande is 0, 1, 2, 3, 4, 5, or 6.

2. A compound of Formula A:Formula A,or a pharmaceutically acceptable salt thereof, wherein:RZ1is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- C6alkyl);Z1is — C(O)—, Z2is O, NRZ2, or CRZ3RZ4, and represents a single bond, or alternatively Z1is N or CRZ3, Z2is N or CRZ3, and = represents a double bond;each of Z3, Z4, and Z5is, independently, CRZ5or N;RZ2is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-Ce alkyl)-O- (Ci-C6alkyl), -C(O)-(Ci-C6alkyl), and RY;RZ3is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Ci-Ce alkyl)-RY, and RY;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY; or alternativelyPage 236 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO RZ3and RZ4are taken together with the carbon atom to which each is attached form 3- 8 membered monocyclic carbocyclylene;each RZ5is, independently, selected from the group consisting of H, halo, cyano, Ci-Ce alkyl, Ci-C6haloalkyl, and -ORza;each Rzais, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of V1, V2, V3, and V4is, independently, CRVor N;each Rvis, independently, selected from the group consisting of H, halo, -NO2, -CN, Ci-Ce alkyl, Ci-Ce haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, -NRvaRvb, -ORVC, -(Ci-Ce alkylene)-NRvaRvb, -(Ci-C6alkylene)ORvc, -(Ci-C6alkylene)O(CH2)i-4ORvc, -NRva- (C1-C6 alkylene)-NRvaRvb, -O-(Ci-C6alkylene)-NRvaRvb, -(C2-C10 alkenylene)- NRvaRvb, -(C2-C10 alkynylene)-NRvaRvb, RVY, -NRva-(Co-C6alkylene)-RVY, -(Ci-C6alkylene) -RVY, -O-(Ci-Ce alkylene) -RVY, -(C2-C10 alkenylene) -RVY, and -(C2-C10 alkynylene)-RVY;each RVYis, independently, selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RVYis unsubstituted or substituted with 1-4 instances of Rvd;each Rvais, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-Ce alkyl)-O-(Ci-Ce alkyl), and -C(O)-(Ci-Ce alkyl);each Rvbis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each Rvcis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Ci-Ce alkyl)-O-(Ci-Ce alkyl), and -C(O)-(Ci-Ce alkyl);each Rvdis, independently, selected from the group consisting of halo, -OH, -NO2, -CN, Ci- C6alkyl, Ci-C6haloalkyl, NRvaRvb, -ORVC, -(Ci-C6alkylene)-NRvaRvb, -(Ci-C6alkylene)ORvc, -(Ci-C6alkylene)O(CH2)i-4ORvc, -NRva-(Ci-C6alkylene)-NRvaRvb, - (C2-C10 alkenylene)-NRvaRvb, and -(C2-C10 alkynylene)-NRvaRvb;each of W1, W2, and W3is, independently, CRWor N;each Rwis, independently, selected from the group consisting of H, halo, -NO2, -CN, Ci-Ce alkyl, Ci-C6haloalkyl, C2-C6alkenyl, C2-C6alkynyl, -NRwaRwb, -ORWC, -(Ci-C6alkylene)-NRwaRwb, -(Ci-C6alkylene) ORWC, -(Ci-C6alkylene)O(CH2)i.4ORwc, -NRwa- (Ci-C6alkylene)-NRwaRwb, -O-(Ci-C6alkylene) -NRwaRwb, -(C2-C10 alkenylene)- NRwaRwb, -(C2-C10 alkynylene)-NRwaRwb, -NRwa-(Co-C6alkylene)-RWY, -(Ci-C6Page 237 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO alkylene)-RWY, -O-(Ci-C6alkylene) -RWY, -(C2-C10 alkenylene) -RWY, and -(C2-C10 alkynylene)-RWY;each RWYis, independently, selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each Rwais, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C,6 alkyl)-O-(Ci-Ce alkyl), and -C(O)-(Ci-Ce alkyl);each Rwbis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each Rwcis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(C1-C6 alkyl)-O-(Ci-C6 alkyl), and -C(O)-(Ci-C6 alkyl);each of R11and R22is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;nis 1, 2, 3, or 4;Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, and 5-14 membered spirocyclic carbocyclyl;each RFis, independently, selected from the group consisting of-CN, -NO2, halo, Ci-Ce alkyl, Ci-C6haloalkyl, -C(O)Rea, -OReb, and -N(Rec)2;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya;each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Recis, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Ryais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl; ande is 0, 1, 2, 3, 4, 5, or 6.

3. A compound of Formula I:Page 238 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula I,or a pharmaceutically acceptable salt thereof, wherein:RZ1is selected from the group consisting of H, C1-C6 alkyl, Ci-Ce haloalkyl, and -C(O)-(Ci- C6alkyl);Z2is NRZ2or CRZ3RZ4;each of Z3, Z4, and Z5is, independently, CRZ5or N;RZ2is selected from the group consisting of H, Ci-C6 alkyl, Ci-Ce haloalkyl, -(Co-Ce alkyl)-O- (Ci-C6alkyl), -C(O)-(Ci-C6alkyl), and RY;RZ3is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Ci-Ce alkyl)-RY, and RY;RZ4is selected from the group consisting of H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and -(Ci-Ce alkyl)-RY; orRZ3and RZ4are taken together with the carbon atom to which each is attached form 3- 8 membered monocyclic carbocyclylene;each Rz5is, independently, selected from the group consisting of H, halo, cyano, Ci-Ce alkyl, Ci-Ce haloalkyl, and -ORza;each Rzais, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of V1, V2, V3, and V4is, independently, CRVor N;each Rvis, independently, selected from the group consisting of H, halo, -NO2. -CN, Ci-Ce alkyl, Ci-Ce haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, -NRvaRvb, -ORVC, -(Ci-Ce Page 239 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO alkylene)-NRvaRvb, -(Ci-C6alkylene)ORvc, -(Ci-C6alkylene)O(CH2)i.4ORvc, -NRva- (Ci-C6alkylene)-NRvaRvb, -O-(Ci-C6alkylene)-NRvaRvb, -(C2-C10 alkenylene)- NRvaRvb, -(C2-C10 alkynylene)-NRvaRvb, RVY, -NRva-(Co-C6alkylene)-RVY, -(Ci-C6alkylene) -RVY, -O-(Ci-Ce alkylene) -RVY, -(C2-C10 alkenylene) -RVY, and -(C2-C10 alkynylene)-RVY;each RVYis, independently, selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RVYis unsubstituted or substituted with 1-4 instances of Rvd;each Rvais, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(C0-C6 alkyl)-O-(Ci-C6 alkyl), and -C(O)-(Ci-C6 alkyl);each Rvbis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each Rvcis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Ci-Ce alkyl)-O-(Ci-Ce alkyl), and -C(O)-(Ci-Ce alkyl);each Rvdis, independently, selected from the group consisting of halo, -OH, -NO2, -CN, Ci- Ce alkyl, Ci-Ce haloalkyl, NRvaRvb, -ORVC, -(Ci-Ce alkylene)-NRvaRvb, -(Ci-C6alkylene)ORvc, -(Ci-C6alkylene)O(CH2)i.4ORvc, -NRva-(Ci-C6alkylene)-NRvaRvb, - (C2-C10 alkenylene)-NRvaRvb, and -(C2-C10 alkynylene)-NRvaRvb;each of W1, W2, and W3is, independently, CRWor N;each Rwis, independently, selected from the group consisting of H, halo, -NO2, -CN, Ci-Ce alkyl, Ci-C6haloalkyl, C2-C6alkenyl, C2-C6alkynyl, -NRwaRwb, -ORWC, -(Ci-C6alkylene)-NRwaRwb, -(Ci-C6alkylene) ORWC, -(Ci-C6alkylene)O(CH2)i.4ORwc, -NRwa- (Ci-C6alkylene)-NRwaRwb, -O-(Ci-C6alkylene)-NRwaRwb, -(C2-C10 alkenylene)- NRwaRwb, -(C2-C10 alkynylene)-NRwaRwb, -NRwa-(Co-C6alkylene)-RWY, -(Ci-C6alkylene) -RWY, -O-(Ci-Ce alkylene) -RWY, -(C2-C10 alkenylene) -RWY, and -(C2-C10 alkyny lene) -RWY;each RWYis, independently, selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each Rwais, independently, selected from the group consisting of H, Ci-C6 alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);each Rwbis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Co-C6alkyl)-O-(Ci-C6alkyl), and -C(O)-(Ci-C6alkyl);Page 240 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO each Rwcis, independently, selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, -(Ci-Ce alkyl)-O-(Ci-C6 alkyl), and -C(O)-(Ci-Ce alkyl);each of R11and R22is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;nis 1, 2, 3, or 4;Ring E is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, and 5-14 membered spirocyclic carbocyclyl;each RFis, independently, selected from the group consisting of-CN, -NO2, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -C(O)Rea, -OReb, and -N(Rec)2;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -C(O)Rya;each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Recis, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Ryais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl; ande is 0, 1, 2, 3, 4, 5, or 6.

4. The compound of any one of claims 1 to 3, wherein RZ1is H.

5. The compound of any one of claims 1 to 4, wherein Z2is NRZ2.

6. The compound of claim 5, wherein RZ2is Ci-Ce alkyl.

7. The compound of any one of claims 1 to 6, wherein Z2is CRZ3RZ4.

8. The compound of claim 7, wherein RZ3is selected from the group consisting of H, Ci-C6alkyl, and -(Ci-C6alkyl)-RY.Page 241 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO 9. The compound of claim 7, wherein R24is selected from the group consisting of H, Ci-Ce alkyl, and -(Ci-Ce alkyl)-RY.

10. The compound of claim 7, wherein RZ3and R24are taken together with the carbon atom to which each is attached form 3-8 membered monocyclic carbocyclylene.

11. The compound of any one of claims 1 to 10, wherein Z3is CRZ5.

12. The compound of any one of claims 1 to 11, wherein Z4is CRZ5.

13. The compound of any one of claims 1 to 12, wherein Z5is CRZ5.

14. The compound of any one of claims 1 to 13, wherein each RZ3is, independently, selected from the group consisting of H and Ci-Ce alkyl.

15. The compound of any one of claims 1 to 14, wherein V2is CRV.

16. The compound of any one of claims 1 to 15, wherein V4is CRV.

17. The compound of any one of claims 1 to 16, wherein the compound is of Formula I- A:Formula I-A,or a pharmaceutically acceptable salt thereof,Page 242 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO 18. The compound of any one of claims 1 to 17, wherein each Rvis, independently, selected from the group consisting of H, halo, -NO2, -CN, Ci-Ce alkyl, Ci-Cs haloalkyl, -NRvaRvb, -ORVC, -(Ci-C6alkylene)-NRvaRvb, -(Ci-C6alkylene)O(CH2)i-4ORvc, -NRva-(Ci-C6alkylene)-NRvaRvb, -(C2-C10 alkynylene)-NRvaRvb, RVY, -NRva-(C0-C6alkylene) -RVY, -(Ci-C'o alkylene)-RVY, and -(C2-C10 alkynylene)-RVY.

19. The compound of claim 18, wherein each Rvis -Me.

20. The compound of claim 18, wherein each Rvis H.

21. The compound of any one of claims 1 to 20, wherein W1is CRW.

22. The compound of any one of claims 1 to 21, wherein W2is CRW.

23. The compound of any one of claims 1 to 22, wherein each Rwis, independently, selected from the group consisting of H, halo, -NO2, -CN, Ci-Ce alkyl, Ci-Ce haloalkyl, C2-C6alkyne, -ORWC, -O-(Ci-C6alkylene)-NRwaRwb, and -O-(Ci-C6alkylene)-RWY.

24. The compound of claim 23, wherein each Rwis H.

25. The compound of any one of claims 1 to 24, wherein W3is N.

26. The compound of any one of claims 1 to 24, wherein each R11is, independently, selected from the group consisting of H and Ci-Ce alkyl.

27. The compound of any one of claims 1 to 26, wherein each R22is, independently, selected from the group consisting of H and Ci-Ce alkyl.

28. The compound of any one of claims 1 to 27, wherein n is 1, 2, or 3.

29. The compound of any one of claims 1 to 28, wherein Ring E is phenyl.

30. The compound of any one of claims 1 to 28, wherein Ring E is 3-8 membered monocyclic carbocyclyl.

31. The compound of claim 30, wherein Ring E is cyclohexanyl.

32. The compound of any one of claims 1 to 31, wherein each REis, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl.Page 243 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO 33. The compound of any one of claims 1 to 32, wherein e is 0, 1, 2, 3, or 4.

34. The compound of claim 1, wherein the compound is of any one of Formula I-B to Formula I-I:Page 244 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOor a pharmaceutically acceptable salt thereof.

35. The compound of claim 1, wherein the compound is of any one of Formula I-B-l to Formula I-B-6:Page 245 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula I-B-3, Formula I-B-4,Page 246 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOor a pharmaceutically acceptable salt thereof.

36. The compound of claim 1, wherein the compound is of any one of Formula I-C-l to Formula I-C-5:Page 247 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula I-C-5,or a pharmaceutically acceptable salt thereof.

37. The compound of claim 1, wherein the compound is any one of Formula I-D-l to Formula I-D-5:Page 248 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 249 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula I-D-5,or a pharmaceutically acceptable salt thereof.

38. The compound of claim 1, wherein the compound is any one of Formula I-H-l to Formula I-H-4:Page 250 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula I-H-3, Formula I-H-4,or a pharmaceutically acceptable salt thereof.

39. The compound of claim 1, wherein the compound is any one of Formula I-G-l to Formula I-G-7:Page 251 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOPage 252 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOFormula I-G-7,or a pharmaceutically acceptable salt thereof.

40. A compound of Formula B:Formula B,or a pharmaceutically acceptable salt thereof, wherein:RZ11is selected from the group consisting of H and Ci-Ce alkyl;RZ12is selected from the group consisting of H and Ci-Ce alkyl;each of Z13, Z14, and Z15is, independently, CRZ15or N;Page 253 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO each RZ13is, independently, selected from the group consisting of H, halo, -NO2, cyano, Ci- Ce alkyl, Ci-Ce haloalkyl, and -ORzb;Rzbis selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;V12is CRV1or N;RV1is selected from the group consisting of H, halo, -NO2, -CN, Ci-Ce alkyl, Ci-Ce haloalkyl, and -ORve;Rveis selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each RW1is, independently, selected from the group consisting of halo, -NO2, -CN, Ci-Ce alkyl, Ci-C6haloalkyl, and-ORwd;Rwdis selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each of R111and R122is, independently, H, halo, Ci-Ce alkyl, Ci-Ce haloalkyl, and 3-6 membered monocyclic carbocyclyl;nl is 1, 2, 3, or 4;Ring El is 3-8 membered monocyclic carbocyclyl;each RE1is, independently, selected from the group consisting of-CN, -NO2, halo, Ci-Ce alkyl, Ci-C6haloalkyl, -C(O)Rea, -OReb, and -N(Rec)2;each Reais, independently, selected from the group consisting of Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rebis, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Recis, independently, selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;el is 0, 1, 2, 3, 4, 5, or 6; andfl is 0, 1, 2, or 3.Page 254 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO 41. The compound of claim 40, wherein RZ11is H.

42. The compound of claim 40 or 41, wherein each of Z13, Z14, and Z15is CRZ15.

43. The compound of any one of claims 40 to 42, wherein each RZ13is H.

44. The compound of any one of claims 40 to 43, wherein RZ12is Ci-Ce alkyl.

45. The compound of any one of claims 40 to 44, wherein V12is CRV1.

46. The compound of any one of claims 40 to 45, wherein each RV1is, independently, H or Ci-C6alkyl.Formula C,Page 255 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO or a pharmaceutically acceptable salt thereof, wherein:RZ21is selected from the group consisting of H and Ci-Ce alkyl;RZ22is selected from the group consisting of H, Ci-Ce alkyl, -(Co-Ce alkyl)-O-(Ci-Ce alkyl), - (Co-C6alkyl)-O-(Ci-C6alkyl)-O-(Ci-C6alkyl), and -(Ci-C6alkyl)-RY;each of Z23, Z24, and Z25is, independently, CH or N;V22is CRV2or N;each RV2is, independently, selected from the group consisting of H, halo, and Ci-C,6 alkyl;Ring W2 is selected from the group consistingeach RW2is, independently, selected from the group consisting of halo, -NO2, -CN, Ci-Ce alkyl, Ci-C6haloalkyl, and -ORwd;or alternatively, two RW2groups, together with the single carbon atom on Ring W2 that they each commonly attach to, form a cyclopropyl;Rwdis selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;Ring E2 is selected from the group consisting of phenyl and 3-8 membered monocyclic carbocyclyl;each RE2is, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl;RYis selected from the group consisting of 3-8 membered monocyclic carbocyclyl and 3-8 membered monocyclic heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein RYis unsubstituted or substituted with one or more instances of -Ryaor -C(O)Rya;each Ryais, independently, selected from the group consisting of Ci-Ce alkyl and Ci-Ce haloalkyl;e2 is 0, 1, 2, 3, 4, 5, or 6; andf2 is 0, 1, 2, or 3,Page 256 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WOprovided that the compound of Formula C is nota pharmaceutically acceptable salt thereof.

49. The compound of claim 48, wherein RZ21is H.

50. The compound of claim 48 or 49, wherein each of Z23, Z24, and Z25is CH.

51. The compound of any one of claims 48 to 50, wherein RZ22is H, Ci-Ce alkyl, -(Co-Ce alkyl)-O-(Ci-C6alkyl), or -(Ci-C6alkyl)-O-(Ci-C6alkyl)-O-(Ci-C6alkyl).

52. The compound of any one of claims 48 to 50, wherein RZ22is -(Ci-Ce alkyl)-RY.

53. The compound of any one of claims 48 to 51, wherein each of V22is CRV2.

54. The compound of any one of claims 48 to 53, wherein each RV2is, independently, H or Ci-Ce alkyl.

55. A compound of F ormula D:Formula D,or a pharmaceutically acceptable salt thereof, wherein:Page 257 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO Q1is selected from the group consisting of a covalent bond, C1-C4 alkyl, and C2-C4 alkenyl; each Rzis, independently, selected from the group consisting of halo, NH2, Ci-Ce alkyl, Ci-Ce haloalkyl,-0-(Co-C4)-RYZ, and RYZ; or alternativelytwo Rzgroups that are connected to two adjacent carbon atoms on Ring Z, which is a phenyl, together with the two adjacent carbon atoms on Ring Z, form a Ring Z1 that is fused to Ring Z;Ring Z1 is 6-membered heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur or a 6-membered heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring Z1 is unsubstituted or substituted with 1-4 instances of Rzc;RYZis selected from the group consisting of phenyl, 5-6 membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5-6 membered heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Rzbis selected from the group consisting of H, Ci-Ce alkyl, and Ci-Ce haloalkyl;each Rzcis, independently, selected from the group consisting of halo, C1-C3 alkyl, C1-C3 alkoxy, and C1-C3 haloalkyl;z is 0, 1, 2, 3, or 4;V32is CRVor N;RV3is selected from the group consisting of H, halogen, and Ci-Ce alkyl;each of W31, W32, and W33is, independently, CRW3or N;each RW3is, independently, selected from the group consisting of H, halogen, and Ci-Ce alkyl; each of R311and R322is, independently, selected from a group consisting of H, halogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;n3 is 1, 2, 3, or 4;Ring E3 is selected from the group consisting of phenyl and 3-8 membered monocyclic carbocyclyl;each RE3is, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl; ande3 is 0, 1, 2, 3, 4, 5, or 6.

56. The compound of claim 55, wherein Q1is a covalent bond.

57. The compound of claim 55, wherein Q1is C1-C4 alkyl or C2-C4 alkenyl.Page 258 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO 58. The compound of any one of claims 55 to 57, wherein z is 0, 1, or 2.

59. The compound of any one of claims 55 to 57, wherein each Rzis, independently, selected from the group consisting of Ci-Ce alkyl, -O-(Ci-C4)-Rzb, -C(O)-(CI-C4)-RYZ, and RYZ.

60. The compound of any one of claims 55 to 59, wherein RYZis selected from the group consisting of phenyl, pyridinonyl, pyrrolidinonyl, imidazolyl, thiazolyl, pyridinyl, tetrahydrofuranyl, and piperidinyl.

62. The compound of any one of claims 55 to 61, wherein V32is CRV3.

63. The compound of any one of claims 55 to 62, wherein each RV3is, independently, H or Ci-C6alkyl.

64. The compound of any one of claims 55 to 63, wherein n3 is 1.

65. The compound of any one of claims 55 to 64, wherein Ring E3 is phenyl.Page 259 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO 66. The compound of any one of claims 55 to 64, wherein Ring E3 is 6 membered monocyclic carbocyclyl.

67. A compound of F ormula E:Formula E,or a pharmaceutically acceptable salt thereof, wherein:RZ41is selected from the group consisting of H and Ci-Ce alkyl;RZ42is selected from the group consisting of H, Ci-Ce alkyl, and -(Ci-Ce alkyl)-RY;RV4ais selected from the group consisting of Ci-Ce alkyl and 3-6 membered monocyclic carbocyclyl;Q2is a covalent bond or N, wherein:when Q2is N, then:Q3is Ci-C6alkyl,6alkyl, and Q2and RVYare taken together with the carbon atom to which each is attached to form 5-6 membered heterocyclyl, andwhen Q2is a covalent bond, then:Q3is selected from the group consisting of a covalent bond, Ci-Ce alkyl,Page 260 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WORqnis selected from the group consisting of H, Ci-Ce alkyl and phenyl optionally substituted with one or more groups selected from halo, C1-C3 alkyl, and C1-C3 haloalkyl; each of R55and R66is, independently, selected from a group consisting of H, halogen, Ci-Ce alkyl, and Ci-Ce haloalkyl;ql is O, 1, 2, 3, or 4;Ring E4 is selected from the group consisting of phenyl, 3-8 membered monocyclic carbocyclyl, 5-14 membered bridged bicyclic carbocyclyl, 5-14 membered spirocyclic carbocyclyl, 5-6 membered monocyclic heteroaryl, 8-10 membered bicyclic heteroaryl, and 8-10 membered bicyclic heterocyclyl;each RE4is, independently, selected from the group consisting of-CN, -NC, halo, Ci-Ce alkyl, Ci-C6haloalkyl, -C(O)Rea, -OReb, -N(Rec)2, and REY;REYis selected from the group consisting of phenyl and 5-6 membered monocyclic heterocyclyl, wherein REYis unsubstituted or substituted with 1-3 instances of Red;each Redis, independently, selected from the group consisting of halo, Ci-Ce alkyl, and Ci-Ce haloalkyl; ande4 is 0, 1, 2, 3, 4, 5, or 6.

68. The compound of claim 67, wherein Q2is a covalent bond.

69. The compound of claim 67 or 68, wherein Q3is a covalent bond.

70. The compound of claim 67, wherein Q2is N.

71. The compound of any one of claims 67 to 70, wherein Q3is Ci-Ce alkyl,72. The compound of any one of claims 67 to 70, wherein Q4is H.Page 261 of 263IPTS / 200423678.1Attorney Docket No.: KME-305WO73. The compound of any one of claims 67 to 70, wherein74. The compound of claim 73, wherein Ring E4 is selected from the group consisting of phenyl, 4-6 membered monocyclic carbocyclyl, 10 membered bridged bicyclic carbocyclyl, 7 membered spirocyclic carbocyclyl, 5 membered monocyclic heteroaryl, 8-9 membered bicyclic heteroaryl, and 8-9 membered bicyclic heterocyclyl.

75. A compound of Table 1, or a pharmaceutically acceptable salt thereof.

76. The compound of any one of claims 1 to 75, or a pharmaceutically acceptable salt thereof, wherein one or more hydrogen atoms of the compound is replaced by deuterium.

77. A pharmaceutical composition comprising a compound of any one of claims 1 to 75, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient thereof.

78. A method of treating an IRF5-mediated disorder, disease, or condition in a subject in need thereof, the method comprising administering to said subject a compound of any one of claims 1 to 75, or a pharmaceutical composition of claim 77.

79. The method of claim 78, wherein the IRF5-mediated disorder, disease, or condition is an autoimmune disease.

80. The method of claim 79, wherein the IRF5-mediated disorder, disease, or condition is selected from ankylosing spondylitis, arthritis, asthma, autoimmune hepatitis, chronic obstructive pulmonary disease, Crohn’s disease, dermatomyositis, vasculitis, inflammatory bowel disease, juvenile idiopathic arthritis, lupus nephritis, myositis, polymyositis, psoriasis, rheumatoid arthritis, psoriatic arthritis, sclerosing cholangitis, Sjogren syndrome, cutaneous lupus erythematosus (CLE), discoid lupus erythematosus (DLE), systemic lupus erythematosus (SLE), systemic scleroderma, Type 1 diabetes mellitus, ulcerative colitis, macrophage activation syndrome (MAS), multiple sclerosis (MS), primary biliary cirrhosis (PBC), myocardial inflammation, and atherosclerosis.Page 262 of 263IPTS / 200423678.1